



GASTROINTESTINAL SYMPTOMS AND THE GUT IN 
AUTISM SPECTRUM DISORDERS: 















 A dissertation submitted to Johns Hopkins University in conformity with the requirements for 
























Individuals with ASD are more likely to experience gastrointestinal symptoms (GI).  The 
goal of this dissertation was to shed light on the burden GI symptoms place on individuals with 
ASD and their families, improve the detection of GI symptoms, and assess the role of the gut as 
an etiologic risk factor for the incidence of ASD. 
Methods: 
The first study analyzed 12 qualitative interviews to summarize the experiences that 
families with a child with ASD and GI symptoms face.  The second study reviewed the literature 
(n=144 studies between 1/1/1980 to 1/31/2017) on ASD and GI symptoms and described the 
range of approaches to ascertaining GI symptoms and conditions.  The third study developed a 
questionnaire to assess GI symptoms in children with ASD and reported psychometric (n=537).  
The fourth study assessed for interaction between maternal immune activation and antibiotic use 
during pregnancy on the risk of ASD diagnosis in the offspring, in an enriched-risk prospective 
birth cohort (n= 142 ASD, 2,953 non-ASD). 
Results: 
Three themes emerged from qualitative interviews: Parents rely on behavioral indicators 
to detect GI symptoms in their child.  GI symptoms are associated with poorer functioning and 
lower wellbeing and families tended to report negative experiences seeking healthcare for their 
child’s GI symptoms.  In the second study, GI symptoms were assessed many ways, and the 
assessment tool was significantly associated with symptom estimates.  In the third study, we 
developed an internally consistent 35-item tool for assessing the presence of GI symptoms.  In 
the fourth study, we found that the association between flu in the second trimester on risk for 
 iii 
ASD is modified by antibiotic use in pregnancy.  Among women who did not receive an 
antibiotic during pregnancy, flu in the second trimester was associated with 4.4 times the odds of 
ASD diagnosis (OR=4.43 95% 1.13-14.69), but not among women who did receive an antibiotic 
(OR=1.06 95% 0.46-2.13). 
Conclusions: 
This work highlights the need for more work on the accurate measurement of GI 
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CHAPTER 1: BACKGROUND AND DISSERTATION OUTLINE 
1.1 Overview of Epidemiology of Autism Spectrum Disorder 
1.1.1 Autism history and core symptoms 
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by two core 
domains of deficits: social communication and impairment, and restricted, repetitive behaviors, 
interests, or activities1.  Autism as a condition was first described in a case series of 11 children, 
published 1943 by Leo Kanner, a child psychiatrist at Johns Hopkins University, in his seminal 
paper, “Autistic Disturbances of Affective Conduct”2. The main features of autism, as described 
by Kanner, were the lack of affective contact with people, obsessive need for sameness, 
repetitive of verbal/motor behaviors, restrictive interests or obsessions with particular things, and 
communication impairments.  Notably, Kanner emphasized the variability in cognitive 
impairments across the children he saw2,3. He wrote, “Even though most of these children were 
at one time or another looked upon as feebleminded, they are all unquestionably endowed with 
good cognitive potentialities2.” Kanner’s paper was followed a year later by a description of four 
boys of similar presentation by pediatrician Hans Asperger4 in Germany. The term ‘autistic’ was 
in fact first coined by Swiss psychiatrist Eugen Bleuler in 1911 in his description of a symptom 
of severe schizophrenia5. Bleuler used ‘autism’ to describe the person’s ‘inner life’, which was 
not observable to others.  Specifically, Bleuler wrote that autistic thinking was concerned with 
childish/infantile desires to avoid the discomfort of reality and instead replace I with fantasies 
and hallucinations. 
The field initially struggled with whether autism was a manifestation of childhood schizophrenia 
or its own diagnostic entity6. The conceptualization and classification of ASD has evolved since 
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it was first described.  In the Diagnostic Statistical Manual (DSM-III-R) published in 1987, it 
was noted that the stereotyped, repetitive aspects of autism/pervasive developmental disorder 
could be confused for a delusion, but the additional diagnosis of schizophrenia should only be 
made in the rare case where ‘prominent delusions or hallucinations’ can be documented and meet 
the criteria for schizophrenia7. The DSM-III-R specified three domains of symptoms in autism: 
impairment in reciprocal social interaction, communication, and restricted and repetitive 
behaviors7. Waterhouse et al (1992) note that this criteria reflected Kanner’s original description 
of autism8. 
 
In the DSM-IV and DSM-IV-R (1994 and 2000, respectively), Asperger’s disorder, childhood 
disintegrate disorder, Rett’s disorder, and pervasive developmental disorder not otherwise 
specified were added as ‘Disorders Usually First Diagnosed in Infancy, Childhood, or 
Adolescence9,10.” Debate followed regarding whether Asperger’s disorder and Autism were 
distinct conditions.  Ultimately, with the introduction of DSM-V, all conditions (autistic disorder, 
Asperger’s, childhood disintegrate disorder, and PDD-NOS) were combined under one disorder: 
Autism Spectrum Disorder1. The decision to integrate Asperger’s disorder into ASD stemmed 
from overlap in diagnostic criteria between the two disorders (Asperger’s and autistic disorder) 
in DSM-IV11. Both autism and Asperger criteria included ‘qualitative impairment in social 
interaction’ and ‘restricted repetitive and stereotyped patterns of behavior, interest and 
activities.’  The key difference in diagnosis was the ‘lack of delay or deviance in early language 
development’ in Asperger’s Disorder relative to autistic disorder10,11. In reality, however, both 
individuals with autism and Asperger typically had impairment in communication or abilities to 
sustain a conversation.  The ‘precedence rule’ specified to only diagnose Asperger’s disorder if 
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criteria for autistic disorder were not met; however, the overlap in criteria made this 
challenging10–14. The other main change that occurred in DSM-5 is that the three core domains of 
ASD where combined into two core domains: 1) social and communication impairments and 2) 
repetitive and restricted behaviors and interests1. 
1.1.2 Comorbidities in ASD 
ASD is a clinically and etiologically heterogeneous disorder and is strongly associated with co-
occurring psychiatric and medical conditions, which contribute to the burden of disease 
associated with ASD15–18. Children and youth with ASD are more likely to experience comorbid 
mental health conditions, including language disorders, tic disorders, attention-deficit 
hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder, major 
depressive disorder, bipolar and related disorders, psychosis, separation anxiety disorder, specific 
phobias, generalized anxiety disorder, agoraphobia, social phobia, and obsessive-compulsive 
disorder (OCD).  The exception is substance use disorders, which are less prevalent in 
individuals with ASD16,19. Further, children and youth with ASD are more likely to have physical 
health disorders, including epilepsy/seizure disorders, sleep disorders, gastrointestinal disorders, 
metabolic disorders, hormonal dysfunction, hydrocephalus, fetal alcohol syndrome and cerebral 
palsy20,21. The higher rates of these conditions contribute to greater health services utilization 
(though, interestingly, less preventive services), poorer quality of life, and increased burden and 
decreased wellbeing in the family22–24. 
 
Like children, adults with ASD also disproportionally experience mental and physical health 
conditions.  They are at an increased risk for all major psychiatric disorders (with the exception 
of substance use disorders), including depression, anxiety, bipolar disorder, OCD, schizophrenia, 
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and suicide attempts.  Medical conditions are also elevated compared to adults without ASD, 
including immune conditions, gastrointestinal disorders, sleep disorders, epilepsy/seizure 
disorders, obesity, dyslipidemia, hypertension, diabetes, and even some rare conditions such as 
stroke and Parkinson’s disease25,26. A possible exception is cancer, which in some studies has 
been shown to be decreased in ASD, although the evidence is conflicting25,27–29. Importantly, the 
psychiatric and physical health conditions seen in ASD typically co-occur, meaning it is not 
uncommon for an individual with ASD to have multiple comorbidities18. 
1.1.3 Prevalence of ASD 
The prevalence of ASD has increased dramatically over the last several decades.  In the 1980s, 
ASD was believed to occur in 5 out of every 10,000 children (0.05%) in the United States 
(US)30.  Data from 2012 indicated that 1 in 68 school-age children had ASD31, while more recent 
2014 data estimate prevalence among US children age 8 years to be 1 in 5932. Notably, the 
prevalence of ASD is 4-5 times higher in males relative to females32. This increasing prevalence 
has raised public concern and has turned attention towards possible explanations.  It is very 
complicated to determine whether the increase in prevalence we’ve observed is in fact due to 
true risk factors.  Research suggests that changes in diagnostic criteria, younger age at diagnosis, 
and increased ASD awareness in part contribute to the increased estimates33–37. However, as 
stated by Newschaffer et al., ‘the question of whether this historical increase can be fully 
accounted for by these and other changes in diagnosis and classification remains open to debate, 
largely because it is very difficult to develop quantifiable estimates of diagnostic effects and 
virtually impossible to prove or disprove temporal changes in autism population risk profiles 
given the condition's unknown etiology34.’ Notably, there has not been a dramatic rise in the 
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prevalence of ASD with comorbid intellectual disability, suggesting that milder cases of ASD are 
responsible for the visible increase38. 
 
 It’s important to note that the prevalence estimates of ASD in the US vary by a number of 
demographic characteristics, especially race/ethnicity and socioeconomic status.  Specifically, 
children who are Black, Hispanic, or of another race/ethnicity are less likely to receive a 
diagnosis of ASD compared to white children39. Critically, this variability does not reflect a 
biological difference in the risk of ASD but rather a disparity in access to diagnostic and other 
services.  Communities with greater resources also have a higher prevalence of ASD diagnosis36.  
 
Estimates of ASD prevalence also vary across the world.  Studies estimate that 0.6-0.8% of 
children globally have ASD, though we do not have data from many individual countries40–42. 
Registry based studies from Scandinavian countries estimate that 1-1.5% of children have 
ASD43. The study with the highest prevalence came out of South Korea and estimated that 2.64% 
of 7-12 year olds between the years of 2005-2009 had ASD44.  
 
1.1.4 Etiology of ASD 
Twin and family studies support a strong genetic contribution to ASD, with estimates placing the 
heritability of ASD between 50% and 95%45–47. Correspondingly, one of the strongest risk 
factors for the development of ASD is having a sibling with ASD; studies suggest that the risk of 
autism varies from 3% to 18% in this population47–49. The genetic variants for ASD include both 
common variants with small effect sizes, and rare variants, including inherited and de novo 
mutations and copy number variations, that carry a larger ASD risk50–53.  
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However, environmental factors also contribute to the risk of ASD, including advanced parental 
age54–57, short (<12 months) as well as long (>60-84 month) inter pregnancy intervals58–61, 
medication use62–68, and pregnancy and birth complications, such as lower gestational 
age/preterm birth69–72 , c-section73, and metabolic conditions in the mother74,75. Environmental 
chemicals, such as air pollution76–79 and endocrine-disrupting chemicals80,81 have also been 
implicated in ASD risk. 
 
Maternal immune activation has emerged as an important risk factor for ASD.  Bacterial, viral, 
genitourinary infections, as well as fever during pregnancy have all been associated with 
increased risk for ASD in the child.  The exact trimester in which the various MIA exposures 
influence ASD risk is not fully elucidated82–88. Further the understanding of how MIA exposures 
in pregnant women affect ASD risk in the child is an area of current investigation.  
 
 
Critically, the interaction between a person’s genetic makeup and exposure to environmental 
factors may influence their ASD risk.  For example, there are instances in which an 
environmental stressor may only increase ASD risk in the context of a particular genetic 
variant89–91. Genetics and the environment also interact through epigenetics, which are heritable 
changes in gene expression that occur without any changes to the DNA sequence itself92. 
Epigenetics can be useful in ASD for a number of reasons: First, epigenetic marks might be 
involved in the etiology of ASD, by mediating the pathway between an environmental exposure 
and changes in gene expression.  Further, epigenetic marks can be influenced by genetic 
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variation.  Alternatively, an epigenetic mark can serve as a proxy or biomarker for a previous 
exposure or for a disease of interest93,94. 
1.1.4 Public health impact 
ASD develops in childhood and tends to cause lifelong impairments.  In addition to the core 
symptoms of ASD, medical and psychiatric comorbidities significantly increase the burden to the 
individual as well as their family/caregivers, and reduce the overall quality of life16,24,95–98. For 
these reasons, globally, ASD is among the leading causes of disability, in terms of years of life 
lost.  In the year 2010, among children ages 5-14 years, ASD was the fourth leading cause of 
disability within the mental disorders.  ASD also accounted for 7.7 million of disability-adjusted 
life years in the whole population40. Sadly, ASD is also associated with an increased risk of 
premature mortality99–101. The economic cost associated with ASD is also substantial.  It’s been 
estimated that in the US, the total annual costs of ASD are close to $250 billion and individual 
lifetime costs between $1.5-2.5 million102. Health care utilization costs contribute to these 
economic costs103. 
1.2 Gastrointestinal Symptoms in ASD 
Gastrointestinal disorders are one of the most prevalent medical comorbidities in ASD, along 
with sleep disorders and seizures/epilepsy21,104.  In Kanner’s 1943 paper first describing autism, 
he wrote that 6 of the 11 children with autism “presented severe feeding difficulty from the 
beginning of life”2. 
 
Studies of individuals with ASD have consistently found elevated estimates of gastrointestinal 
(GI) symptoms, compared to individuals with typical development (TD) as well as those with 
other developmental delays (DD)105–125.  There is no evidence of an ASD-specific gut pathology.  
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Rather, individuals with ASD appear to be an elevated risk of GI symptoms and disorders107. The 
most common GI symptoms found in ASD are chronic constipation, diarrhea, or alternating 
constipation/diarrhea, abdominal pain, and acid reflux, though other disorders are elevated as 
well107,126. Notably, GI symptom estimates have varied considerably across studies, likely due to 
the heterogeneity of ASD as well as the lack of standardized and validated GI symptom 
assessment tools for ASD, which will be discussed in greater depth below. 
 
Gastrointestinal symptoms are distressing not only because of the pain, discomfort, and 
functional limitations, but also because of their effect on mental and physical health.  Individuals 
with ASD and GI symptoms are more likely to have sleep disruptions127,128, aggressive, 
irritability, externalizing, or self-injurious behaviors128–132, anxiety and mood problems131–133, 
sensory sensitivities/over-responsiveness133, toileting problems such as soiling134, food 
sensitivities and eating issues128,135–137, and other psychopathology and somatic issues131,138,139. 
The high prevalence of GI symptoms in this population has contributed to the popularity of 
complementary and alternative treatments or medicines (CAMS), which are therapies developed 
outside of conventional Western medicine that are either used with (complementary) or in the 
place of (alternative) conventional medicine140. Families with a child with ASD may turn to 
CAMs when western medical approaches have failed them141–144.  With respect to ASD, 
biological therapies (e.g. special diets, nutritional supplements, detoxification, chelation) in 
particular, are often touted as ways to heal the gut and therefore cure autism145. Unfortunately, 
there is little data on the safety and efficacy of such CAMs141–144.  Further research needs to be 
done to understand the benefits and risks of these CAMs and their interaction with the 
gastrointestinal system.  
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1.3 Explanations for Association between ASD and Gastrointestinal Symptoms 
There are a number of possible explanations for the association between the gut/GI symptoms 
and ASD.  The bidirectional communication that occurs between the brain and the 
gastrointestinal tract is broadly referred to as the “gut-brain axis”146–149. The gut-brain axis is 
mediated through a number of pathways: endocrine (e.g. cortisol), immune, neural (vagus nerve 
and enteric nervous system), neurotransmitters produced in the gut (serotonin and tryptophan), 
production of short chain fatty acids, and the gut microbiome, which may interact with the other 
pathways149. 
 
Gastrointestinal symptoms in ASD may reflect dysbiosis, or imbalance, of the gut microbiome.  
The human microbiome, comprising trillions of bacteria and other microorganisms, coexists with 
the human body and is involved in critical functions such as digestion and stimulation of the 
immune system150,151. The microbiome is dynamic across the life course, influenced by early life 
exposures, highly variable across body sites within a person, and has been associated with a 
number of diseases including gastrointestinal cancers, inflammatory bowel disease, type 1 
diabetes, rheumatoid arthritis and multiple sclerosis150,151. Gut microbes are known to influence 
intestinal barrier integrity, epithelial cell proliferation, mucus production, and GI motility152–154. 
There is also growing evidence that the gut microbiome plays a significant role in immune 
dysregulation, which is also a risk factor in ASD155.  
 
Existing studies have found that individuals with ASD have increased relative abundance of 
Clostridium bacteria156–158, Sutterella159,160, Lactobacillus and Desulfovibrio161, and decreased 
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relative abundance of Prevotella, Coprococcus, and Veillonellaceae162,163, relative to people 
without ASD.  A decreased Bacteroidetes/Firmicutes ratio has also been linked to ASD161. 
However, findings have been inconsistent across studies164. Few behavioral traits or co-occurring 
issues in ASD have been examined for associations with the gut microbiome.  Kang et al. found 
that among children with ASD, ASD severity, GI symptom severity, being on a gluten-
free/casein-free diet, consumption of probiotics, nutritional supplements, eating too much, or 
having an extremely limited diet were not significantly associated with the top 10 genera found 
in the ASD group162. However, other co-occurring issues, including sensory sensitivities, and 
medical and psychiatric comorbidities have not been examined for associations with the gut 
microbiome among individuals with ASD. 
 
Further evidence for the role of the gut microbiome in causing or influencing ASD symptoms is 
provided by a recent open-label trial which found that a 2-week antibiotic treatment, bowel 
cleanse, and extended fecal microbiota transplant led to reductions in GI and ASD symptoms165. 
However, this study was not blinded and did not have a placebo-controlled ASD group.  It is also 
not clear from this work whether improvements in ASD behavioral symptoms were due to 
biological changes in the gut microbiota, or due to improvements in GI, which in turn improved 
the participants’ overall wellness. 
 
Animal literature thus far provides the best evidence for the importance of the gut and gut 
microbiome in influencing neurodevelopment and possibly causing ASD.  A 2017 study by Kim 
et al. demonstrated that in a mouse model, the composition of the maternal gut microbiome 
modifies the effect of maternal immune activation on the developing brain.  Treatment with a 
broad-spectrum antibiotic suppressed differentiation of Th17 Cells and ultimately secretion of 
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IL-17a, by wiping out bacteria that are responsible for promoting this inflammatory response.  
This in turn prevented development of ASD-like behavioral symptoms and cortical patches in the 
offspring, which typically occurs in this maternal immune activation mouse model166 (see Figure 
1a & b). T1his work has since been replicated by others167.  This research highlights the potential 
for the maternal gut microbiome and early-life infant gut microbiota to have critical effects on 
neurodevelopment, including incidence of ASD. 
Figure 1a.  Maternal immune activation leads to neurobehavioral abnormalities and 
cortical patches in mice offspring (Kim et al. 2017) 
 
Figure 1b.  Administration of antibiotic blocks the effect of maternal immune activation, 




Another way in which GI symptoms may be linked to ASD is through the behavioral 
consequences of having significant GI distress.  Gastrointestinal symptoms are likely to cause or 
exacerbate behaviors such as irritability, sensory sensitivities, anxiety, aggression, or even self-
injurious behaviors, particularly in an individual who is not able to communicate regarding the 
presence or nature of their GI symptoms.  Behaviors that are typically ascribed to ASD may 
sometimes may manifestations of underlying medical distress107.  Unfortunately, diagnostic 
overshadowing, or the process of misattributing symptoms to a mental disorder, can lead to these 
GI symptoms being under recognized and therefore undertreated168. 
 
Finally, having ASD may be a risk factor for the development of GI symptoms.  People with 
ASD are more likely to have a restricted, particular diet (e.g. avoiding entire food groups, eating 
only certain colors food, having dietary allergies or sensitivities) which can affect the health of 
their gastrointestinal system and lead to symptoms such as diarrhea, constipation, and abdominal 
pain135,169.  The presence of physical and mental health comorbidities, such as anxiety, 
depression, or seizures, and the medications taken for those conditions, may also affect the 
gastrointestinal system133.  
 
The various pathways by which ASD and GI symptoms/the gut may be associated are depicted 








Figure 2a.  Pathways by which ASD may lead to GI symptoms.  
  
Figure 2b.  Pathways by which the gut may lead to the development of ASD or comorbid 






1.4 Measurement of GI symptoms in ASD 
A serious obstacle to carrying out rigorous research on the gut-brain connection in autism is the 
lack of reliable and valid tools for the assessment of GI symptoms.  Because children with ASD 
in particular may have limited ability to self-report due to communication impairments, 
traditional approaches that query GI symptoms and distress may misclassify persons.  Valid tools 
for detecting GI symptoms in ASD will likely include behavioral indicators.  The importance of 
these types of indicators has previously been outlined, including in a 2010 consensus report by 
Buie et al. titled ‘Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals 
with ASDs: a consensus report107.’   
 
Currently, one single tool for assessing gastrointestinal symptoms in individuals with ASD has 
been assessed for psychometric performance126.  While the development and assessment of this 
tool meets a critical need in the field, limitations to this tool remain, including the limited 
assessment of dietary and mealtime factors, which are often related to gastrointestinal symptoms 
in individuals with ASD.  A reliable and valid questionnaire would enable comparisons of 
symptom estimates across studies, over time, following interventions, and with respect to risk 
factors.  Development of a standardized, reliable, and valid questionnaire will help reduce the 
influence of noise and bias on GI symptom estimates in observational and experimental studies.  
The field can then begin to understand what role the gut plays in ASD, if and how GI symptoms 
help distinguish between subgroups of individuals with ASD, and how these subgroups differ in 
terms of comorbidities and trajectories. 
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Clinically, it is also important to be able to better detect when individuals with ASD have GI 
symptoms.  In individuals who have difficulty communicating GI symptoms/distress to their 
parents/caregiver or healthcare providers, gastrointestinal disorders may go undetected and 
therefore untreated, exacerbating the distress for the person with ASD107, and leading to medical 
and psychiatric comorbidities. Being able to prevent or treat gastrointestinal symptoms can 
significantly improve the quality of life of someone with ASD.  
 
1.5 Statement of Problem and Motivation for Research 
Despite decades of evidence showing that GI symptoms are elevated in individuals with ASD, 
our understanding of the role of these GI symptoms, and the gut, in ASD is still in its infancy.  
Further, our ability to accurately measure GI symptoms and our understanding of how these 
symptoms manifest and affect the functioning of individuals with ASD is also limited.  In this 
dissertation, I took a tripartite approach to studying the gastrointestinal system/gut in ASD 
(Figure 3).  
 
Figure 3.  Tripartite Approach to 
the Gastrointestinal System/Gut 
in ASD 
 
First, I sought to better understand 
the experiences with and burden of 
GI symptoms in individuals with 
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ASD and their families.  Second, given the current state of measurement of GI symptoms among 
individuals with ASD, I worked to develop and evaluate a better GI symptoms questionnaire tool 
for use in research, and potentially also clinically.  Lastly, I pursued further evidence for a direct 
relationship between the gut and the etiology of ASD. 
 
The first motivation for this dissertation is that GI symptoms in ASD may significantly impact 
functioning of the child as well as the family, as well as increasing the risk for other co-occurring 
issues including behavioral problems, sleep problems, and psychopathology.  Sadly, less 
attention is paid to GI symptoms, as well as other comorbidities, because they are often 
attributed to the child having autism.  Therefore, individuals with ASD and GI symptoms 
typically do not receive the same evaluation and treatment as typically developing individuals.  
Further, ASD-specific issues such as communication impairment and, restrictive and repetitive 
behaviors, sensory sensitivities and aversions, and strong dietary reactions or sensitivities, may 
interact with the presentation, development, and impact of the GI symptoms.  Given this context, 
GI symptoms can significantly decrease the quality of life of a child with ASD.  The goal of Aim 
1 was to gain a deeper understanding of the issues children with ASD and their families face in 
regards to GI symptoms and to describe how GI symptoms can manifest in this population.  The 
qualitative data from this aim highlights the burden that GI and related issues face on individuals 
with ASD as well as their families, and emphasizes the importance of further work in this area.  
 
Next, because of the challenges associated with measurement, GI symptoms in individuals with 
ASD are more likely to go unrecognized.  Physicians are less likely to pursue full diagnostic 
assessments, and therefore individuals with ASD are less likely to receive treatment and the 
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same quality of care as their typically developing counterparts.  Further, the epidemiologic study 
of ASD, as it pertains to GI symptoms and the gut, is complicated and potentially biased.  In 
order to accurately assess the role that GI symptoms and the gut plays in 1) causing ASD, 2) 
influencing the safety, efficacy, and effectiveness of interventions/treatments, 3) responding to 
interventions, including CAMs, 4) and affecting and being influenced by co-occurring issues, we 
need to improve our assessment of GI symptoms.  This is the motivation for Aims 2 and 3.  The 
goal of Aim 2 is to describe the range of approaches to ascertaining GI symptoms and conditions 
in studies of ASD, and to assess how the variation in measurement approach is associated with 
GI symptom prevalence estimates.  The goal of Aim 3 is to develop a reliable and valid 
questionnaire that assesses gastrointestinal (GI) symptoms in children with autism spectrum 
disorder for use in epidemiologic studies. 
 
The last motivation for this dissertation is the possibility of the GI system/gut playing a role in 
the etiology of ASD.  Prior human and animal literature has documented differences in the gut 
microbiome of children with ASD, and has implicated early-life infections and maternal immune 
activation as risk factors for the development of ASD.  Recent animal work has shown that 
administration of an antibiotic (through affecting the composition of the maternal gut microbiota) 
at the time of MIA blocked the neurodevelopmental abnormalities that are typically seen in the 
context of MIA.  This has not been tested in humans however.  The goal of Aim 4 is to assess for 
interaction between maternal immune activation and antibiotic use during pregnancy on the 




1.6 Dissertation Aims and Outline 
This dissertation is organized into 6 chapters.  This introductory chapter provides an overview of 
the rationale for examining the link between the gut and ASD and provides an outline of the 
specific aims of this dissertation.  
In Chapter 2, the results of the Aim 1 qualitative study are presented.  I summarized the 
experiences of parents with a child with ASD and GI symptoms, describe how GI symptoms can 
manifest in this population, and highlight the burden that GI symptoms place in children with 
ASD.  
 
Chapter 3 describes the results of Aim 2 study, a literature review to describe the range of 
approaches to ascertaining GI symptoms and conditions in studies of ASD, and to assess how the 
variation in measurement approach is associated with GI symptom prevalence estimates.  
Epidemiologic studies of ASD including information on gastrointestinal symptoms/disorders 
were reviewed (years 1980-2017).  Recommendations were outlined for the critical components 
needed in a reliable and valid GI questionnaire. 
‘ 
Chapter 4 describes the results for Aim 3, development of a reliable and valid questionnaire that 
assesses GI symptoms in children with ASD, for use in epidemiologic studies.  I developed this 
questionnaire using two existing tools as well as new items, which I derived from the extant 
literature, an expert panel, and qualitative interviews with parents of children with ASD and co-
occurring GI symptoms.  I administered this questionnaire along with the Child Behavior 
Checklist (CBCL) to an online research registry of parents who have a child with ASD between 
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the ages of 3 and 17 years old.  I tested the questionnaire for reliability and validity and reported 
the psychometric characteristics. 
 
Chapter 5 describes results for Aim 4, assessing for interaction between maternal immune 
activation and antibiotic use during pregnancy on the subsequent risk of ASD diagnosis in the 
offspring, within an enriched-risk prospective birth cohort using electronic medical record data, 
extracted medical chart information, and a maternal postpartum questionnaire. 
 
Lastly, in Chapter 6, I summarize and synthesize the results of all these studies, discuss the 
implications of this work, and outline the next steps for research in this area.  The ultimate goal 
of this work is to improve the detection of GI symptoms in individuals with ASD, assess the role 
of the gut as a causal risk factor for the incidence of ASD, and to decrease the burden that GI 
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Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder consisting of two core 
domains of symptoms: social communication and impairment, and restricted, repetitive 
behaviors, interests, or activities1. Psychiatric and medical comorbidities are very common and 
contribute to the burden associated with having ASD2–4.   
 
Gastrointestinal symptoms, in particular, are prevalent among individuals with ASD; common 
symptoms include constipation, diarrhea, and abdominal pain5–26.  These GI symptoms typically 
co-occur with feeding issues including strong dietary preferences and sensitivities or allergies, as 
well as toileting problems such as delayed potty training, encopresis, and wetting the bed.  
Individuals with ASD who have GI symptoms are more likely to exhibit aggressive, irritable, 
externalizing, and self-injurious behavior; experience anxiety and mood problems; and, have 
other co-occurring psychological or somatic conditions27–37. 
 
Despite the high prevalence of GI symptoms in this population, there has been little research 
aimed at understanding the experiences of children with GI symptoms and pain or the resulting 
challenges experienced within families.  Sensory issues, impairments in communication, and 
restrictive and repetitive interests (including strong food preferences) common to ASD may 
interact with the GI symptoms to introduce new challenges and considerations to the evaluation, 
management, and burden in comparison to typically developing populations.  Thus while GI 
issues are associated with chronic pain and both psychiatric and non-psychiatric comorbidities38–
40 in general child populations as well, research done with typically developing samples of 
children may not generalize or be applicable to children living with ASD. 
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Qualitative research is a valuable tool for identifying the scope of an issue, capturing the 
complexities and nuances of human experience, and identifying targets for intervention 41.  
While prior qualitative research has examined food sensitivities, picky eating behavior, and other 
feeding challenges among children with ASD, these studies have only peripherally explored GI 
symptoms as co-occurring issues42–46.  To address this gap in knowledge, we conducted semi-
structured interviews to explore parents’ perceptions of their and their children’s experiences of 
gastrointestinal symptoms while living with ASD.  Specifically, we sought to understand how 
parents identify when their child is having GI symptoms or distress to aid in the development of 
a GI questionnaire for children with ASD (as discussed in Chapter 4).  Secondly, we wanted to 
gain a deeper understanding of the issues families and individuals with ASD face regarding GI 




One-on-one semi-structured interviews were conducted with parents of children with ASD.  
Parents were also given the option to have their child join the interview.  Participants were 
eligible if they were a parent or primary caregiver of a child with an ASD diagnosis who 
experienced GI symptoms anytime from the age of 3 to 17.  These interviews were initially 
designed to aid in the development of the item pool for a GI questionnaire for children with ASD 
(Chapter 4).  Social media outlets (e.g. Facebook), email listservs, and website postings were 
used to recruit individuals from advocacy groups and other ASD-centered groups.  Participants 
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received a $10 Amazon gift card for participating, as well as access to a free webinar for study 
participants describing study findings.   
 
2.2.2 Data Collection 
Interviews were conducted by the first author and took place either in person in a private location 
convenient to the participant (e.g. the participant’s home) or remotely via Zoom Video 
Conferencing Platform.  Interviews lasted approximately 30-45 minutes on average.  All 
interviews were audio-recorded with permission and transcribed, incorporating notes taken by 
the interviewer.  An interview guide was used that included the following key questions:  
1. What are the gastrointestinal issues your child currently struggles with or has struggled with 
in the past? 
2. What are things you notice about your child when they are having GI symptoms/distress? 
3. What are some signs/behaviors that you see? 
4. What areas related to GI issues have affected your family or your child’s functioning? 
We also asked follow-up questions and probed answers for more details.  Given the semi-
structure nature of the interviews, the exact language was adapted to each participant and simpler 
language was used when interviewing a child or person with cognitive impairment.   
 
2.2.3 Analysis 
The first author re-read all transcripts prior to analysis to familiarize herself with the whole of the 
data.  A directed content analysis was then conducted using the core questions to partially inform 
the identification of themes across interviews following a general inductive approach47,48.  We 
assigned quotes from the transcripts to themes.  References to potentially identifying information 
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were removed from any quoted text to preserve the anonymity of participants.  Because dietary 
issues by themselves have been thoroughly outlined in prior literature, we focused on themes that 
had to do with non-dietary issues. 
 
2.2.4.  Ethical Considerations 
The local institutional review board approved this study.  Informed consent was obtained from 
all parent participants prior to initiation of the interview.  To be present and participate in the 
interview with their parent, participants with ASD younger than 18 provided assent in addition to 
their parent providing permission.  Participants with ASD age 18 or older who participated with 
their parents consented for themselves, unless the parent or primary caregiver deemed their adult 
child unable to consent, in which case we relied on parental permission and assent as per the 
procedures for children under 18 with ASD.   
 
2.3 Results 
2.3.1 Participant Characteristics 
In total, twelve qualitative interviews were conducted: ten with mothers of a child with ASD and 
two with fathers.  Only two of the children with ASD participated alongside with their parent in 
the interview.  All but one parent was speaking about a child with ASD who was male, and the 
age range of the children with ASD at the time of the interview was 5-25 years old.  Nine of the 
interviews were in reference to children less than 18, though all of our interviews asked about GI 
symptoms in childhood specifically.  Participants lived in the Baltimore/Washington D.C. area. 
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2.3.2 Thematic Analysis 
Three overarching thematic categories emerged from the data: 1) indicators of GI symptoms/pain 
in children with ASD, 2) impact of GI issues on individual and family functioning, and 3) 
experiences with the healthcare system related to children’s GI symptoms.  Below we summarize 
each theme and provide illustrative quotes.   
 
Theme 1: Indicators of GI symptoms/pain in children with ASD 
Most parents reported that their child did not directly, verbally communicate that they were 
experiencing GI symptoms.  Rather, parents reported needing to rely on indicators or signals to 
identify when their child was in pain.  
 
“…It's hard you know, children, people with autism in general, [child name] does, I 
noticed others have a very high pain tolerance.  It's exceptionally high…he's more crabby 
or more irritable, more demanding.  Those are days that you would assume that he's just 
not feeling right…he's nonverbal and it's hard…it's like communicating with an 18 month 
old.” 
 This was often the case even for parents of high-functioning, verbal children, who still were 
described as having difficulties expressing or describing pain to their parents verbally.  
Sometimes, this might be that children could indicate the experience of some pain, but not fully 
describe what was going on to the point the parent could understand.  In other words, children 
themselves had difficulty understanding the nature of the symptoms or trouble communicating to 
their parent the type of GI symptoms they were experiencing. 
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 “He is verbal to the extent where he can talk to you about things but when something 
about his body or his feelings or anything that makes him uncomfortable, he doesn't have 
any words for it” 
“A lot of it felt like needles almost...Other times it just felt like pushing…outward kind 
of…”  [Child with ASD describing GI symptoms] 
“He gets angry.  Short, kind of semi belligerent with really basic questions, very atypical 
for him on a daily basis and then find out that he had just had to go to the bathroom.  
That's how he kind of presents.  But then if you ask him, “Do you need to go to the 
bathroom”…‘No, I'm fine.’” 
Parents discussed a variety of behaviors they observed in their child that alerted them to the 
possibility of GI symptoms.  These behaviors ranged from non-GI specific, e.g. irritability or 
sleep issues, to aggression.  Parents explained that they learned to identify these behaviors 
through trial and error, particularly by noting improvement in the behavior after the child’s GI 
symptoms improved.  For example, as one parent described: 
 “When he was feeling hurt [with gas in his belly] he wasn't just crying, but like kind of 
had this pleading look on this face…kind of like surprise and shock…I just was able to 
draw the connection because when I would rock him like that or soak him…he would 
pass the gas.  But there wasn't any trick, like he wasn't rubbing his tummy or he wasn't 
like pointing to it or you know…the only way I knew is probably trial and error.” 
“My very first cue was difficulties sleeping…He was upset…really upset…He was 
hardly sleeping…” 
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In some cases, the presence of GI symptoms was more obvious, because of symptoms such as 
bloating or gas.   
“…I think he would even act like his stomach hurt him, like you know holding his 
stomach…His stomach was bloated, like his stomach was very full always…He always 
had this big round the belly.  And he might even have said his stomach hurt from time to 
time.  He would complain of like ‘my tummy hurts.’” 
“Well he had them [GI symptoms] starting as a baby.  And so I mean something as 
simple as putting my hand on his stomach, I could feel everything moving and 
growling...he would pull his legs up and scream.  I mean he had severe gas.  They tried to 
work on a lot of that to no real avail.  And so you could you could see it in his 
movements…Sometimes I would have to bring him to the doctor and they would 
basically have to assist because it would become so dried out [stool] that it would no 
longer move through his system.” 
Parents shared that in some cases of extreme GI distress; their child would act very aggressively 
or violently, either to themselves or to others. 
“…When the police had to come because she was destroying a lot, she would tell them 
‘my tummy hurts’...anxiety seems to have a direct reaction.  Whatever it is that is 
upsetting her seems to manifest itself in her stomach.  And that's when she acts out….  
When the stomach hurts, there's an almost immediate physical reaction.  She could 
scream, she could throw things.  And after she calms down then she tells us 'My tummy 
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hurts'.  Every time the police had to come out because she was really being destructive, 
first thing she would say as she regained her composure was 'my tummy hurts'.   
“The only way I can really tell to be honest is that his behavior just is very radically 
aggressive and violent.  Or if he doesn't want to sit down.” 
“…When my tummy hurts I hit my head.”  [Child with ASD] 
“…He has [number of siblings]…when he is violent when he's constipated, I cannot 
always protect them.  I had to teach them, if he is looking like he's going to hurt them 
they need to get away and be safe.  Because at school he has many more people to his 
one's self than I am…  
Lastly, a child’s prior experiences with GI symptoms were described as contributing or 
potentially exacerbating future symptoms.  For example, one parent noted “…withholding the 
stool I think is because he must have gotten constipated and then had a painful stool one time.”   
 
Theme 2: The impact of GI issues on functioning among children with ASD and their 
family 
Parents shared that the child’s GI symptoms affected multiple domains of the child’s life, as well 
as the family’s overall functioning and wellbeing.  One of the major domains of life affected by 
the child’s GI symptoms was his or her ability to attend and stay in school.  Parents noted 
challenges with getting their child out the door in the morning because of toileting issues.  
“It affects the ability for him to get out of the house and leave in the morning.  So it was 
very stressful for him and for us you know you get up early and it might take him…two 
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hours or one day it might be right away and another day is you know three hours or 
…gets there [school] and he's in the bathroom.  And there are definitely behaviors 
associated with the frustration of having stomach pain and having nobody be able to fix 
that.” 
In addition, parents mentioned having to pick up their child from school because of GI symptoms 
or accidents.  For example:  
 “School will call and just say things like 'you know he just doesn't feel well today.  He's 
been in the bathroom a lot too.’  And I just throw in the towel and I go get him.  That's all 
you have to say, we're going to come get him.” 
One family noted that their choice of school was influenced by the presence of their child’s GI 
symptoms.  
“…He ended up in a special school… because his combination of disabilities including 
autism was so severe that…our school system did not have a particular program for him.  
And the gastrointestinal actually was one of the major problems they were having 
because you know they did not have a one-on-one to sit in the bathroom with him while 
he had to sit there for 30 minutes or more.  So they decided he needed to be in a special 
school.” 
In addition, while at school, children’s’ GI symptoms were described as affecting their ability to 
focus and learn.    
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 “It will inhibit his ability to go out and do things sometimes because he can't stay off the 
toilet all day.  It affects his behaviors...I think it affects his ability to learn at school 
because he feels so rotten.” 
 “When he is not right in his gut, He is not right and the whole world isn't right… now 
that I think about it a lot of his behavior and his issues really crop up when he is 
constipated and he will get in trouble more.  He will lose privileges.  He will get low 
point chart numbers from school.  So I mean it impacts his daily life because of his 
behavior changes.  And he's also sometimes afraid of going to the bathroom at school 
because he knows that sometimes his bowel movements are rather large and he doesn't 
not want to clog the potty.  And he has had the janitor have to come and unclog it and I 
think that was really, really embarrassing” 
Children also expressed to their parents embarrassment about going to school having GI 
symptoms.  One parent stated that at school their child ‘might really need to go to the bathroom 
and maybe there's a way that …someone could go and be his bathroom buddy or something.  
Just to make it more comfortable for him.” 
Aside from school, GI symptoms also affected the child’s likelihood to engage in social or 
extracurricular activities. 
 “…On good days she enjoyed going out and participating.  On days where her tummy 
hurts sometimes she doesn't even want to go out.” 
“…You will observe certain days that you know he's just not into his preferred activities.  
He'd rather lay down…” 
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Parents reported that the entire wellbeing of the household was affected by the child’s GI 
symptoms.  The severe pain and distress that accompanies severe GI issues causes not only pain 
for the child with ASD, but also pain and trauma for the family overall.  
 “ Well with the constipation…he'll start screaming or start crying or start breaking out 
into a sweat.  Yeah I mean he's just inconsolable in pain.  I sort of figured out how to get 
him through it.  There is only one time where I was like …‘Do I have to call the 
emergency room?’  But every other time it's kind of taken about 30 to 45 minutes where 
we figured out a way to get it out of him….  [he is] a wreck…crawled up into a ball and 
it's just awful…it's traumatic for everybody.” 
“…I cannot always give him the support he needs…so it hugely impacts what kind of 
temperament the household has.” 
“…Trying to administer things like suppositories or things that we know he didn't 
like…it's painful as a parent to have to try and do something that's uncomfortable or out 
of the norm to your child just because you know they don't really care for it” 
“…Not only are we trying to deal with him and his problems and you know come up with 
new foods and eliminate … but we're also arguing with everybody… the school…kind of 
arguing with the doctors who think we're exaggerating…we're arguing with family 
members who are thinking you're just being you know helicopter parents ...ruins our 
whole family life but also disturbs his sleep.  You know everything.  So you know it puts 
a lot more tension on the entire family.” 
 51 
A particular area that was affected by the child’s GI symptoms was the ability to go out as a 
family, because of symptoms like diarrhea, or because of the child’s special dietary needs or 
strong food preferences. 
“The sensory issues around eating used to stress us out like crazy…it's really hard to go 
out to restaurants with him because it just depends on his mood.  And sometimes 
Mommy doesn't want to cook.  We want to go out and treat ourselves or something…We 
kind of figured out what time of best, and what type of restaurant is best as far as not 
being too loud and noisy...Puts a damper on everybody's well-being when you can't 
always eat out and we have to factor in the wait time for getting seated and for how long 
it's going to take to get the food on the table.” 
“…If he really has you know the diarrhea we you know we just can't go anywhere.  And 
he won't wear a pull up…. a lot revolves around him in our house.  Around his toileting.” 
“…You know wanting to not go anywhere or do anything until we could resolve it…” 
Lastly, parents also reported financial stress associated with the child’s GI symptoms or noted 
spending a lot of money on GI-related interventions. 
 “…He's almost 10 now.  I don't have the resources anymore to go see the doctors that 
don't take insurance and to try the therapies my insurance isn’t going to cover…we're still 
paying for all of the other stuff we did.  And I can continue to dig our family into a hole 
which causes a different kind of stress…There's almost an acceptance sort of issue 
happening now…Do we just have to accept that this is the way things are going to be for 
him…” 
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“Oh God.  We spent so much money on probiotics.” 
 
Theme 3: Experiences with the healthcare system. 
 
The last core theme identified from the interviews related to the experience of families with the 
healthcare system regarding their child’s GI issues.  While some parents reported satisfaction 
with a particular provider or health care setting (“…Liked them both...  I think they were really 
good at what they do…”), parents tended to have negative experiences when seeking medical 
help for their child’s GI symptoms.   
One of the frustrations parents had was with the long wait time between making an appointment 
and seeing a provider, and relatedly, with the shortage of providers.  
 “The time lag is horrendous.  I don't think there are enough GI doctors who get this…So 
that's my frustration is that the lag time…it takes, you know, weeks to get the 
appointment.” 
One parent noted that these long ‘lag times’ play a role in the promotion of complementary and 
alternative medicine use for GI symptoms among families with a child with ASD.  Another 
strategy to cope with these lags included the sharing of information among parents:  
“...So there's a lot of a lot of parents who [say] ‘This happened to me and this is what I 
did.  Maybe try it because like how bad could it be.’  To have them do a cleansing and 
see if a reset helps.  I mean you don't really need a physician for that.  Check with your 
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pediatrician; see if it's OK.  So there's a lot of parent advocacy and sharing of information 
because the lag is bad.” 
Parents were also frustrated with financial obstacles, and in particular, insurance companies and 
the many steps it takes to get approval to see a provider. 
 “A lot of it is the insurance company.  Because so many things of what you do with 
these children are not covered by insurance.  Providers don't take insurance, you have to 
bill it on your own.  And the insurance company is a huge aspect in all of it…” 
“I guess there's financial obstacles that a lot of the treatments are not necessarily 
traditional treatments and would be outside of the scope of your traditional health care 
coverage.  So basically you would generally have to go out of pocket because it's not 
going to be approved under your typical medical ...There's usually 30 steps you go 
through…[to] get a referral.” 
Another challenge in seeking healthcare is that office setting environments in general are not 
generally accommodating to children with ASD and staff and medical professionals are not 
trained in how to care for these children.   
 “A lot can be attributed to the setting of offices.  A lot of these gastrointestinal and any 
other physicians that we've seen they have these huge practices.  The waiting rooms are 
loud and noisy and full of fluorescent light...just being in the building is hard.  “ 
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“There's sensory issues, there's medical and there's practical issues that you know it's 
dragging a 6 year old with severe autism to doctors appointment after doctors 
appointment.  They don't sit quietly…it's hard to do.” 
“I've brought him places and they have looked at his behavior just as we walked in the 
door and said you know ‘we cannot provide service.’  He's throwing furniture in doctors 
offices...If the waiting rooms weren't so big and so crowded and it didn't take so long to 
get in and the little room didn't take so long to see the doctor…I feel like you know all of 
the courage that he brings to the doctor's office wears off by the time the doctor gets 
there.” 
An additional challenge for the parents was how to physically get the child to the office visit.   
“…It's driving a six year old son with severe autism to do it…and then when you go to 
these places and have to go somewhere that they’ve never been before and they're not 
happy about it and then you're waiting an hour…just the emotional physical toll it takes 
on you.  To what end.  And then you know then what do they need…they need blood 
work and I don't know if you're familiar with what it's like to get blood from a child 
severe autism but…you would literally need to gas my child in order to get blood.  So it's 
like what what's the point… if there's just so little in the way of what can be done.” 
Parents shared strategies that they used to cope with the environmental challenges associated 
with these GI appointments.  For example, one parent stated, “…You need to have the ability to 
maybe have a quieter space to get to prep your kid.  They need to prep the hospital and the 
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nurses like ‘this isn't going to be like your regular 15 year old’.  You know we need to do a little 
sedating on the way…” 
Lastly, a critical concern is that parents felt they were not taken seriously due to their child 
having ASD.  Further, they felt that providers were not used to seeing complex medical cases 
like the ones their children have.  Parents expressed wanting to find someone who is curious 
enough to dig deeper and help them find solutions for their child. 
 “A lot of physicians seem uninterested...It's sort of like ‘your child has autism.  This 
goes with it.’” 
“…It feels like we have to push to even get them [the physicians] to test…” 
“ ...  I haven't found anyone yet who curious enough yet to be willing to dig a little 
deeper...There are times I wish I hadn't told them he had autism.” 
“I just want someone to care.  I just want someone to like look me in the eye and say ‘I'll 
help you find it’…and I haven't found that person yet.” 
“I think that some of the issues that happen are more complex and they are expecting a 
child to come in with a fever and you know figure out the cause of that fever and whether 
or not they require medication.  And that's the end of it.  We have a lot of ongoing issues 
and things that may affect other things and it's just more complex.” 
2.4 Discussion 
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In this qualitative study, we explored three key categories of experiences related to GI symptoms 
experienced by children with ASD: 1) indicators of GI symptoms, 2) impact of GI symptoms on 
the child’s and the family’s functioning, and 3) experiences with the healthcare system.   
 
Related to how parents learned or could identify that their child with ASD had GI symptoms, 
typically this was not through child self-report, either because of general communication deficits 
or an inability to describe what symptoms felt like even among highly verbal children 7,19.  This 
was confirmed in our qualitative interviews, in which parents described the sorts of behaviors 
they use to identify when their child is in distress.  Although these behaviors are non-specific and 
could indicate a host of underlying medical or psychiatric problems, they are useful as a signal 
that something is awry, and therefore deserve attention.   
 
In some instances, parents shared that these GI symptoms made their children very aggressive or 
violent, to the point of having to call police or advise other siblings to stay away from the child 
with ASD.  It’s important to note that people with mental illness are much more likely to be 
victims of violence than to perpetuate49.  The findings of this study, however, remind us that acts 
of aggression or violence may be indicators of severe pain or distress, and underlying medical 
issues need to be assessed as possible causes of these serious behaviors.  Self-injurious behavior 
is also, unfortunately, common in ASD, and again, may point to distress due to a medical 
problem50–52.  This should be considered in the context of emergency response and de-escalation 




The second major theme that emerged from the qualitative interviews was the impact that the 
child’s GI symptoms have on their own functioning as well as the functioning and wellbeing of 
the family unit.  A major focus of parents’ discussion of this topic was around the challenges that 
GI symptoms posed for the child’s ability to go to school and learn.  
 
School challenges, and absenteeism in particular, have been associated with GI disorders and 
other medical conditions have been described in literature focused on typically developing 
children53–58.  The high prevalence of GI symptoms in children with autism, with the evidence 
that these symptoms impair the quality of their education, begs for more research and more 
importantly, interventions that support children with GI issues by promoting accessibility.  
Qualitative interviews showed that social and extracurricular activities were also affected by a 
child’s GI symptoms.  Prior research demonstrates that children with ASD are less likely to 
participate in social, extracurricular or leisure activities, and that sensory, mental, behavioral, and 
motor issues influenced likelihood of participation59,60.  Addressing GI-related challenges may 
encourage children with be more involved sand remove barriers to participation. 
 
GI symptoms also had an important impact on the overall functioning and wellbeing of the 
family, and in particular, the ability of the family to leave the house, the family’s stress level, and 
the family’s financial wellness.  Elsewhere in the literature, strong dietary aversions or special 
diets that are common in ASD have been shown to play a role in influencing the family’s 
activities61,62.  This study demonstrates that a child’s toileting problems may also dictate the 
activities their families can pursue.  This highlights not only the need for respite, but also for 
accessible locations for families who have a child with ASD.   
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Financial health can also be affected by GI issues.  Aside from costs due to seeing medical 
providers, some families reported high costs of exploring complementary alternative medicines, 
including special diets and probiotics.  This last finding stresses the importance of better 
understanding the safety and efficacy of complementary and alternative treatments, as over 70% 
of families with a child with ASD report using a CAM63. 
 
The last main theme of this qualitative work was the negative experiences that families with a 
child with ASD and comorbid GI symptoms often faced when seeking care.  Some challenges 
were not necessarily unique to ASD, such as the long wait-times between receiving an 
appointment and seeing the physician, or dealing with financial stress and complex insurance 
systems.  However, some obstacles were specific to ASD or greatly increased in this population, 
for example difficulties in bringing their child to a medical appointment.  One parent in our study 
noted that their child was denied service immediately upon walking in because of his ASD 
symptoms.  
 
Perhaps the most disturbing obstacle that parents faced when attempting to resolve their child’s 
GI symptoms was the issue of not being taken seriously by medical professionals.  This is not the 
first qualitative study of autism parents to share these sentiments.  In a qualitative study of 
feeding challenges in children with ASD, a mother felt that her child’s symptoms were viewed as 
behavioral problems due to autism and perhaps even dismissed by medical professionals for this 
reason.  Another mother in that study who sought medical help for their child’s GI issues also 
felt dismissed, explaining that her son’s autism diagnosis meant that he was not regarded as a 
child with a physical illness.46 
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To our knowledge, this is the first qualitative study to explore family experiences with having a 
child with ASD with GI symptoms.  Our study is limited, however, in that it examined GI 
symptoms in childhood, since it was in part designed to aid in the development of a GI 
questionnaire for children with ASD.  Future work needs to include adults with ASD and inquire 
about GI and related symptoms across the life course.  We also did not have as many individuals 
with ASD participate in the interviews, as we would have liked.  Future analyses would benefit 
from a greater inclusion of individuals with ASD if possible. 
In this qualitative study of children with ASD and GI symptoms, we summarized indicators of 
GI symptoms or pain, described how GI distress impacts the functioning of the child and the 
family, and demonstrated that families often have negative encounters with the medical 
community as they seek to alleviate their child’s GI symptoms and pain.  Findings from this 
qualitative study stress the importance of better understanding the landscape of GI-related issues 
in individuals with ASD, including the importance of accurate measurement of symptoms, the 
association with co-occurring mental and physical health issues, use of medical services as well 
as complementary and alternative medical treatments.  GI symptoms in children with ASD place 
an incredible toll on the wellness of both the child and also the surrounding family.   
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In his seminal paper first describing autism, Leo Kanner noted that 6 of the 10 children with 
autism “presented severe feeding difficulty from the beginning of life”1.  Since then, many 
studies have explored the association between autism spectrum disorder (ASD), gastrointestinal 
(GI) symptoms, and diet2–5.  The argument that individuals with ASD have a non-healthy gut 
stems from the apparent increased prevalence of GI symptoms, as cited widely in the literature 
since Kanner’s 1943 paper6–9.  For example, a study published in 2014 reported that 13% of their 
ASD sample had current frequent diarrhea, compared to 6.1% in the developmental delay group 
and 1.6% in the typically developing group9.  Other symptoms were elevated in ASD as well, 
though they were not statistically significantly different across groups.  Although five 
questionnaires (Autism Treatment Evaluation Checklist (ATEC) subscale, Autism Treatment 
Network (ATN) Gastrointestinal Symptom Inventory, Childhood Autism Risks from Genetics 
and Environment (CHARGE) Gastrointestinal History Questionnaire, Parental Concerns 
Questionnaire, and ATN Diagnoses and Problems form) that query GI symptoms have been 
designed for the ASD population, to our knowledge none have been formally assessed for 
validity10.  Therefore, the true prevalence of various GI symptoms in this population is unknown.   
 
Epidemiologists and experts in pediatric gastroenterology have recognized many limitations in 
the interpretation of published studies on the epidemiology of GI problems among children with 
ASD.  In a report from a 2009 symposium of the North American Society of Pediatric 
Gastroenterology and its follow-up workshop, Coury et al. noted the very wide range of 
prevalence estimates of GI disorders in ASD, and recognized several methodological limitations 
among the studies11.  These included retrospective study design and inappropriate control groups, 
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which potentially lead to measurement error and bias; enrollment of groups of children with 
ASD that are clinically heterogeneous, which generates wide estimates of symptom prevalence; 
bias in case selection, which may make the sample appear to have more or less symptoms than 
the underlying target population; as well as reliance on parent report of symptoms, which may 
provide incomplete or biased information, especially when symptoms are not defined precisely. 
 
Buie et al. published a consensus report from a multidisciplinary panel on the evaluation and 
treatment of GI disorders and symptoms among people with ASD10 noting the wide variability 
among prevalence estimates, and recommended the use of “validated instruments and outcome 
measures”.  The authors further noted that GI symptoms may contribute to problem behaviors 
among people with ASD, and that the problem behaviors may complicate the clinical recognition 
of GI disorders. 
 
Ascertaining accurate estimates of GI symptoms in children is a challenging issue in general.  
For example, while the Rome II criteria for functional constipation required at least 2 weeks of a 
defined type of stool “for the majority of stools” or another type of stool “2 or more times per 
week”12, the North American Society of Gastroenterology and Nutrition (NASPGHAN) defined 
constipation in terms of the timing of and the distress caused by defecation, present for at least 2 
weeks13.  Van den Berg et al. found that while some studies used these recognized, albeit 
disparate, criteria, other studies created their own criteria.  They postulated that “it is unlikely 
that parents have comparable notions regarding constipation or about what constitutes normal 
bowel habits in children,” and that both these sources of heterogeneity (the variety of definitions 
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and the variability of parental perceptions) contributed to the wide range of prevalence observed 
in their review of the literature14. 
 
However, these measurement challenges are compounded when assessing GI symptoms among 
children with social and communication difficulties, such as those with ASD.  Even among 
neurotypical children, there can be low concordance between child and parent on intensity of 
pain/discomfort (children tend to rate pain/discomfort as more severe), pain during bowel 
movements, holding bowel movements, and heartburn, among others.15 This low concordance 
may be more pronounced in younger age groups.  Because studies of ASD usually rely on proxy 
respondents, it is likely that frequency estimates of GI symptoms and pain are biased in this 
population, and may be more biased among children in the younger age groups or with more 
severe autism.  Other populations with neurodevelopmental disabilities such as cerebral palsy 
(CP) have experienced similar challenges in assessing the presence of GI symptoms.  Early 
studies in CP used their own questionnaires and for children the questionnaires were filled out by 
parents16,17.  A recent study among adults with CP used a combination of questionnaires in a 
two-step process18, specifically a questionnaire based on Rome III criteria and, if the criteria for 
constipation were met, then the Patient Assessment of Constipation-Symptom Scale; this study 
had the advantage of asking adult participants for information about their own bowel habits.  For 
this review, we focused on ASD, since this population has been a primary target of 
complementary alternative therapies that aim to heal the gut and prevent or treat ASD, as well as 
research attempting to prove vaccines cause ASD through a damaged gastrointestinal system.  
All of this research rests on having an accurate measure of gastrointestinal symptoms.  The 
implications of not having a reliable and valid assessment tool for GI symptoms are especially 
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critical for the ASD population given the vulnerability of this population to potentially unsafe, 
ineffective interventions.   
 
It is important to better understand the range of GI measurement approaches and their influence 
on symptom prevalence estimates in order to: a) accurately capture the prevalence of various GI 
symptoms, b) assess the safety and effectiveness of interventions on GI symptoms, and c) 
understand risk factors for and trajectories of ASD. 
 
The aims of this study were to 1) describe the range of approaches to ascertaining GI symptoms 
and conditions in studies of ASD since 1980, 2) describe the range of estimates of prevalence 
across studies, and 3) assess how the variation in measurement approach is associated with GI 
symptom prevalence estimates.  Lastly, we outline the critical components needed in a GI 
questionnaire, and hope that this review will provide insight that will help in the creation or 
modification of a reliable and valid tool for measuring GI symptoms among individuals with 
ASD.   
 
3.2 Methods 
We carried out a literature review; not a formal systematic review.  However, we followed many 
of the best practices of PRISMA guidelines including explicit search criteria, inclusion/exclusion 
criteria, standardized extraction of the same fields, and resolution of extraction discrepancies 
across two reviewers.  These are described in detail below. 
 
 74 
3.2.1 Search Criteria 
PubMed was used to find all studies published from 1/1/1980 to 1/31/2017, with a title including 
“Autism”, “Autistic”, “ASD”, “Pervasive Development*”, or “Asperger*”, and with Medical 
Subject Headings terms “Gastrointestinal Disease" or "Signs and Symptoms, Digestive”, or one 
of the following terms in the text: “gastrointestinal”, “gastric”, “gastritis”, “gut”, “GI”, 
“intestine*”.  Reviews and articles not written in English were excluded.  This search returned 
386 studies.  The asterisk (*) returns words that begin with the word truncated by the asterisk.   
 
3.2.2 Exclusion Criteria, Information Extracted 
From these 386 studies, exclusion criteria were: a) having fewer than 10 diagnosed “case” 
participants (ASD, PDD, etc.)  (n=38); b) not ascertaining GI symptoms or diagnoses (n=66); c) 
animal studies (n=32); d) containing no data (n=3); e) including Andrew Wakefield as a coauthor 
(n=11); and f) review articles, hypothesis papers, meta-analyses, narratives, editorials and 
mathematical model papers (n=92).  Andrew Wakefield et al.’s 1998 Lancet paper19, which 
suggested the measles, mumps, rubella vaccine predisposes to behavioral regression, was 
retracted in 2010 due to incorrect elements of the paper as well as ethical violations.  It was later 
discovered that Wakefield et al.  had conducted fraud by picking data that agreed with their 
hypothesis20.  The claims made in the original paper continue to have lasting effects on 
vaccination rates21.  For these reasons, we chose to omit studies on which he was a coauthor.  As 




Figure 1.  Exclusion Flowchart, from Initial 386 Studies to Final Sample of 144 Studies. 
Figure 1 depicts the exclusion flow chart, beginning with 386 studies that were returned from PubMed.  After 
applying our exclusion criteria, 144 studies remained in the final sample of studies we reviewed. 
 
Information was extracted from each of 144 studies by one of two authors (CH & CN).  Both 
authors examined a subset of the studies, and questions regarding any study were resolved 
together.  Information extracted included study design, demographic information, ASD 
diagnostic criteria, and characteristics of data-collecting methods.   
 
3.2.3 Prevalence Estimate Subset 
Of the 144 studies, a subset was identified that contained prevalence estimates, in order to 
summarize GI symptom prevalence estimates across studies.  Studies were excluded if: entry into 
the study, or the sampling frame, was based on the presence or absence of GI 
symptoms/disorders (including GI-related medical comorbidities) (n=20); the study 
included/excluded participants based on diet (n=2); the study was experimental (n=26); or the 
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study did not report GI symptom/diagnosis estimates (n=12).  The flowchart shows these 




Figure 2.  Exclusion Flowchart, Resulting in the Prevalence Estimate Subset of 84 Studies. 
Figure 2 depicts the exclusion flow chart, beginning with the 144 studies that we reviewed.  After applying our 
exclusion criteria, 84 studies remained in the final sample of studies from which we summarized the prevalence 
estimates of GI symptoms.   
 
From the 84 studies that qualified to be included in the prevalence estimate subset, we extracted 
proportions of various GI symptoms and noted whether GI symptoms were assessed at more than 
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one time point in the study.  We summarized the proportions across studies for diarrhea, 
constipation, abdominal pain/discomfort, nausea/vomiting, bloating/flatulence, reflux, 
soiling/incontinence, and difficulty/pain while stooling.  We also summarized non-specific (did 
not refer to a specific symptom) or aggregate (referred to more than one symptom) variables, 
such as “gut complaints”, “any symptom”, or “had either diarrhea or constipation”.  For studies 
in which there were subgroups, such as children with/without language regression, or when there 
was more than one time point, we took the average across these subgroups.  Studies that used 
scores or mean number of symptoms, rather than percentages, were excluded when calculating 
the summary prevalence measure.   
 
We assessed relationships between GI symptom proportions and various study characteristics 
using ANOVA tests.  We estimated the association between the mean proportion for each GI 
symptom and each study characteristics of interest (age, geographic region, publication year, 
diagnostic category, primary goal of study, type of study sample, study design, who reported the 
symptoms, and type of questionnaire).  P-values less than 0.05 were considered statistically 
significant.  All statistical analyses were performed using RStudio Version 0.98.10912223.   
 
3.3 Results 
3.3.1 Characteristics of Studies  
Study characteristics are summarized in Table 1.  The number of study participants ranged from 
10 to 4927 individuals (median 73).  The source of study participants was clinic-based in 57 
studies, population-based in 18 studies, both clinic- and population-based in 1 study, enriched-
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risk in 2 studies, and in 66 studies, insufficient information was provided to determine the source 
population.   
 
There were 62 case-control studies, 48 cross-sectional studies, (15 of which included a 
comparison group), 25 experimental studies, 6 cohort studies, and 3 with mixed study designs.  
One hundred and sixteen studies were observational in nature, 25 were experimental, and 3 had 
both observational and experimental components.   
 
The primary goals of the studies were to: 1) assess the relationships of GI symptoms and 
conditions with any other variable (n=51); 2) compare GI symptom estimates among groups of 
participants (e.g. ASD, Developmental Delay, PDD-NOS) (n=24); 3) assess outcomes of 
experimental treatments (n=24); and 4) other primary goal (n=42).  Three studies had both 
primary goals of comparing prevalence estimates as well assessing associations between GI 
















Sample Size 73 (10-4927) 
Type of study sample 
 Clinic-based  57 (40%) 
Population-based  18 (12.5%) 
Clinic-based & Population-based  1 (0.7%) 
Enriched-risk  2 (1.4%) 
Other, or insufficient description 66 (46.0%) 
Study Design 
 Experimental  25 (17.4%) 
Cross-sectional  33 (22.9%) 
Cross-sectional with comparison group  15 (10.4%) 
Case-control  62 (43.1%) 
Cohort   6 (4.2%) 
Mixed designs  3 (2.1%) 
Primary goal of study 
 Obtaining estimate of GI symptoms/comparing across  
Outcomes 24 (16.7%) 
Associating GI symptoms with other variable  51 (35.4%) 
Obtaining estimate of GI symptoms/comparing across  
outcomes and Associating GI symptoms with other  
variable 3 (2.1%) 
Intervention effect on outcomes  24 (16.7%) 
Other  42 (29.2%) 
Region of Sample 
 Africa  2 (1.4%) 
Asia 10 (6.9%) 
Europe  22 (15.3%) 
Oceania  8 (5.6%) 
South America 1 (0.7%) 
United Kingdom  12 (8.3%) 
US/Canada 89 (61.8%) 
Race/Ethnicity (among US/Canada, UK studies) 
 All white, majority white 46 (45.5%) 
Mostly Latino/Hispanic  3 (3.0%) 
Not specified  49 (48.5%) 
No distributions provided 3 (3.0%) 
Age categories, median of means (years) 
 <2 0 (0%) 
2-5 9 (10.3%) 
5-12 68 (78.2%) 
 80 
13-18 5 (5.7%) 
18+  5 (5.7%) 
Missing 57 (39.6%) 
Diagnostic Categories 
 DSM III-Ra 1 (0.01%) 
DSM IVa 73 (50.7%) 
DSM Va 6 (4.2%) 
ICD-9 (but no DSM code) 5 (3.5%) 
ICD-10 (but no DSM code) 11 (7.6%) 
ICD-9 and ICD-10, but no DSM code 1 (0.01%) 
No DSM or ICD code reported, but used ADI-R and/or  
ADOS 23 (16.0%) 
No DSM or ICD code, or ADI-R and/or ADOS, but used  
Medical Record 1 (0.01%) 
Other, Not Specified 23 (16.0%) 































3.3.2 Demographic Information 
Of the 144 studies, 61.8% were conducted in the United States or Canada, 15.3% in Europe, 
6.9% in Asia, with a smaller proportion in the United Kingdom (8.3%), Oceania (5.6%), Africa 
(1.4%), and South America (0.7%)  (Table 1).  Of the 101 studies in the US, Canada, or UK, 
over half (51.5%) did not report the race/ethnicity composition of their study sample.  Among 
the 49 studies that did report race/ethnicity, 94.0% of them included exclusively white 
participants or a very small proportion of participants were non-white.  The ages of participants 
ranged from <1 to 64 years old.  The median age within studies ranged from 4.5 to 36 years, and 
the median age (median of medians) across studies was 6.7 years (Table 1).  Of the 87 studies 
that reported age, nine (10.3%) had a median of means between the ages of 2-5 years, 68 studies 
(78.2%) between ages 6-12 years, 5 studies (5.7%) between the ages of 13-18 years, and 5 
studies (5.7%) ages 18 or older.   
 
3.3.3 Diagnostic Classification of ASD Individuals 
Studies used a variety of methods to diagnose ASD.  Most studies either relied on prior 
assessment of ASD by a practitioner (sometimes with written verification) or assessment with 
the ADI-R, ADOS, or Mullen.  Some studies relied on parent interviews as well as observation 
by a clinical team involving psychologists, psychiatrists, and/or developmental pediatricians.   
 
A variety of diagnostic classifications were used among studies.  Most studies required that 
participants meet DSM-IV criteria for Autistic Disorder, with or without including Asperger’s 
Disorder or PDD-NOS (n=73, 50.7%), or DSM-V criteria for Autism Spectrum Disorder (n=6, 
4.2%), and one earlier study used DSM-III-R (0.01%).  These studies may or may not have used 
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an ICD code in addition to DSM codes.  Sixteen studies (11.1%) used an ICD code but did not 
use a DSM code.  In addition, twenty-three (16.0%) studies did not report the specific DSM or 
ICD diagnosis but did use the ADI-R or ADOS.  Twenty-three studies (16.0%) did not use ADI-
R or ADOS and did not report a DSM or ICD diagnosis (Table 1).  One study relied on medical 
records for diagnosis without specifying DSM or ICD category (0.7%).   
 
3.3.4 Methods of Ascertainment of GI Symptoms and Conditions 
Studies used the following methods to assess GI symptoms or diagnoses: 83 of 144 studies used 
questionnaires administered exclusively to parents or caregivers; 3 used questionnaires 
administered to either parents/caregivers or teachers; 6 used questionnaires administered to 
parents/caregivers or to the individuals with ASD themselves (Table 2).  Only 18 studies used 
both questionnaires administered to parents/caregivers and also information from a professional 
medical source (8 from physicians and 10 from medical records).  Of the 8 studies that involved 
a physician in the ascertainment of GI symptoms, only one mentioned that the physician was a 
gastroenterology specialist24.  Medical record studies may have depended on GI specialists, but 
often who diagnosed the medical condition was not specified.  Of the 8 studies that involved a 
physician, 3 mentioned that some participants also underwent endoscopic procedures.  Two of 
these studies described that a portion of participants had undergone endoscopy and/or 
colonoscopy in their initial GI evaluation, independent of the study.  In one study25, about 17% 
of individuals underwent endoscopic procedures (half of which showed pathologic results), and 
in the other study26 15% underwent both an endoscopy and colonoscopy as well as a biopsy of 
GI mucosa.  The third study24, also the one that incorporated a GI specialist, stated that 
endoscopic procedures were performed when clinically relevant, as part of the study.  Thirty-
 83 
give percent (35%) of children with ASD and GI dysfunction underwent an 
esophagogastroduodenoscopy, 7.5% received a flexiblesigmoidoscopy, and 10% received a 
colonoscopy.   
 
Fifteen studies used medical records exclusively.  One study used claims data.  Eighteen studies 
(12.5%) did not clearly specify who reported the GI symptoms or diagnoses (Table 2); 9 of these 
18 studies used a questionnaire, although who filled out the questionnaire was not clear. 
 
Of the 119 studies that used a questionnaire, 68 created their own instrument (i.e.  a 
questionnaire never used before in other studies), while 51 studies used or modified an existing 
instrument.  Three of the 68 studies that used their own approach noted that their method was 
informed by the literature, in particular the consensus report on GI disorders in people with ASD 
by Buie et al10.  The questionnaires that were used the most often were the Rome II (n=4) or III 
criteria (n=12), The Gastrointestinal Severity Index (Schneider)27 (n=5), the Autism Treatment 
Network Gastrointestinal Symptom Inventory6 (n=3) and the Bowel Symptom Questionnaire 
(Smith)28 (n=3) (Table 2).  Symptom diaries (concurrent daily or weekly observations) were used 
in 9 studies.  Supplementary Table 2 lists which studies used which questionnaires.
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Table 2.  Measurement Approaches Across Studies (count) 
 N=144 Studiesb N=84 Studiesbc 
Respondent of GI Symptoms/Diagnoses 
  Parent/caregiver questionnaires only 83 52 
Medical Records 15 13 
Parent/caregiver and medical records 10 7 
Parent/caregiver and physician 8 6 
Parent/caregiver or self 6 0 
Parent/caregiver or teacher 3 0 
Claims data 1 1 
Respondent unclear, not specified 18 5 
Measurement Approach 
  Daily or weekly symptom diaries 9 0 
Medical Records 16 13 
Questionnaire 119 68 
Questionnaire 
  Custom design for study 65 44 
Custom design for study, informed by literature 3 2 
Based on Existing Instrument 51 22 
Rome III 12 3 
The Gastrointestinal Severity Index (Schneider) 5 2 
Rome II 4 3 
Autism Treatment Network (ATN)- The Gastrointestinal Symptom  










Questionnaire (continued) N=144 Studiesb N=84 Studiesbc 
Bowel Symptom Questionnaire (Smith) 3 2 
Childhood Autism Risks from Genetics and Environment (CHARGE)  
Gastrointestinal History Questionnaire (GIH) 2 2 
GI Symptom Questionnaire (Chandler) 2 2 
Global Behavior Rating Scale 2 0 
Secretin Outcome Survey 2 0 
Child Behavior Checklist (CBCL) 1 1 
Gastrointestinal Symptom Rating Scale (GSRS) (Chisholm) 2 1 
Lower Urinary Tract Symptoms (LUTS) 1 1 
Modified GI symptom severity index questionnaire 1 1 
Parental Concerns Questionnaire & ATN Diagnoses and Problems &  
Clinician Form, & Health and Mental Health History 1 1 
ATEC subscale 1 0 
Autism Treatment Evaluation Checklist (ATEC) subscale & Global  
Impressions Survey 1 0 
Global Behavior Rating Scale & Additional Rating Scale 1 0 
Global Impressions Survey 1 0 
Irritable Bowel Syndrome (IBS) Global Improvement Scale 1 0 
National Health Interview Survey (NHIS) questionnaire 1 0 
Rome III & their own approach 1 0 
Safety Monitoring Uniform Report Form 1 0 
Safety Monitoring Uniform Report Form & Global Impressions Survey 1 0 
Side Effects Review Form 1 0 
bCategories are not mutually exclusive.  cEighty-four studies from the total set of 144 studies were used to summarize prevalence 
estimates of GI symptoms across the studies.
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3.3.5 GI Symptoms and Conditions Ascertained in the Studies 
The following symptoms and/or diagnoses were measured in the 144 studies (Table 3): 
constipation/chronic constipation (n=94), diarrhea/chronic diarrhea (n=95), abdominal pain or 
discomfort (n=66), nausea or vomiting (n=53), stool qualities or patterns (frequency, color, 
smell, presence of mucus) (n=51), bloating, gas, or flatulence (n=47), reflux or heartburn (n=41), 
food selectivity issues or allergies (n=36), soiling, incontinence or bedwetting (n=25), pain or 
difficulty having a bowel movement (n=20), and colic (n=4).  Seventy-five studies measured a 
non-specific GI symptom or a variable that was a combination of several symptoms, such as 
constipation, diarrhea, or abdominal bloating.  Twenty-three of those seventy-five studies 
reported only the category of non-specific/aggregate symptoms, while the other 52 reported 
specific symptoms as well.  The variables that were analyzed most commonly for an association 
with GI symptoms/conditions were the diagnostic outcome group of the study (e.g.  
ASD/Developmental Delay/PDD-NOS) (n=46), behavioral, psychological, and IQ variables 
(n=28), and demographic variables (n=13) (Supplementary Table 3).
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Table 3.  Symptoms Ascertained Across 144 Studies (count (%)) 
Symptomb N=144 studies 
Constipation 89 (61.8%) 
Chronic/Persistent Constipation 5 (3.5%) 
Diarrhea 86 (59.7%) 
Chronic/Persistent Diarrhea 9 (6.3%) 
Abdominal pain or discomfort 66 (45.8%) 
Nausea or vomiting 53 (36.8%) 
Stool qualities or patterns 51 (35.4%) 
Bloating, gas, or flatulence 47 (32.6%) 
Reflux or heartburn 41 (28.5%) 
Food sensitivities, eating issues 36 (25.0%) 
Incontinence or bedwetting 25 (17.4%) 
Pain or difficulty having bowel movement 20 (13.9%) 
Colic 4 (2.8%) 
Non-specific GI symptom/Aggregate of symptoms with or without  
specific symptoms 75 (52.1%) 
Only non-specific GI symptom/Aggregate of symptoms 23 (16.0%) 








3.3.6 Prevalence Estimate Subset 
The distribution of measurement approaches in the subset of 84 studies is summarized in Table 
2.  Sixty-eight of the 84 studies used questionnaires, 13 used medical records, and none used 
symptom diaries.   
 
The symptoms with the highest median prevalence proportion across studies were “any GI 
symptom/aggregate of symptoms” (46.8%), constipation (22.0%), chronic/persistent constipation 
(19.7%), diarrhea (13.0%), chronic/persistent diarrhea (16.2%), and abdominal pain or 
discomfort (14.0%)  (Table 4).  The ranges of prevalence proportions were quite wide.  Among 
the 62 studies that reported results on a category of “any” GI symptom, the range was 4.2 to 
96.8% of participants.  For constipation (n=32), the range was 4.3 to 45.5%, and for diarrhea 
(n=29), the range was 2.3 to 75.6%. 
 
A number of symptom prevalence proportions varied significantly by study characteristics.  
There were multiple differences in symptom proportions depending on who reported the 
symptoms (Figure 3).  Proportions of diarrhea, abdominal pain/discomfort, nausea/vomiting, and 
bloating/flatulence/gas, all different significantly by respondent type (p<0.05; Figure 3).  
Symptoms had the highest prevalence proportion in studies that did not specify the respondent of 
symptoms, with the exception of the reflux symptoms, which did not have studies in this 
category.  Reflux symptoms were highest in studies that used medical records or claims data.  
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Table 4.  Prevalence Proportions of GI Symptoms/Conditions Among 84 Studies (median (range)) 
Symptom Estimate 
Number of Studies Contributing 
to this Estimate; 
Reported Measuring Symptoms 
Any GI symptom/Aggregate of symptoms 46.8 (4.2, 96.8) 62; 64 
Constipation 22.0 (4.3, 45.5) 32; 53 
Chronic/Persistent Constipation 19.7 (8.8, 38.5) 6; 6 
Diarrhea 13 (2.3, 75.6) 29; 51 
Chronic/Persistent Diarrhea 16.2 (7.1, 37.0) 9; 9 
Abdominal Pain/Discomfort 14 (2.1, 46.6) 20; 35 
Nausea or Vomiting 6.1 (1.3, 21.5) 13; 24 
Stool qualities (frequency, color, small, mucus) -- -- 
Bloating, Flatulence, Gas 12.5 (0, 55.2) 14; 24 
Reflux, heartburn, acidic stomach, GERD, spitting up 7.4 (0, 21.5) 11; 21 
Food selectivity/sensitivities, allergies -- -- 
Soiling, incontinence, bedwetting 12.5 (2.3, 24.0) 5; 12 





Figure 3.  GI Symptom Prevalence Estimates, Across Reporter of Symptoms (N=84). 
Figure 3 summarizes the associations between specific GI symptoms and the respondent of GI symptoms in 84 
studies.  GI symptom proportions are the median prevalence proportions across 84 possible studies.  The number of 
studies contributing to the estimate is shown in the horizontal axis.  An ANOVA test was carried out for each 
symptom to test for differences in estimates across types of respondent.  P-values are indicated below the F-values. 
 
Notably, both abdominal pain/discomfort and reflux proportions differed across age groups, with 
the highest proportions for both symptoms being in studies in which the mean age range was 13-
18 (p<0.1, p<0.005, respectively, data not shown).  Soiling/incontinence proportions different by 
the primary goal of the study; studies with the primary goal of comparing GI symptom 
proportions across outcome groups had the highest proportions (p<0.05, data not shown).  
Chronic or persistent constipation proportions differed significantly across study design types, 
with the highest proportions in observational studies with a comparison group (p<0.05, data not 
shown).  Prevalence proportions of constipation differed significantly across types of study 
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samples, with clinic-based and enriched-risk samples having the highest proportions (p<0.03, 
Table S3).   
 
No symptom prevalence proportions differed significantly (p<0.05) or had a discernable 
association with diagnostic category, geographic region, publication year, or by the type of 
questionnaire (e.g. ATN, Rome criteria, Child Behavior Checklist).  We were unable to examine 
associations with other variables such as intellectual disability or verbal ability due to the 
scarcity of proportions specific to these subgroups. 
 
3.4 Discussion and Conclusion 
3.4.1 Key Findings 
In this review of 144 studies published 1980-2017, a broad range of approaches to ascertaining 
the presence of GI symptoms and conditions was observed.  Most studies relied on 
questionnaires given to parents or caregivers, some used medical records, and a few used 
concurrent observations such as symptom and stool diaries or results of clinical diagnostic 
examinations.  Of the 84 studies used in the calculation of GI prevalence estimates, only one 
obtained information directly from the participants and none used observational symptom 
diaries.  Some studies were based on population samples while others recruited participants from 
clinical settings.  Among the 116 observational studies, 82 studies (71%) included a comparison 
group.  Future studies measuring GI symptoms in ASD should continue to use a comparison 




Importantly, we found that over half of the studies that used a questionnaire used their own 
approach, while the rest used an instrument that had been previously developed.  Among the 
existing instruments, only five (ATEC subscale, ATN Gastrointestinal Symptom Inventory, 
CHARGE Gastrointestinal History Questionnaire, Parental Concerns Questionnaire, and ATN 
Diagnoses and Problems form) were designed with individuals with ASD in mind, and none 
have been formally validated.  This diversity in measurement approaches makes it difficult to 
derive an accurate epidemiologic estimate of GI symptoms and an understanding of the risk 
factors that contribute to ASD and GI symptoms.  The symptoms that were most commonly 
ascertained across the studies reviewed here were constipation, diarrhea, abdominal pain or 
discomfort, and nausea or vomiting.  Twenty-three (16.0%) of the studies only reported a non-
specific or aggregate GI variable, making it difficult to specify the particular symptoms that are 
reported in this population.   
 
Not surprisingly, a wide range of proportions of symptom prevalences was observed.  Notably, 
the proportion of non-specific/aggregate GI symptoms ranged from 4.2 to 96.8% of participants.  
Yet, more specific symptoms also had a wide range of proportions.  For example, diarrhea, 
which is arguably one of the easier symptoms to detect or measure, still had a range of 2.3 to 
75.6% across studies.  It is not clear if these results are specific to ASD or reflect a broader group 
of central nervous system disorders.  Some research suggests that individuals with ASD may 
experience a higher prevalence of GI symptoms than other developmental delay groups, 
however, the lack of precision and validity around measuring GI symptoms makes it difficult to 
confirm this9.  Importantly, current data may represent an under-estimate of GI symptoms and 
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disorders, because behaviors that are reflective of GI distress (aggression, disruptive behaviors, 
self-injury) may be interpreted as features of ASD and therefore may go uninvestigated.   
 
Ascertaining the presence of even one of the more common GI symptoms, functional 
constipation (that is, constipation not due to anatomic structural disorders), is a challenging 
problem, even among children who do not have developmental disorders.  As noted in a 2006 
review by van den Berg et al., the need to rely on reporting by parents, the lack of 
standardization of the definition of specific symptoms, as well as the reliance by physicians on 
parental interpretation, all contribute to the problem of inaccurate symptom measurement14.   
 
In support of this, we found that many GI symptom prevalence estimates were significantly 
associated with study characteristics.  Diarrhea, abdominal pain/discomfort, nausea/vomiting, 
and bloating/flatulence/gas differed significantly by respondent type, soiling/incontinence 
differed by the primary goal of the study, and constipation differed significantly across study 
design types as well as type of study sample. 
 
Our review has important limitations.  First, we used a single database (PubMed), so studies that 
measured GI symptoms in ASD, but were published in journals not available through PubMed, 
are not reflected in this review.  Secondly, since many studies did not specify the prevalence of 
GI symptoms in subgroups of their populations, such as individuals with an intellectual disability 
or who are non-verbal, we were unable to determine how GI symptoms differed across these 
groups.  Despite these limitations, this review, and previous ones, highlight the need for 
standardized, validated tools to assess GI symptoms among people with ASD.  There are a few 
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notable examples of questionnaires that do assess GI symptoms and have been designed for 
ASD, yet each has current drawbacks, and none of the GI-specific sections have been validated.  
We briefly summarize three of these questionnaires and describe their strengths and limitations. 
 
3.4.2 Strengths and Limitations of Current GI Symptom Questionnaires for ASD populations 
The Autism Treatment Evaluation Checklist (ATEC) subscale29, developed by Bernard Rimland 
and Stephan M.  Edelson at the Autism Research Institute, is a one-page form to be filled out by 
parents, teachers, or caregivers.  The four subsections of the scale are 1) Speech/Language 
Communication, 2) Sociability, 3) Sensory/ Cognitive Awareness, and 4) 
Health/Physical/Behavior.  The ATEC provides subscale scores and a total score, used to 
monitor how the child is doing over time, or following an intervention.  The 
Health/Physical/Behavior section consists of 25 items, which the individual rates as Not a 
problem; Minor Problem; Moderate Problem; Serious Problem.  The items that have to do with 
the gastrointestinal system are: bed-wetting; wets pants/diapers; soils pants/diapers; diarrhea; 
constipation; eats too much/too little; extremely limited diet29,30.  The strengths of the ATEC 
subscale are that it covers multiple constructs of ASD through its four subsections, it allows for a 
severity rating, it includes items on GI-related issues such as diet, bed-wetting and incontinence, 
and it has been used in a number of studies.  Further, the ATEC total and sub-scale scores, 
including the health/physical/behavior subscale, have demonstrated good reliability and validity 
31,32.  However, diarrhea, constipation, and incontinence/bed-wetting make up only 5 of the 25 
items in this subscale, limiting its usefulness for assessing the breadth of GI symptoms and 




The Childhood Autism Risks from Genetics and Environment (CHARGE) Gastrointestinal 
History Questionnaire is a parent-administered questionnaire.  The questionnaire includes 10 
Likert scale items on current gastrointestinal symptoms, food allergies, and dietary restrictions 
(0=never; 1=rarely; 2=sometimes; 3=frequently; 4=always).  The symptoms assessed are 
abdominal pain, gaseousness/bloating, diarrhea, constipation, pain on stooling, vomiting, 
sensitivity to foods, difficulty swallowing, blood in stool, and blood in vomit, as well as four 
yes/no questions about presence of food allergies, diet restrictions, food dislikes, and whether the 
child has ever received a GI diagnosis.  In addition, the form includes open-ended questions for 
parents to list food allergies, reasons for diet or food restrictions, and what GI condition(s) have 
been diagnosed9,33.  The strengths of this questionnaire are that it assesses many GI symptoms, 
provides information on frequency, has many questions on mealtime behaviors and diet, and 
allows parents/caregivers to provide qualitative data.  The major limitation of this questionnaire 
is that it doesn’t incorporate behavioral symptoms that may reflect GI distress.   
 
The Autism Treatment Network Gastrointestinal Symptom Inventory is an especially useful 
questionnaire34.  It is comprised of 35 items, plus additional items if a participant exhibits certain 
symptomatology, totaling 77 items.  Parents fill out the inventory, which includes questions 
about presence, duration, and nature of a number of GI symptoms.  For each item, parents are 
asked “has your child experienced any of the following gastrointestinal (tummy) symptoms?”, to 
which they can reply with “Yes”, “No”, or “Unsure”.  For symptoms that are present, parents can 
also specify the duration of the symptoms (<3 months, 3-5 months, 6-11 months, 1 year or 
longer).  This inventory is scored to provide binary variables for individual symptoms, any GI 
symptoms, and can provide the total number of GI symptoms experienced.  In addition, the 
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inventory allows for branching into specific types of symptoms (abdominal pain, abnormal 
bowel movements, reflux, and food insensitivity), which allows for the estimation of these 
symptom categories.  Unfortunately, the tool has not been validated 6,35,36.  The strengths of this 
questionnaire are that it provides information on duration of symptoms, assesses a number of GI 
symptoms, and queries behaviors that might be reflective of GI distress.  The limitation of this 
questionnaire is that mealtime behaviors or dietary practices are not explored to any great degree 
despite their potential role in the expression of GI symptoms. 
 
3.4.3 Recommendations for Creation and Psychometric Testing of GI Questionnaire 
To our knowledge, this is the first literature review to assess GI symptoms in studies of ASD 
reaching back to 1980 and to examine study design features, particularly approaches to 
measurement of GI symptoms, for associations with GI symptom prevalence estimates.  This 
study builds on McElhanon et al.’s meta-analysis of 15 studies which found that studies relied 
primarily on parental reports or chart reviews, and used a wide variety of definitions of GI 
symptoms37.  They too recommended the development of “a standardized measure focusing on 
GI issues among children with ASD” and the use of a toileting diary of visual observations.  Our 
review also confirms Dalton et al.’s hypothesis that the wide variability in prevalence estimates 
in ASD may be due to factors including the definition and type of GI symptoms, the sample of 
children, and the method by which the symptoms are investigated38.   
 
A standardized method for the ascertainment of GI symptoms and conditions must be designed 
for people with ASD, in order not only to have reliable and valid prevalence estimates but also to 
compare GI symptom estimates with various risk factors, and to evaluate the outcome of trials or 
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interventions.  We recommend that an expert panel of clinicians, researchers, and individuals 
with ASD or their families be consulted to construct an item pool of symptoms and behaviors 
that are prevalent, meaningful, and relevant to the ASD population.  The questionnaire should 
include not only GI symptoms but also stool patterns and qualities, mealtime and dietary 
behaviors, and behaviors that might be indicative of GI distress.  In individuals who have 
difficulties communicating, behaviors or co-morbid conditions such as self-injury, aggression, 
chewing on non-edibles, putting pressure on the abdomen, sleep disruption or fragmentation, and 
any other unusual behaviors may be an indication of GI distress10.  We refer the reader to the 
Consensus Report by Buie et al.  for more vocal and motor behaviors and changes to overall state 
that may be indicative of abdominal pain or discomfort in people with ASD10.  Not querying 
these behaviors could lead to an individual with ASD being incorrectly classified as not having a 
GI disorder or being in pain.  This is relevant in research as well as clinical settings, where a 
patient’s report of symptoms or pain typically precedes seeking care.  Assessing for behaviors 
that might reflect GI distress as part of the clinical diagnostic process may help identify 
individuals in need of treatment.  Although these behaviors and co-morbid conditions alone may 
not allow a questionnaire to be able to correctly diagnose a specific GI disorder such as reflux, 
Crohn’s disease, ulcers, or tight rectal sphincter, it may indicate the need for a more 
comprehensive evaluation including endoscopy or colonoscopy when clinically indicated.  
Questions about GI symptoms should also include definitions, and information about duration, 
frequency, and severity.  If possible, direct observations and prospective diaries of stool patterns, 
symptoms, and behaviors should be incorporated.  After constructing the item pool, the GI 
questionnaire should be tested in a pilot sample of parent/caregiver/self-reporters for reliability 
and validity.  We recommend factor analysis also be carried out to determine how individual 
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items map onto constructs.  These results, as well as feedback from participants, should be used 
to revise the questionnaire before administering to a second, independent sample of individuals.  
Although the types of reliability and validity that can be assessed will vary by study, we suggest 
that internal consistency, test-retest reliability, content validity, criterion-validity, construct 
validity, and exploratory and confirmatory factor analyses are important analyses to consider 
when psychometrically testing this questionnaire.  Importantly, no GI questionnaire based on 
parent/caregiver/self-report data will be able to diagnose specific disorders.  However, A GI 
questionnaire represents a rapid, feasible way to assess symptoms, and could be combined with 
physician evaluation and diagnostic tests when relevant to a specific condition of interest in 
particular settings.   
 
In the absence of a standardized approach to measuring GI symptoms, current reports should at 
the minimum state explicitly which questionnaire was used, who filled out the questionnaire, the 
ages of participants, study design, and other pertinent characteristics.  We found that 12.5% of 
studies did not specify who reported symptoms, and 46% of studies did not describe their study 
sample with enough detail to know if it was a clinic-based sample, population-based sample, or 
enriched-risk sample.  This is especially problematic given that studies which did not specify 
who reported the GI symptoms tended to have significantly higher proportions of diarrhea, 
abdominal pain/discomfort, bloating, as well as non-specific GI complaints.   
 
Another troubling finding is that among studies in the US, Canada, and UK, 48% did not specify 
the race/ethnicity distributions of their sample, and of those that did, 94% were comprised of all 
or almost all white individuals.  This highlights the dearth of racial or ethnic diversity among 
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participants in ASD research studies and begs for a greater focus on underrepresented 
populations.  Similarly, the vast majority of studies did not report any information on 
socioeconomic status, making it difficult to assess how this impacts a family’s ability to access 
GI specialists for diagnosis and treatment.  This also reinforces the need for a more diverse 
sampling of individuals, greater reporting of socioeconomic variables, and an examination of 
how care is influenced by factors such as race, education, and income.   
 
In summary, we found that ASD studies used a broad array of approaches to measuring the 
presence of GI symptoms and conditions, that most replied on parent or caregiver reports, and 
that the prevalence of GI symptom estimates across studies was very wide.  Further, GI 
symptoms estimates were significantly associated with study characteristics such as respondent 
type, goal of the study, study design, type of study sample, and age of the participants.  The 
current state of measuring GI symptoms in ASD hinders our ability to judge how symptoms vary 
over time and with other factors such as diet, sensory aversions, medication, psychological 
factors including anxiety or depression, the development of the child, and the various 
interventions that are explored.  This review highlights the lack of consensus regarding 
frequency and subgrouping of GI symptoms in ASD.  We argue that ASD individuals, their 
families, and the research community in general, would benefit from a standardized and valid 
approach to assessing GI symptoms in ASD.  Psychometric testing of a GI questionnaire is an 
important first step in establishing the epidemiology of GI symptoms in individuals with ASD.  
If a reliable and valid open-access questionnaire were available to researchers, GI estimates 
across studies would be more comparable.  By designing a questionnaire that has an item pool 
informed by an expert panel, that includes behaviors that could be indicative of GI distress 
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(aggression, self-injury, pushing abdomen, etc.), and that undergoes psychometric testing and 
revision, we think GI estimates will be more precise, accurate, and the items queried will be of 
interest to researchers, clinicians, and individuals or families with ASD.  The consistent and 
accurate measurement of specific symptoms is crucial to understanding the role that the gut plays 
in the expression and course of ASD. 
Acknowledgements and Funding 
Calliope Holingue is supported by the NIMH Psychiatric Epidemiology Training Program 
(5T32MH014592-39; PI: Zandi, Peter).  Thank you to the coauthors of this study: Carol Newill 
MD PhD, Li-Ching Lee PhD, Pankaj Pasricha MBBS MD., and M.  Daniele Fallin PhD.  We 
















1.   Kanner L.  Autistic disturbances of affective contact.  Nerv.  Child 1943;2(3):217-250. 
2.   Goodwin MS, Goodwin TC, Cowen MA.  Malabsorption and cerebral dysfunction: A 
multivariate and comparative study of autistic children.  J.  Autism Child.  Schizophr.  
1971;1(1):48-62.  doi:10.1007/BF01537742. 
3.   Panksepp J.  A neurochemical theory of autism.  Trends Neurosci.  1979;2(C):174-177.  
doi:10.1016/0166-2236(79)90071-7. 
4.   D’Eufemia P, Celli M, Finocchiaro R, et al.  Abnormal intestinal permeability in children 
with autism.  Acta Paediatr.  1996;85(9):1076-1079.  doi:10.1111/j.1651-
2227.1996.tb14220.x. 
5.   Bresnahan M, Hornig M, Schultz AF, et al.  Association of Maternal Report of Infant and 
Toddler Gastrointestinal Symptoms With Autism: Evidence From a Prospective Birth 
Cohort.  JAMA psychiatry 2015;10032(5):1-9.  doi:10.1001/jamapsychiatry.2014.3034. 
6.   Mazurek MO, Vasa RA, Kalb LG, et al.  Anxiety, sensory over-responsivity, and 
gastrointestinal problems in children with autism spectrum disorders.  J.  Abnorm.  Child 
Psychol.  2013;41(1):165-176.  doi:10.1007/s10802-012-9668-x. 
7.   Mouridsen SE, Rich B, Isager T.  A longitudinal study of gastrointestinal diseases in 
individuals diagnosed with infantile autism as children.  Child.  Care.  Health Dev.  
2010;36(3):437-443.  doi:10.1111/j.1365-2214.2009.01021.x. 
8.   Galli-Carminati G, Chauvet I, Deriaz N.  Prevalence of gastrointestinal disorders in adult 
clients with pervasive developmental disorders.  J.  Intellect.  Disabil.  Res.  
2006;50(10):711-718.  doi:10.1111/j.1365-2788.2006.00833.x. 
9.   Chaidez V, Hansen RL, Hertz-Picciotto I.  Gastrointestinal problems in children with 
 
 102 
autism, developmental delays or typical development.  J.  Autism Dev.  Disord.  
2014;44(5):1117-1127.  doi:10.1007/s10803-013-1973-x. 
10.   Buie T, Campbell DB, Fuchs GJ, et al.  Evaluation, diagnosis, and treatment of 
gastrointestinal disorders in individuals with ASDs: a consensus report.  Pediatrics 
2010;125 Suppl(January):S1-S18.  doi:10.1542/peds.2009-1878C. 
11.   Coury DL, Ashwood P, Fasano  a., et al.  Gastrointestinal Conditions in Children With 
Autism Spectrum Disorder: Developing a Research Agenda.  Pediatrics 
2012;130(Supplement):S160-S168.  doi:10.1542/peds.2012-0900N. 
12.   Rasquin-Weber A, Hyman PE, Cucchiara S, et al.  Childhood functional gastrointestinal 
disorders.  Gut 1999;45 Suppl 2(Suppl II):II60-8.  doi:10.1136/gut.45.2008.ii60. 
13.   Tabbers MM, DiLorenzo C, Berger MY, et al.  Evaluation and treatment of functional 
constipation in infants and children: evidence-based recommendations from ESPGHAN 
and NASPGHAN.  J.  Pediatr.  Gastroenterol.  Nutr.  2014;58(2):258-274. 
14.   Van Den Berg MM, Benninga MA, Di Lorenzo C.  Epidemiology of childhood 
constipation: A systematic review.  Am.  J.  Gastroenterol.  2006;101(10):2401-2409.  
doi:10.1111/j.1572-0241.2006.00771.x. 
15.   Caplan A, Walker L, Rasquin A.  Development and preliminary validation of the 
questionnaire on pediatric gastrointestinal symptoms to assess functional gastrointestinal 
disorders in children and adolescents.  J.  Pediatr.  Gastroenterol.  Nutr.  2005;41(3):296-
304.  doi:10.1097/01.mpg.0000172748.64103.33. 
16.   Del Giudice E, Staiano A, Capano G, et al.  Gastrointestinal manifestations in children 
with cerebral palsy.  Brain Dev.  1999;21(5):307-311. 
17.   Sullivan PB, Lambert B, Rose M, Ford-Adams M, Johnson A, Griffiths P.  Prevalence and 
 
 103 
severity of feeding and nutritional problems in children with neurological impairment: 
Oxford Feeding Study.  Dev.  Med.  Child Neurol.  2000;42(10):674-680. 
18.   Marciniak CM, Lee J, Jesselson M, Gaebler-Spira D.  Cross-Sectional Study of Bowel 
Symptoms in Adults With Cerebral Palsy: Prevalence and Impact on Quality of Life.  
Arch.  Phys.  Med.  Rehabil.  2015;96(12):2176-2183. 
19.   Wakefield AJ, Murch SH, Anthony A, et al.  Ileal-lymphoid-nodular hyperplasia, non-
specific colitis, and pervasive developmental disorder in children (Retracted article.  See 
vol 363, pg 750, 2004).  Lancet 1998;351(9103):637-641. 
20.   Rao TSS, Andrade C.  The MMR vaccine and autism: Sensation, refutation, retraction, 
and fraud.  Indian J.  Psychiatry 2011;53(2):95. 
21.   Flaherty DK.  The vaccine-autism connection: A public health crisis caused by unethical 
medical practices and fraudulent science.  Ann.  Pharmacother.  2011;45(10):1302-1304.  
doi:10.1345/aph.1Q318. 
22.   R Developement Core Team.  R: A Language and Environment for Statistical Computing.  
R Found.  Stat.  Comput.  2015;1:409.  doi:10.1007/978-3-540-74686-7. 
23.   Team RC.  R: A language and environment for statistical computing.  R Foundation for 
Statistical Computing, Vienna, Austria.  2013.  2014. 
24.   Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P.  Gastrointestinal 
dysfunction in autism: Parental report, clinical evaluation, and associated factors.  Autism 
Res.  2012;5(2):101-108.  doi:10.1002/aur.237. 
25.   Ming X, Brimacombe M, Chaaban J, Zimmerman-Bier B, Wagner GC.  Autism spectrum 
disorders: concurrent clinical disorders.  J.  Child Neurol.  2008;23(1):6-13. 
26.   Kang V, Wagner GC, Ming X.  Gastrointestinal dysfunction in children with autism 
 
 104 
spectrum disorders.  Autism Res.  2014;7(4):501-506. 
27.   Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger-Moore J, Ostrem JA.  Oral 
human immunoglobulin for children with autism and gastrointestinal dysfunction: A 
prospective, open-label study.  J.  Autism Dev.  Disord.  2006;36(8):1053-1064.  
doi:10.1007/s10803-006-0141-y. 
28.   Smith R a, Farnworth H, Wright B, Allgar V.  Are there more bowel symptoms in children 
with autism compared to normal children and children with other developmental and 
neurological disorders?: A case control study.  Autism 2009;13(4):343-355.  
doi:10.1177/1362361309106418. 
29.   Autism Research Institute.  Autism Treatment Evaluation Checklist (ATEC).  2016.  
Available at: https://www.autism.com/ind_atec.  Accessed January 8, 2017. 
30.   Rimland B, Edelson SM.  Autism treatment evaluation checklist (ATEC).  Retrieved Oct.  
2000;23:2006. 
31.   Magiati I, Moss J, Yates R, Charman T, Howlin P.  Is the Autism Treatment Evaluation 
Checklist a useful tool for monitoring progress in children with autism spectrum 
disorders? J.  Intellect.  Disabil.  Res.  2011;55(3):302-312. 
32.   Geier DA, Kern JK, Geier MR.  A comparison of the Autism Treatment Evaluation 
Checklist (ATEC) and the Childhood Autism Rating Scale (CARS) for the quantitative 
evaluation of autism.  J.  Ment.  Health Res.  Intellect.  Disabil.  2013;6(4):255-267. 
33.   Hansen RL, Ozonoff S, Krakowiak P, et al.  Regression in autism: prevalence and 
associated factors in the CHARGE Study.  Ambul.  Pediatr.  2008;8(1):25-31. 
34.   Autism Network.  GI symptom inventory questionnaire, vers.  3.0.  New York, NY Autism 
Speak.  2005. 
 
 105 
35.   Abdelrahman HM, Sherief LM, Alghobashy AA, et al.  Association of 5-HT2A receptor 
gene polymorphisms with gastrointestinal disorders in Egyptian children with autistic 
disorder.  Res.  Dev.  Disabil.  2015;36:485-490. 
36.   Mazefsky CA, Schreiber DR, Olino TM, Minshew NJ.  The association between 
emotional and behavioral problems and gastrointestinal symptoms among children with 
high-functioning autism.  Autism 2014;18(5):493-501.  doi:10.1177/1362361313485164. 
37.   McElhanon BO, McCracken C, Karpen S, Sharp WG.  Gastrointestinal Symptoms in 
Autism Spectrum Disorder: A Meta-analysis.  Pediatrics 2014:peds.2013-3995.  
doi:10.1542/peds.2013-3995. 
38.   Dalton N, Chandler S, Turner C, et al.  Gut permeability in autism spectrum disorders.  
Autism Res.  2014;7(3):305-313.  doi:10.1002/aur.1350. 
 
 106 
Table S1.  List of 144 studies included in review.  
  
1) Molloy C, Manning-Courtney P. Prevalence of chronic gastrointestinal symptoms in children with autism and autistic 
spectrum disorders. Autism. 2003;7(2):165–71. 
2) Kern JK, Miller VS, Evans PA, Trivedi MH. Efficacy of Porcine Secretin in Children with Autism and Pervasive 
Developmental Disorder. J Autism Dev Disord. 2002;32(3):153–60. 
3) Valicenti-McDermott M, McVicar K, Rapin I, Wershil BK, Cohen H, Shinnar S. Frequency of gastrointestinal symptoms in 
children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr. 
2006;27(2):128-S136. 
4) Asano E, Kuivaniemi H, Mahbubul Huq AHM, Tromp G, Behen M, Rothermel R, et al. A Study of Novel Polymorphisms in 
the Upstream Region of Vasoactive Intestinal Peptide Receptor Type 2 Gene in Autism. J Child Neurol [Internet]. 
2001;16(5):357–63. Available from: http://jcn.sagepub.com/cgi/content/abstract/16/5/357 
5) Mostafa G a, Al-Ayadhi LY. Reduced levels of plasma polyunsaturated fatty acids and serum carnitine in autistic 
children: relation to gastrointestinal manifestations. Behav Brain Funct [Internet]. 2015;11:4. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4332725&tool=pmcentrez&rendertype=abstract 
6) Valicenti-McDermott MD, McVicar K, Cohen HJ, Wershil BK, Shinnar S. Gastrointestinal Symptoms in Children with an 
Autism Spectrum Disorder and Language Regression. Pediatr Neurol [Internet]. Elsevier Inc.; 2008;39(6):392–8. Available 
from: http://dx.doi.org/10.1016/j.pediatrneurol.2008.07.019 
7) Vohra R, Madhavan S, Sambamoorthi U, StPeter C, Poe S, Dwibedi N, et al. Prescription Drug Use and Polypharmacy 
Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis. Drugs-Real World Outcomes. 
Springer; 2016;3(4):409–25. 
8) Pang KH, Croaker GDH. Constipation in children with autism and autistic spectrum disorder. Pediatr Surg Int. 
2011;27(4):353–8. 
9) Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, et al. Blood–brain barrier and intestinal epithelial 
barrier alterations in autism spectrum disorders. Mol Autism. BioMed Central; 2016;7(1):49. 
10) Gorrindo P, Lane CJ, Lee EB, McLaughlin BA, Levitt P. Enrichment of Elevated Plasma F2t-Isoprostane Levels in 
Individuals with Autism Who Are Stratified by Presence of Gastrointestinal Dysfunction. PLoS One. 2013;8(7). 
11) Mouridsen SE, Isager T, Rich B. Diseases of the gastrointestinal tract in individuals diagnosed as children with atypical 
autism: a Danish register study based on hospital diagnoses. Autism [Internet]. 2013;17(1):55–63. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/22987890 
12) Galli-Carminati G, Chauvet I, Deriaz N. Prevalence of gastrointestinal disorders in adult clients with pervasive 
developmental disorders. J Intellect Disabil Res. 2006;50(10):711–8. 
 
 107 
13) Black C, Kaye J a, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data 
from the UK General Practice Research Database. BMJ. 2002;325(7361):419–21. 
14) Wier ML, Yoshida CK, Odouli R, Grether JK, Croen L a. Congenital anomalies associated with autism spectrum disorders. 
Dev Med Child Neurol. 2006;48(2006):500–7. 
15) Croen L a., Zerbo O, Qian Y, Massolo ML, Rich S, Sidney S, et al. The health status of adults on the autism spectrum. 
Autism [Internet]. 2015;19(7):1362361315577517-. Available from: 
http://aut.sagepub.com/cgi/doi/10.1177/1362361315577517%5Cnhttp://aut.sagepub.com/content/early/2015/04/23/13
62361315577517.abstract 
16) Ibrahim SH, Voigt RG, Katusic SK, Weaver AL, Barbaresi WJ. Incidence of gastrointestinal symptoms in children with 
autism: a population-based study. Pediatrics. 2009;124(2):680–6. 
17) Mouridsen SE, Rich B, Isager T. A longitudinal study of gastrointestinal diseases in individuals diagnosed with infantile 
autism as children. Child Care Health Dev. 2010;36(3):437–43. 
18) Niehus R, Lord C. Early medical history of children with autism spectrum disorders. J Dev Behav Pediatr. 2006;27(2 
Suppl):S120–7. 
19) Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, et al. Disruptive CHD8 mutations define a subtype of autism 
early in development. Cell [Internet]. Elsevier Inc.; 2014;158(2):263–76. Available from: 
http://dx.doi.org/10.1016/j.cell.2014.06.017 
20) Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J, et al. Measles, mumps, and rubella vaccination and bowel 




21) Cohen-Silver JH, Muskat B, Ratnapalan S. Autism in the emergency department. Clin Pediatr (Phila) [Internet]. 
2014;53(12):1134–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25031320 
22) Doshi-Velez F, Ge Y, Kohane I. Comorbidity Clusters in Autism Spectrum Disorders: An Electronic Health Record Time-
Series Analysis. Pediatrics [Internet]. 2013;133(1):e54–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24323995 
23) Maenner MJ, Arneson CL, Levy SE, Kirby RS, Nicholas JS, Durkin MS. Brief report: Association between behavioral 
features and gastrointestinal problems among children with autism spectrum disorder. J Autism Dev Disord. 
2012;42(7):1520–5. 
24) Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon M a. Increased abundance of Sutterella spp. and 
Ruminococcus torques in feces of children with autism spectrum disorder. Mol Autism [Internet]. 2013;4(1):42. Available 
from: Molecular Autism 
 
 108 
25) Phillips KL, Schieve LA, Visser S, Boulet S, Sharma AJ, Kogan MD, et al. Prevalence and Impact of Unhealthy Weight in a 
National Sample of US Adolescents with Autism and Other Learning and Behavioral Disabilities. Matern Child Health J. 
2014;18(8):1964–75. 
26) Iovene MR, Bombace F, Maresca R, Sapone A, Iardino P, Picardi A, et al. Intestinal Dysbiosis and Yeast Isolation in Stool 
of Subjects with Autism Spectrum Disorders. Mycopathologia. Springer; 2016;1–15. 
27) Son JS, Zheng LJ, Rowehl LM, Tian X, Zhang Y, Zhu W, et al. Comparison of fecal microbiota in children with autism 
spectrum disorders and neurotypical siblings in the Simons Simplex Collection. PLoS One. Public Library of Science; 
2015;10(10):e0137725. 
28) Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Elevated fecal short chain fatty acid and 
ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012;57(8):2096–102. 
29) Fulceri F, Morelli M, Santocchi E, Cena H, Del T, Narzisi A, et al. Gastrointestinal symptoms and behavioral problems in 
preschoolers with Autism Spectrum Disorder. Dig Liver Dis [Internet]. Editrice Gastroenterologica Italiana; 2016;48(3):248–
54. Available from: http://dx.doi.org/10.1016/j.dld.2015.11.026 
30) Gontard A Von, Pirrung M, Niemczyk J, Equit M. Incontinence in children with autism spectrum disorder. J Pediatr Urol 
[Internet]. Elsevier Ltd; 2015;11(5):264.e1-264.e7. Available from: http://dx.doi.org/10.1016/j.jpurol.2015.04.015 
31) Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Low relative abundances of the mucolytic 
bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism. Appl Environ Microbiol. 
2011;77(18):6718–21. 
32) Kheirouri S, Kalejahi P, Noorazar SG. Plasma levels of serotonin, gastrointestinal symptoms, and sleep problems in 
children with autism. Turkish J Med Sci. The Scientific and Technological Research Council of Turkey; 2016;46(6):1765–72. 
33) Pusponegoro HD, Ismael S, Sastroasmoro S, Firmansyah A, Vandenplas Y. Maladaptive Behavior and Gastrointestinal 
Disorders in Children with Autism Spectrum Disorder. Pediatr Gastroenterol Hepatol Nutr [Internet]. 2015;18(4):230–7. 
Available from: http://synapse.koreamed.org/DOIx.php?id=10.5223/pghn.2015.18.4.230 
34) Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with 
autism--comparisons to typical children and correlation with autism severity. BMC Gastroenterol [Internet]. BioMed Central 
Ltd; 2011;11(1):22. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3072352&tool=pmcentrez&rendertype=abstract 
35) Dalton N, Chandler S, Turner C, Charman T, Pickles A, Loucas T, et al. Gut permeability in autism spectrum disorders. 
Autism Res. 2014;7(3):305–13. 
36) Dalton NR, Chandler S, Turner C, Charman T, Pickles A, Simonoff E, et al. Measurement of urine indolylacroylglycine is 
not useful in the diagnosis or dietary management of autism. Autism Res. Wiley Online Library; 2016; 
37) Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or 
typical development. J Autism Dev Disord. 2014;44(5):1117–27. 
 
 109 
38) Gabriele S, Sacco R, Altieri L, Neri C, Urbani A, Bravaccio C, et al. Slow intestinal transit contributes to elevate urinary p-
cresol level in Italian autistic children. Autism Res [Internet]. 2015;(October 2015):1–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26437875 
39) Ferguson BJ, Marler S, Altstein LL, Lee EB, Akers J, Sohl K, et al. Psychophysiological Associations with Gastrointestinal 
Symptomatology in Autism Spectrum Disorder. Autism Res [Internet]. 2016;1–13. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27321113 
40) Harris C, Card B. A pilot study to evaluate nutritional influences on gastrointestinal symptoms and behavior patterns in 
children with Autism Spectrum Disorder. Complement Ther Med [Internet]. Elsevier Ltd; 2012;20(6):437–40. Available from: 
http://dx.doi.org/10.1016/j.ctim.2012.08.004 
41) Mazurek MO, Vasa RA, Kalb LG, Kanne SM, Rosenberg D, Keefer A, et al. Anxiety, sensory over-responsivity, and 
gastrointestinal problems in children with autism spectrum disorders. J Abnorm Child Psychol. 2013;41(1):165–76. 
42) Mazefsky CA, Schreiber DR, Olino TM, Minshew NJ. The association between emotional and behavioral problems and 
gastrointestinal symptoms among children with high-functioning autism. Autism [Internet]. 2014;18(5):493–501. Available 
from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3980202&tool=pmcentrez&rendertype=abstract 
43) Greenlee JL, Mosley AS, Shui AM, Veenstra-VanderWeele J, Gotham KO. Medical and Behavioral Correlates of Depression 
History in Children and Adolescents With Autism Spectrum Disorder. Pediatrics [Internet]. 2016;137(Supplement):S105–14. 
Available from: http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2015-2851I 
44) Hansen RL, Ozonoff S, Krakowiak P, Angkustsiri K, Jones C, Deprey LJ, et al. Regression in autism: prevalence and 
associated factors in the CHARGE Study. Ambul Pediatr. Elsevier; 2008;8(1):25–31. 
45) Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic 
spectrum disorder. J Altern Complement Med [Internet]. 2004;10(6):1033–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15673999 
46) Anagnostou E, Aman MG, Handen BL, Sanders KB, Shui A, Hollway JA, et al. Metformin for treatment of overweight 
induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. Jama 
psychiatry. American Medical Association; 2016;73(9):928–37. 
47) Ghalichi F, Ghaemmaghami J, Malek A, Ostadrahimi A. Effect of gluten free diet on gastrointestinal and behavioral 
indices for children with autism spectrum disorders: a randomized clinical trial. World J Pediatr [Internet]. 2016;(June):1–7. 
Available from: http://link.springer.com/10.1007/s12519-016-0040-z 
48) Munasinghe SA, Oliff C, Finn J, Wray JA. Digestive enzyme supplementation for autism spectrum disorders: A double-
blind randomized controlled trial. J Autism Dev Disord. 2010;40(9):1131–8. 
49) Pusponegoro HD, Ismael S, Firmansyah A, Sastroasmoro S, Vandenplas Y. Gluten and casein supplementation does not 




50) Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger-Moore J, Ostrem JA. Oral human immunoglobulin for 
children with autism and gastrointestinal dysfunction: A prospective, open-label study. J Autism Dev Disord. 
2006;36(8):1053–64. 
51) Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, et al. Effect of a vitamin/mineral supplement on 
children and adults with autism. BMC Pediatr [Internet]. BioMed Central Ltd; 2011;11(1):111. Available from: 
http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/470/CN-
00860470/frame.html%5Cnhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266205/pdf/1471-2431-11-111.pdf 
52) Kang D-W, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, et al. Microbiota Transfer Therapy alters gut 
ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. BioMed Central; 
2017;5(1):10. 
53) Levy SE, Souders MC, Wray J, Jawad AF, Gallagher PR, Coplan J, et al. Children with autistic spectrum disorders. I: 
comparison of placebo and single dose of human synthetic secretin. Arch Dis Child [Internet]. 2003;88(8):731–6. Available 
from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1719589&tool=pmcentrez&rendertype=abstract 
54) Handen BL, Melmed RD, Hansen RL, Aman MG, Burnham DL, Bruss JB, et al. A double-blind, placebo-controlled trial of 
oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord. 
2009;39(5):796–805. 
55) Nikolov RN, Bearss KE, Lettinga J, Erickson C, Rodowski M, Aman MG, et al. Gastrointestinal symptoms in a sample of 
children with pervasive developmental disorders. J Autism Dev Disord. Springer; 2009;39(3):405–13. 
56) Bramati-Castellarin I, Patel VB, Drysdale IP. Repeat-measures longitudinal study evaluating behavioural and 
gastrointestinal symptoms in children with autism before, during and after visceral osteopathic technique (VOT). J Bodyw Mov 
Ther. Elsevier; 2016;20(3):461–70. 
57) De Magistris L, Picardi A, Siniscalco D, Riccio MP, Sapone A, Cariello R, et al. Antibodies against food antigens in patients 
with autistic spectrum disorders. Biomed Res Int. 2013;2013. 
58) Breece E, Paciotti B, Nordahl CW, Ozonoff S, Van de Water JA, Rogers SJ, et al. Myeloid dendritic cells frequencies are 
increased in children with autism spectrum disorder and associated with amygdala volume and repetitive behaviors. Brain 
Behav Immun. 2013;31(916):69–75. 
59) Williams BL, Hornig M, Buie T, Bauman ML, Cho Paik M, Wick I, et al. Impaired carbohydrate digestion and transport 
and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS One. 2011;6(9). 
60) Gondalia S V., Palombo EA, Knowles SR, Cox SB, Meyer D, Austin DW. Molecular Characterisation of Gastrointestinal 




61) Sun C, Xia W, Zhao Y, Li N, Zhao D, Wu L. Nutritional status survey of children with autism and typically developing 
children aged 4-6 years in Heilongjiang Province, China. J Nutr Sci [Internet]. 2013;2:e16. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4153036&tool=pmcentrez&rendertype=abstract 
62) de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of the intestinal barrier in patients 
with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010;51(4):418–24. 
63) Liu X, Liu J, Xiong X, Yang T, Hou N, Liang X, et al. Correlation between Nutrition and Symptoms: Nutritional Survey of 
Children with Autism Spectrum Disorder in Chongqing, China. Nutrients. 2016;8(5):1–15. 
64) Baird G, Charman T, Pickles A, Chandler S, Loucas T, Meldrum D, et al. Regression, developmental trajectory and 
associated problems in disorders in the autism spectrum: The SNAP study. J Autism Dev Disord. 2008;38(10):1827–36. 
65) Smith R a, Farnworth H, Wright B, Allgar V. Are there more bowel symptoms in children with autism compared to 
normal children and children with other developmental and neurological disorders?: A case control study. Autism. 
2009;13(4):343–55. 
66) Lau NM, Green PHR, Taylor AK, Hellberg D, Ajamian M, Tan CZ, et al. Markers of Celiac Disease and Gluten Sensitivity in 
Children with Autism. PLoS One. 2013;8(6):6–11. 
67) Chandler S, Carcani-Rathwell I, Charman T, Pickles A, Loucas T, Meldrum D, et al. Parent-reported gastro-intestinal 
symptoms in children with autism spectrum disorders. J Autism Dev Disord. 2013;43(12):2737–47. 
68) Penn AH, Carver LJ, Herbert C a., Lai TS, McIntire MJ, Howard JT, et al. Breast Milk Protects Against Gastrointestinal 
Symptoms in Infants at High Risk for Autism During Early Development. J Pediatr Gastroenterol Nutr [Internet]. 
2015;62(September):1. Available from: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005176-900000000-97835 
69) Richler J, Luyster R, Risi S, Hsu WL, Dawson G, Bernier R, et al. Is there a “regressive phenotype” of autism spectrum 
disorder associated with the measles-mumps-rubella vaccine? A CPEA study. J Autism Dev Disord. 2006;36(3):299–316. 
70) Napolioni V, Ober-Reynolds B, Szelinger S, Corneveaux JJ, Pawlowski T, Ober-Reynolds S, et al. Plasma cytokine profiling 
in sibling pairs discordant for autism spectrum disorder. J Neuroinflammation [Internet]. 2013;10(1):38. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3616926&tool=pmcentrez&rendertype=abstract 
71) Wang LW, Tancredi DJ, Thomas DW. The prevalence of gastrointestinal problems in children across the United States 
with autism spectrum disorders from families with multiple affected members. J Dev Behav Pediatr. 2011;32(5):351–60. 
72) Levy SE, Souders MC, Ittenbach RF, Giarelli E, Mulberg AE, Pinto-Martin JA. Relationship of Dietary Intake to 
Gastrointestinal Symptoms in Children with Autistic Spectrum Disorders. Biol Psychiatry. 2007;61(4):492–7. 
73) Bresnahan M, Hornig M, Schultz AF, Gunnes N, Hirtz D, Lie KK, et al. Association of Maternal Report of Infant and 
Toddler Gastrointestinal Symptoms With Autism: Evidence From a Prospective Birth Cohort. JAMA psychiatry [Internet]. 
2015;10032(5):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25806498 
 
 112 
74) Sandhu B, Steer C, Golding J, Emond  a. The early stool patterns of young children with autistic spectrum disorder. Arch 
Dis Child. 2009;94(7):497–500. 
75) Attlee A, Kassem H, Hashim M, Obaid RS. Physical Status and Feeding Behavior of Children with Autism. Indian J 
Pediatr. 2015;82(8):682–7. 
76) Wang L, Angley MT, Gerber JP, Young RL, Abarno D V, McKinnon R a, et al. Is urinary indolyl-3-acryloylglycine a 
biomarker for autism with gastrointestinal symptoms? Biomarkers [Internet]. 2009;14(8):596–603. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19697973 
77) Psychiatre M. Brief Report : Preliminary Evidence for Multiple Etiologies in Autism 1. 1986;16(3). 
78) Campbell DB, Buie TM, Winter H, Bauman M, Sutcliffe JS, Perrin JM, et al. Distinct genetic risk based on association of 
MET in families with co-occurring autism and gastrointestinal conditions. Pediatrics. 2009;123(3):1018–24. 
79) Dalrymple NJ, Ruble LA. Toilet training and behaviors of people with autism: Parent views. J Autism Dev Disord. 
1992;22(2):265–75. 
80) Perrin JM, Coury DL, Hyman SL, Cole L, Reynolds  a. M, Clemons T. Complementary and Alternative Medicine Use in a 
Large Pediatric Autism Sample. Pediatrics. 2012;130(Supplement):S77–82. 
81) Coury DL, Anagnostou E, Manning-Courtney P, Reynolds A, Cole L, McCoy R, et al. Use of psychotropic medication in 
children and adolescents with autism spectrum disorders. Pediatrics. Am Acad Pediatrics; 2012;130(Supplement 2):S69–76. 
82) Geier DA, Kern JK, Geier MR. A prospective Cross-sectional Cohort Assessment of Health, Physical, and Behavioral 
Problems in Autism Spectrum Disorders. Mædica [Internet]. 2012;7(3):193–200. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3566881&tool=pmcentrez&rendertype=abstract 
83) Kern JK, Geier DA, Geier MR. Evaluation of regression in autism spectrum disorder based on parental reports. N Am J 
Med Sci. 2014;6(1):41–7. 
84) Harrington JW, Rosen L, Garnecho ANA, Patrick P a. Parental perceptions and use of complementary and alternative 
medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr [Internet]. 2006;27(2 
Suppl):S156-61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16685182 
85) Baker SM, Milivojevich A. Gender differences among children with autism spectrum disorder: differential symptom 
patterns. GlobAdvHealth Med. 2013;2(2164–957X (Print)):8–18. 
86) Campbell DB, Warren D, Sutcliffe JS, Lee EB, Levitt P. Association of MET with social and communication phenotypes in 
individuals with autism spectrum disorder. Am J Med Genet B Neuropsychiatr Genet [Internet]. 2010;153B(2):438–46. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/19548256 
87) Kring SR, Greenberg JS, Seltzer MM. Adolescents and Adults with Autism with and without Co-morbid Psychiatric 
Disorders: Differences in Maternal Well-Being. J Ment Health Res Intellect Disabil. 2008;1(2):53–74. 
88) Peters B, Williams KC, Gorrindo P, Rosenberg D, Lee EB, Levitt P, et al. Rigid-compulsive behaviors are associated with 
mixed bowel symptoms in autism spectrum disorder. J Autism Dev Disord. 2014;44(6):1425–32. 
 
 113 
89) Theoharides TC, Asadi S, Panagiotidou S. A case series of a luteolin formulation (NeuroProtek(R)) in children with 
autism spectrum disorders. Int J Immunopathol Pharmacol [Internet]. 2012;25(2):317–23. Available from: 
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22697063&retmode=ref&cmd=prlinks%5Cnpap
ers3://publication/uuid/828E8577-C8A6-4A32-B9AF-FBAE630D56BA 
90) Corbett B, Khan K, Czapansky-Beilman D, Brady N, Dropik P, Goldman DZ, et al. A double-blind, placebo-controlled 
crossover study investigating the effect of porcine secretin in children with autism. Clin Pediatr (Phila). Westminster 
Publications, Inc. 708 Glen Cove Avenue, Glen Head, NY 11545; 2001;40(6):327–31. 
91) Lightdale JR, Hayer C, Duer  a, Lind-White C, Jenkins S, Siegel B, et al. Effects of intravenous secretin on language and 
behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study. Pediatrics [Internet]. 
2001;108(5):E90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11694674 
92) Chez. Secretin and autism: A two-part clinical investigation [2]. J Autism Dev Disord. 2000;30(2):248–9. 
93) Molloy CA, Manning-Courtney P, Swayne S, Bean J, Brown JM, Murray DS, et al. Lack of Benefit of Intravenous Synthetic 
Human Secretin in the Treatment of Autism. J Autism Dev Disord. 2002;32(6):545–51. 
94) Tomova A, Husarova V, Lakatosova S, Bakos J, Vlkova B, Babinska K, et al. Gastrointestinal microbiota in children with 
autism in Slovakia. Physiol Behav [Internet]. Elsevier Inc.; 2015;138:179–87. Available from: 
http://dx.doi.org/10.1016/j.physbeh.2014.10.033 
95) Unwin LM, Maybery MT, Wray JA, Whitehouse AJO. A “bottom-up” approach to aetiological research in autism spectrum 
disorders. Front Hum Neurosci. 2013;7(606):1–8. 
96) Postorino V, Sanges V, Giovagnoli G, Fatta LM, De Peppo L, Armando M, et al. Clinical differences in children with autism 
spectrum disorder with and without food selectivity. Appetite [Internet]. Elsevier Ltd; 2015;92:126–32. Available from: 
http://dx.doi.org/10.1016/j.appet.2015.05.016 
97) Wilson J, Wright B, Jost S, Smith R, Pearce H, Richardson S. Can urinary indolylacroylglycine (IAG) levels be used to 
determine whether children with autism will benefit from dietary intervention? Pediatr Res. Springer Nature; 2016; 
98) Calderoni S, Santocchi E, Del Bianco T, Brunori E, Caponi L, Paolicchi A, et al. Serological screening for Celiac Disease in 
382 pre-schoolers with Autism Spectrum Disorder. Ital J Pediatr. BioMed Central; 2016;42(1):98. 
99) Valicenti-McDermott M, Burrows B, Bernstein L, Hottinger K, Lawson K, Seijo R, et al. Use of complementary and 
alternative medicine in children with autism and other developmental disabilities: associations with ethnicity, child comorbid 
symptoms, and parental stress. J Child Neurol [Internet]. 2014;29(3):360–7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23372032 
100) Valicenti-McDermott M, Lawson K, Hottinger K, Seijo R, Schechtman M, Shulman L, et al. Parental Stress in Families of 




101) Jyonouchi H, Geng L, Streck DL, Toruner GA. Children with autism spectrum disorders (ASD) who exhibit chronic 
gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities 
and transcriptional profiles of peripheral blood (PB) monocytes. J Neuroimmunol [Internet]. Elsevier B.V.; 2011;238(1–2):73–
80. Available from: http://dx.doi.org/10.1016/j.jneuroim.2011.07.001 
102) Kemperman RFJ, Muskiet FD, Boutier AI, Kema IP, Muskiet FAJ. Brief report: normal intestinal permeability at elevated 
platelet serotonin levels in a subgroup of children with pervasive developmental disorders in Curacao (The Netherlands 
antilles). J Autism Dev Disord. Springer; 2008;38(2):401–6. 
103) Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with 
autistic disorder. J Pediatr [Internet]. 1999;135(5):559–63. Available from: 
http://www.sciencedirect.com/science/article/pii/S0022347699700521 
104) Afzal N, Murch S, Thirrupathy K, Berger L, Fagbemi A, Heuschkel R. Constipation with acquired megarectum in children 
with autism. Pediatrics [Internet]. 2003;112(4):939–42. Available from: 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14523189 
105) Aldinger KA, Lane CJ, Veenstra-VanderWeele J, Levitt P. Patterns of Risk for Multiple Co-Occurring Medical Conditions 
Replicate Across Distinct Cohorts of Children with Autism Spectrum Disorder. Autism Res [Internet]. 2015;(May):771–81. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/26011086 
106) Ekinci O, Arman AR, Melek I, Bez Y, Berkem M. The phenomenology of autistic regression: Subtypes and associated 
factors. Eur Child Adolesc Psychiatry. 2012;21(1):23–9. 
107) McCue LM, Flick LH, Twyman KA, Xian H, Conturo TE. Prevalence of non-febrile seizures in children with idiopathic 
autism spectrum disorder and their unaffected siblings: a retrospective cohort study. BMC Neurol. BioMed Central; 
2016;16(1):245. 
108) Ming X, Stein TP, Barnes V, Rhodes N, Guo L. Metabolic perturbance in autism spectrum disorders: A metabolomics 
study. J Proteome Res. 2012;11(12):5856–62. 
109) Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P. Gastrointestinal dysfunction in autism: Parental 
report, clinical evaluation, and associated factors. Autism Res. 2012;5(2):101–8. 
110) Santocchi E, Guiducci L, Fulceri F, Billeci L, Buzzigoli E, Apicella F, et al. Gut to brain interaction in Autism Spectrum 
Disorders: a randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters. 
BMC Psychiatry [Internet]. BMC Psychiatry; 2016;16(1):183. Available from: 
http://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-016-0887-5 
111) Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism 




112) Jyonouchi H, Geng L, Ruby A, Reddy C, Zimmerman-Bier B. Evaluation of an association between gastrointestinal 
symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr. 
2005;146(5):605–10. 
113) Saad K, Eltayeb AA, Mohamad IL, Al-Atram AA, Elserogy Y, Bjørklund G, et al. A Randomized, Placebo-controlled Trial of 
Digestive Enzymes in Children with Autism Spectrum Disorders. Clin Psychopharmacol Neurosci [Internet]. 2015;13(2):188–
93. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4540030&tool=pmcentrez&rendertype=abstract 
114) Frye RE, Rose S, Slattery J, MacFabe DF. Gastrointestinal dysfunction in autism spectrum disorder: the role of the 
mitochondria and the enteric microbiome. Microb Ecol Health Dis [Internet]. 2015;26:27458. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4425813&tool=pmcentrez&rendertype=abstract 
115) Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella–induced autism. Pediatrics. Am 
Acad Pediatrics; 2001;108(4):e58–e58. 
116) Ferguson BJ, Marler S, Altstein LL, Lee EB, Mazurek MO, McLaughlin A, et al. Associations between cytokines, endocrine 
stress response, and gastrointestinal symptoms in autism spectrum disorder. Brain Behav Immun [Internet]. Elsevier Inc.; 
2016; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27181180 
117) Marler S, Ferguson BJ, Lee EB, Peters B, Williams KC, McDonnell E, et al. Brief Report: Whole Blood Serotonin Levels and 
Gastrointestinal Symptoms in Autism Spectrum Disorder. J Autism Dev Disord. Springer US; 2016;46(3):1124–30. 
118) Kushak RI, Buie TM, Murray KF, Newburg DS, Chen C, Nestoridi E, et al. Evaluation of Intestinal Function in Children 
with Autism and Gastrointestinal Symptoms. J Pediatr Gastroenterol Nutr [Internet]. 2016;62(2004):1. Available from: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005176-900000000-97603 
119) Theoharides TC. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol. 2009;22(4):859–65. 
120) Navarro F, Pearson D a, Fatheree N, Mansour R, Hashmi SS, Rhoads JM. Are “leaky gut” and behavior associated with 
gluten and dairy containing diet in children with autism spectrum disorders? Nutr Neurosci [Internet]. 2014;18(4):177–85. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24564346 
121) Ghosh A, Mahajan PB, Tripathy PR, Mishra BR, Mahapatra SC, Nanda P. Exploring health situation of Indian children 
with autism spectrum disorder using autism treatment evaluation checklist (ATEC) in an urban area of Odisha: A case study. J 
Clin Diagnostic Res. 2015;9(12):VC05-VC08. 
122) Unis AS, Munson JA, Rogers SJ, Goldson E, Osterling J, Gabriels R, et al. A randomized, double-blind, placebo-controlled 
trial of porcine versus synthetic secretin for reducing symptoms of autism. J Am Acad Child Adolesc Psychiatry. Elsevier; 
2002;41(11):1315–21. 
123) Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production 
against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46(2):76–84. 
 
 116 
124) Kang DW, Park JG, Ilhan ZE, Wallstrom G, LaBaer J, Adams JB, et al. Reduced Incidence of Prevotella and Other 
Fermenters in Intestinal Microflora of Autistic Children. PLoS One. 2013;8(7). 
125) Peeters B, Noens I, Philips EM, Kuppens S, Benninga MA. Autism spectrum disorders in children with functional 
defecation disorders. J Pediatr [Internet]. Elsevier Ltd; 2013;163(3):873–8. Available from: 
http://dx.doi.org/10.1016/j.jpeds.2013.02.028 
126) King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with 
autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen 
Psychiatry. American Medical Association; 2009;66(6):583–90. 
127) Russo AJ. Anti-metallothionein IgG and levels of metallothionein in autistic families. Swiss Med Wkly. Basel: EMH Swiss 
Medical Publishers Ltd., c2001-; 2008;138(5–6):70–7. 
128) Russo AJ, Neville L, Wroge C. Low serum alpha-1 antitrypsin (AAT) in family members of individuals with autism 
correlates with PiMZ genotype. Biomark Insights. 2009;2009(4):45–56. 
129) Kazek B, Huzarska M, Grzybowska-Chlebowczyk U, Kajor M, Ciupinska-Kajor M, Wos H, et al. Platelet and intestinal 5-
HT2A receptor mRNA in autistic spectrum disorders - results of a pilot study. Acta Neurobiol Exp [Internet]. 2010;70(2):232–
8. Available from: 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20628446 
130) Walker SJ, Beavers DP, Fortunato J, Krigsman A. A Putative Blood-Based Biomarker for Autism Spectrum Disorder-
Associated Ileocolitis. Sci Rep. Nature Publishing Group; 2016;6. 
131) Walker SJ, Fortunato J, Gonzalez LG, Krigsman A. Identification of Unique Gene Expression Profile in Children with 
Regressive Autism Spectrum Disorder (ASD) and Ileocolitis. PLoS One. 2013;8(3). 
132) Parracho HMRT, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with 
autistic spectrum disorders and that of healthy children. J Med Microbiol. 2005;54(10):987–91. 
133) D’Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from 
children with autism spectrum disorder. Pediatrics [Internet]. 2006;118(4):1664–75. Available from: 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17015560 
134) Hollway JA, Aman MG, Butter E. Correlates and risk markers for sleep disturbance in participants of the autism 
treatment network. J Autism Dev Disord. 2013;43(12):2830–43. 
135) Becker MM, Riesgo RS, Roesler R, Bosa C, Ohlweiler L, Backes B, et al. Improvement in Symptoms of Autism Spectrum 
Disorder in Children With the Use of Gastrin-Releasing Peptide: An Open Trial. Clin Neuropharmacol. LWW; 2016;39(5):215–
9. 
136) Tsilioni I, Dodman N, Petra  a I, Taliou  a, Francis K, Moon-Fanelli  a, et al. Elevated serum neurotensin and CRH levels in 
children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism. Transl Psychiatry 
[Internet]. Nature Publishing Group; 2014;4(10):e466. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25313509 
 
 117 
137) Babinská K, Bucová M, Ďurmanová V, Lakatošová S, Jánošíková D, Bakoš J, et al. Increased plasma levels of the high 
mobility group box 1 protein (HMGB1) are associated with a higher score of gastrointestinal dysfunction in individuals with 
autism. Physiol Res [Internet]. 2014;63 Suppl 4:S613-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25669692 
138) Saresella M, Piancone F, Marventano I, Zoppis M, Hernis A, Zanette M, et al. Multiple inflammasome complexes are 
activated in autistic spectrum disorders. Brain Behav Immun [Internet]. Elsevier Inc.; 2015;57:125–33. Available from: 
http://dx.doi.org/10.1016/j.bbi.2016.03.009 
139) Troost PW, Steenhuis M-P, Tuynman-Qua HG, Kalverdijk LJ, Buitelaar JK, Minderaa RB, et al. Atomoxetine for Attention-
Deficit/Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: APilot Study. J Child Adolesc 
Psychopharmacol. Mary Ann Liebert, Inc. 2 Madison Avenue Larchmont, NY 10538 USA; 2006;16(5):611–9. 
140) Russo AJ. Increased Copper in Individuals with Autism Normalizes Post Zinc Therapy More Efficiently in Individuals 
with Concurrent GI Disease. Nutr Metab Insights [Internet]. 2011;4:49–54. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3738468&tool=pmcentrez&rendertype=abstract 
141) Arnold LE, Aman MG, Hollway J, Hurt E, Bates B, Li X, et al. Placebo-controlled pilot trial of mecamylamine for treatment 
of autism spectrum disorders. J Child Adolesc Psychopharmacol [Internet]. 2012;22(3):198–205. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3417385&tool=pmcentrez&rendertype=abstract 
142) Abdelrahman HM, Sherief LM, Alghobashy AA, Salam SMA, Hashim HM, Fattah NRA, et al. Association of 5-HT2A 
receptor gene polymorphisms with gastrointestinal disorders in Egyptian children with autistic disorder. Res Dev Disabil. 
Elsevier; 2015;36:485–90. 
143) Ming X, Brimacombe M, Chaaban J, Zimmerman-Bier B, Wagner GC. Autism spectrum disorders: concurrent clinical 
disorders. J Child Neurol. SAGE Publications; 2008;23(1):6–13. 
144) Pennesi CM, Klein LC. Effectiveness of the gluten-free, casein-free diet for children diagnosed with autism spectrum 




Table S2. Map of which studies used which GI questionnaires. 
Questionnaires Used in Studies 
ATEC subscale 
Ghosh et al. / 2015 / Journal of Clinical and Diagnostic Research 
ATEC subscale and Global Impressions Survey 
J B Adams et al. / 2011 / BMC Pediatrics 
ATN The Gastrointestinal Symptom Inventory 
Mazurek et al. / 2013 / Journal of Abnormal Child Psychology 
Abdelrahman et al. / 2015 / Research in Developmental Disabilities 
Mazefsky, Schreiber, Olino, & Minshew / 2014 / Autism : The International Journal of Research and Practice 
Bowel Symptom Questionnaire 
Wang et al. / 2012 / Digestive Diseases and Sciences 
Wang et al. / 2013 / Molecular Autism 
Wang et al. / 2011 / Applied and Environmental Microbiology 
CHARGE GIH questionnaire 
Chaidez, Hansen, & Hertz-Picciotto / 2014 / Journal of Autism and Developmental Disorders 
Hansen et al. / 2008 / Ambulatory Pediatrics 
Child Behavior Checklist 
Fulceri et al. / 2016 / Digestive and Liver Disease 
GI symptom questionnaire 
N. Dalton et al. / 2014 / Autism Research 
N. R. Dalton et al. / 2016 / Autism Research 
Global Behavior Rating Scale 
Saad et al. / 2015 / Clinical Psychopharmacology and Neuroscience : The Official Scientific Journal of the Korean  
College of Neuropsychopharmacology 
Levy et al. / 2003 / Archives of Disease in Childhood 
Global Behavior Rating Scale and Additional Rating Scale 
Munasinghe, Oliff, Finn, & Wray / 2010 / Journal of Autism and Developmental Disorders 
Global Impressions Survey 




D.-W. Kang et al. / 2017 / Microbiome 
Health and Mental Health History 
Greenlee, Mosley, Shui, Veenstra-VanderWeele, & Gotham / 2016 / Pediatrics 
IBS global improvement scale 
Handen et al. / 2009 / Journal of Autism and Developmental Disorders 
LUTS 
Gontard, Pirrung, Niemczyk, & Equit / 2015 / Journal of Pediatric Urology 
Modified GI symptom severity index questionnaire 
Pusponegoro, Ismael, Sastroasmoro, Firmansyah, & Vandenplas / 2015 / Pediatric Gastroenterology, Hepatology &  
Nutrition 
NHIS questionnaire 
Phillips et al. / 2014 / Maternal and Child Health Journal 
Parental Concerns Questionnaire & ATN Diagnoses and Problems–Clinician form 
Greenlee et al. / 2016 / Pediatrics 
Rome II 
Pang & Croaker / 2011 / Pediatric Surgery International 
M. Valicenti-McDermott et al. / 2006 / Journal of Developmental and Behavioral Pediatrics : JDBP 
M. D. Valicenti-McDermott, McVicar, Cohen, Wershil, & Shinnar / 2008 / Neurology 
M. Valicenti-McDermott et al. / 2014 / Journal of Child Neurology 
Rome III 
Ferguson et al. / 2016 / Brain, Behavior, and Immunity 
Peeters, Noens, Philips, Kuppens, & Benninga / 2013 / Journal of Pediatrics  
 Marler et al. / 2016 / Journal of Autism and Developmental Disorders 
 Ghalichi, Ghaemmaghami, Malek, & Ostadrahimi / 2016 / World Journal of Pediatrics 
Gorrindo et al. / 2012 / Autism Research 
Pusponegoro, Ismael, Firmansyah, Sastroasmoro, & Vandenplas / 2015 / Acta Paediatrica (Oslo, Norway : 1992) 
Iovene et al. / 2016 / Mycopathologia 
M. Valicenti-McDermott et al. / 2015 / Journal of Child Neurology 
Kheirouri, Kalejahi, & Noorazar / 2016 / Turkish Journal of Medical Sciences 
Ferguson et al. / 2016 / Autism Research : Official Journal of the International Society for Autism Research 
Mostafa & Al-Ayadhi / 2015 / Behavioral and Brain Functions : BBF 
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Gabriele et al. / 2015 / Autism Research : Official Journal of the International Society for Autism Research 
Rome III and their own approach 
Son et al. / 2015 / PloS One 
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King et al. / 2009 / Archives of General Psychiatry 
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Anagnostou et al. / 2016 / Jama Psychiatry 
Secretin Outcome Survey 
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Nikolov et al. / 2009 / Journal of Autism and Developmental Disorders 
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James B Adams, Johansen, Powell, Quig, & Rubin / 2011 / BMC Gastroenterology 
Santocchi et al. / 2016 / BMC Psychiatry 
Ming, Stein, Barnes, Rhodes, & Guo / 2012 / Journal of Proteome Research.  
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Table S3. Associations Examined Between GI Variable and Other Variables among 144 Studies (%) 
Associations examined 
 None 17% 




Outcome group (including age of onset) 46% 
Parental/Family History Factors 3% 
Microbiota-related 3% 
Biological sample 20% 
Health-related variable (such as weight) 10% 
Diet, food selectivity, weaning 12% 
Medications 3% 




Table S4. GI Symptom Estimates, Across Types of Study Samples 























s Population Based 0.29 0.26 
1.80 
(0.14) 
Population Based & Clinic Based 0.19 -- 
Clinic Based 0.49 0.23 
Enriched Risk Sample 0.55 -- 







n Population Based 0.16 0.07 
3.03 
(0.03) 
Population Based & Clinic Based 0.09 -- 
Clinic Based 0.30 0.15 
Enriched Risk Sample 0.45 -- 






Population Based 0.21 0.16 
0.379 
(0.77) 
Population Based & Clinic Based 0.03 -- 
Clinic Based 0.15 0.13 
Enriched Risk Sample -- -- 














rt Population Based 0.15 0.12 
1.79 
(0.51) 
Population Based & Clinic Based 0.05 -- 
Clinic Based 0.13 0.08 
Enriched Risk Sample -- -- 










 Population Based 0.06 0.09 
0.63 
(0.55) 
Population Based & Clinic Based -- -- 
Clinic Based 0.10 0.06 
Enriched Risk Sample -- -- 
























 Population Based 0.12 0.02 
0.55 
(0.59) 
Population Based & Clinic Based -- -- 
Clinic Based 0.12 0.09 
Enriched Risk Sample -- -- 



























p Population Based 0.21 -- 
3.88 
(0.07) 
Population Based & Clinic Based -- -- 
Clinic Based 0.07 0.05 
Enriched Risk Sample -- -- 
















g Population Based 0.19 -- 
0.91 
(0.52) 
Population Based & Clinic Based -- -- 
Clinic Based 0.14 0.09 
Enriched Risk Sample -- -- 
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Individuals with Autism Spectrum Disorder (ASD) tend to have more gastrointestinal (GI) 
symptoms than their typically developing counterparts1–21.  As demonstrated in Chapter 3 of this 
dissertation, the range of symptom estimates across ASD studies is very wide, in part due to the 
many approaches used to assess GI symptoms.  Children with ASD may have difficulties self-
reporting medical symptoms, including GI symptoms and pain.  Questionnaires designed to 
measure GI symptoms in typically developing individuals may not be able to capture GI 
symptoms in all people with ASD.  Questionnaires that have been designed for ASD also have 
limitation, such as not including mealtime or dietary behaviors or not assessing behavioral 
symptoms that may indicate GI distress.  While a number of GI questionnaires have been 
developed specifically for ASD, none reported psychometric properties until very recently 22.   
 
This recent study adapted the Autism Treatment Network Gastrointestinal Inventory (ATN-GI 
Inventory) into a 17-item screener called the AS-ATN GI Signs and Symptoms Inventory-17.  
The four dimensions (factors) identified in this tool (Retentive, Expulsive, Gas, and Motoric) 
were able to predict functional constipation, functional diarrhea, and gastroesophageal reflux 
disease (GERD).  The tool had a sensitivity of 84%, specificity of 43%, and positive predictive 
value of 67% for identifying children with one more of these GI disorders.  The advantage of this 
tool, relative to others, is its inclusion of GI-motoric items such as ‘In the last 3 months, did your 
child appear to feel pain when having a BM?’ or ‘In the last 3 months, did your child push his 
abdomen with his/her hands or your hands, push his/ her abdomen against or lean forward over 
furniture?’  Items such as these may be particularly helpful in identifying GI distress in a non- or 
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hypo-verbal child with ASD.  However, this tool had a limited number of items having to do 
with mealtime or dietary preferences/behaviors, which might be reflective of GI symptoms22.   
 
Therefore, we were interested in developing a modified questionnaire, the ASD Gastrointestinal 
and Related Behaviors Inventory (ASD-GIRBI), that included GI signs and symptoms, 
behavioral items, as well specific items on mealtimes, diet, or eating.  We achieved this by 
drawing on two existing tools, the ATN-GI Inventory and the Brief Autism Mealtime Behavior 
Inventory (BAMBI), as well as deriving new items.  We also evaluate the psychometric 
characteristics of the ASD-GIRBI. 
 
4.2 Methods 
4.2.1.  Phase 1: Development of questionnaire 
4.2.1.1 Review of the literature 
We used the NIH Patient-Reported Outcomes Measurement Information System (PROMIS®) 
Instrument Development and Psychometric Evaluation Scientific Standards to guide the 
development of the Autism Spectrum Disorder Gastrointestinal and Related Behaviors Inventory 
(ASD-GIRBI)23.  We began developing the tool by reviewing the literature on approaches to 
assessing gastrointestinal symptoms in epidemiologic studies of ASD (dissertation Chapter 3- 
published in Autism Research24).  This review guided our development of the item pool and 
signaled to us what relevant items were missing from previous autism gastrointestinal 
questionnaires.  A key finding from this review was that no existing tool assessed GI symptoms, 
mealtime behaviors, as well as other behavioral systems (e.g. aggression, self-injurious behavior, 
sensory sensitivities) that could signal GI distress in a hypo/non-verbal child with ASD.   
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4.2.1.2.  Design of Item Pool 
With permission from the authors, we extracted items from two existing autism tools to begin 
developing the item pool: The ATN-GI25 and the BAMBI26–28.  The ATN-GI Inventory was 
developed by pediatric gastroenterologists from the Autism Speaks-Autism Treatment Network, 
and was designed to assess for functional constipation, functional diarrhea, and GERD22.  The 
BAMBI, an 18-item caregiver-report questionnaire, was designed to evaluate mealtime behaviors 
in children with ASD and has been shown to have good internal consistency, high test-retest 
reliability, and strong criterion-related validity26.  We also added de novo items to our item pool, 
based on our review of the literature, qualitative interviews of children with ASD and their 
parents, and feedback from an expert panel, described below. 
4.2.1.3 Interviews with parents/individuals with ASD 
Prior to, during, and following the development of our initial GI inventory, we held one-on-one 
qualitative interviews with parents of children with ASD.  In some cases, their children would 
join the interview.  Individuals were eligible to participate if they were the parent or caregiver of 
a child with ASD that had a history of GI symptoms during the ages of 3-18.  Individuals with 
ASD who had GI symptoms during these ages were also eligible.  We intentionally did not 
define ‘gastrointestinal symptoms’ or provide examples, unless a potential participant asked for 
clarification, because we wanted to capture all possible GI-related issues to ensure our item pool 
covered all relevant domains.   
 
We used social media outlets (e.g.  Facebook), email listservs, and website postings to recruit 
individuals from advocacy groups and other ASD-centered groups.  We asked individuals to 
share the post with anyone who might be interested, with the aim of attracting a diverse group of 
 
 128 
individuals.  Participants received a $10 Amazon gift card for participating, as well as access to a 
private (for study participants) free webinar, during which we will explain the study findings and 
how the results are being used.   
 
Interviews took 30-45 minutes and were held either in person in a private location such as the 
participant’s home, or through a video/audio conversation using the Zoom Video Conferencing 
Platform.  Interviews were audio recorded and transcribed, and notes were also taken during each 
interview.  One-on-one qualitative interviews were carried out instead of focus groups because of 
difficulties in scheduling multiple parents together.   
 
Participants were asked questions such as ‘What are the gastrointestinal issues your child 
currently struggles with or has struggled with in the past?  What are things you notice about your 
child when they are having GI symptoms/distress?  What are some signs/behaviors that you see?  
What areas related to GI issues have affected your family or your child’s functioning?’  We 
probed participants to expand on their experiences, provide examples, or clarify any remarks.  
The exact language that was used was adapted to each participant.  Simpler language was used 
when also interviewing the child, especially in the case of a co-morbid intellectual disability or 
communication impairment.   
4.2.1.4 Feedback/revisions from experts 
After the initial development of the item pool, a panel of experts was consulted on whether items 
or domains were missing from the tool and whether language or directions were unclear.  The 
panel consisted of experts in ASD, gastroenterology, psychometrics, epidemiology, and public 
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health.  Items were added, removed, or edited for clarity based on feedback from this expert 
group. 
 4.2.1.5 Cognitive Debriefing 
Lastly, cognitive interviews were carried out.  During this in-person session, parents completed a 
sample of items on the tool and were asked to provide feedback on the clarity of wording, the 
relevance of the item, what construct the item conjured for them, and whether the items were 
upsetting or insensitive.  Revisions were made to the questionnaire based on these interviews. 
 
4.2.2 Phase 2: Administering the Questionnaire 
4.2.2.1 Sample 
The study population for phase 2 consisted of a registry of parents with a child with ASD at 
Kennedy Krieger Institute (KKI), a center that combines research, clinical service, therapeutic 
day programs, and training programs for children with developmental disabilities and disorders 
of the brain, spinal cord, and musculoskeletal system.  These parents had previously consented to 
being contacted for research purposes.  We sent an invitation to the 2,335 families whose child 
had a confirmed diagnosis of ASD.  If parents were interested in joining the study, they were 
provided a Qualtrics survey link, which included a consent form, as well as the ASD-GIRBI and 
the Child Behavior Checklist (described below).  All data collection happened electronically.  
Five hundred thirty seven (537) families consented to join the study, of which 444 (83%) 
completed both the ASD-GIRBI and the Child Behavior Checklist.  Parents with a child with 
ASD between the ages of 3-18 were eligible to join the study, regardless of the child’s 




4.2.3.  Ethical Considerations 
For the qualitative, phase 1, portion of the study, parents participating by themselves (without 
their child present) consented to the study.  Individuals with ASD younger than 18 who 
participated with their parents needed parental permission and provided assent.  Individuals with 
ASD 18 or older consented for themselves, unless a caregiver deemed they were not able to, in 
which they case the parent provided permission, and we relied on assent from the individual with 
ASD.   
 
For the online registry phase, the parent or primary caregiver was the informant for all children 
and young adults with ASD (ages 3-17).  Parents completed a consent form online prior to 
completing the study questionnaires.  Participants were provided a phone number and email 
address to contact study staff, as well as contact information for the IRB.   
 
Both phases of this study were approved by the local institutional review board. 
 
4.2.4.  Measures 
4.2.4.1 CBCL 
Participants from the KKI research registry completed either the Child Behavior Checklist 
(CBCL) 1.5-5 or the CBCL 6-18, depending on their age.  The CBCL is a reliable, valid 99-item 
questionnaire completed by the parent/caregiver who spends the most time with the child.  The 
CBCL can be completed at home in 10-20 minutes.  For each problem item, such as “disturbed 
by any change in routine”, parents are asked to rate how true each item is for their child is: not 
true (within past 6 months), somewhat or sometimes true (within past 6 months), or very true or 
 
 131 
often true (based on the past 2 months)29–31.  Each syndrome domain can be scored as being in 
the normal range, in an area of concern but not considered very deviant, or in the clinical range, 
based on scores from a national normative sample.  We derived a score from each of the 
following CBCL domains: Anxiety/Depression, Emotionally Reactive, Somatic Complaints, 
Withdrawn, Attention Problems, Aggressive Behavior, and Sleep Problems.   
4.2.4.2.  GI questionnaire 
The initial GI questionnaire, prior to revision following the psychometric analysis, consisted of 
56 core items, with an additional 8 follow-up questions if certain core items were endorsed.  
Only the 56 core items were used in the psychometric analysis.  The first section asked parents to 
report physical/mental health diagnoses (n=14 items).  The core set of questions included four 
sections: 1) 11 gastrointestinal symptoms, with follow-up questions on symptom duration (within 
the last 3 months only, 3-5 months, 6-11 months, 1 year or longer, not sure) and GI symptom 
association with bowel movements, eating, and weight (2) frequency of bowel movements and 
stool consistency (Bristol stool chart32) in addition to seven items on bathroom/toileting 
behaviors, 3) 20 items on mealtime and dietary behaviors , and 4) 13 other behaviors (e.g.  
unexplained irritability, agitation, aggression, or screaming; chewing on shirts, eating non-edible 
objects; pointing to stomach/tummy as if in pain).  Parents were also asked about medications 
their child was taking, how GI symptoms impacted their child’s functioning, and their 
confidence in accurately assessing their child’s pain level.  The full questionnaire can be found in 
the Appendix. 
 
4.2.5.  Analysis 
4.2.5.1.  Phase 1 Qualitative Interviews 
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Directed content analysis was carried out using a general inductive approach for each qualitative 
interview33,34.  Major themes were identified and summarized.  In addition, particular examples 
of GI symptoms, mealtime/dietary behaviors, and other signs/behaviors that indicate GI distress 
in children with ASD were extracted for inclusion in the questionnaire. 
 
4.2.5.2 Phase 2 Statistical Analysis 
We carried out a psychometric assessment of the ASD-GIRBI by performing exploratory factor 
analysis, assessing the reliability of the tool with Cronbach’s alpha, and assessing convergent 
validity.  The 56 core GI questionnaire items were used for psychometric assessment (GI 
symptoms, toileting behavior and bowel movements, mealtime and dietary behaviors, other 
behaviors).  Questions only answered by a subset of participants, for example, questions about 
the duration of GI symptoms, were not included in the psychometric analysis.  All data cleaning 
and analyses were performed in R Studio version 1.1.383 (R version 3.4.3).  Because of 
insufficient sample size for children ages 3-5, we only carried out the factor analysis and 
assessments of reliability and convergent validity in the group 6-17 years of age.   
4.2.5.3 Factor Analysis 
We performed exploratory factor analysis (EFA) on the individuals ages 6-17 in order to 
determine the factor structure of the GI questionnaire.  We first dropped items endorsed by <10% 
of individuals, items that decreased the scale’s internal consistency (Cronbach’s alpha), and 
items that did not load onto a factor (score <0.30).  No two items had a pairwise correlation 
greater than 0.70, suggesting we did not have redundant items.  We followed the 5-step 
procedure recommended by Costello and Osborne35.  The Psych package in R was used to 
perform parallel analysis of principal components using minimum residuals, in order to extract 
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factors.  We chose oblimin rotation (oblique), allowing factors to be correlated to each other.  
After dropping items from the measure based on the EFA findings, we evaluated the factor 
structure using fit indices, including the root mean square error of approximation (RMSEA), the 
comparative fit index (CFI), and the Tucker-Lewis index (TLI).  A CFI and TLI of >0.9 is 
considered an acceptable fit and a RMSEA <0.10 is considered a good fit36,37. 
 
We calculated factor scores by taking the sum of the number of items endorsed by the person for 
each factor.  For example, if a factor consisted of 7 items, individuals who endorsed all 7 items 
would receive a factor score of 7, while those who did not endorse any of the items would 
receive a score of 0. 
 
4.2.5.3 Reliability 
We assessed the reliability of the total scale and of each item via Cronbach’s alpha and item-rest 
correlations, respectively.  Dropped items that decreased the scale’s internal consistency 
(Cronbach’s alpha) were omitted. 
4.2.5.3 Convergent validity 
Convergent validity is ‘evidence of similarity between measures of theoretically related 
constructs’.  This was assessed by estimating associations between factor scores and subscales on 
the CBCL, parent-report GI diagnoses, and parent-report functioning impairment due to GI 
symptoms38.  Associations with directions and magnitudes as expected suggest good convergent 




4.3.1.  Participant Characteristics 
4.3.1.1 Phase 1 
We carried out 12 qualitative interviews with parents of children with ASD, two of which also 
included the child.  Ten of the interviews were with the mother, and the remaining two were with 
the father.  All but three interviews were in reference to children still under the age of 18.  
Eleven of the individuals with ASD were male, and one was female.  
 
4.3.1.2 Phase 2 
Of the 2,335 study invitations sent to KKI registry families, 537 participants consented to 
complete the survey.  Individuals who did not complete both the GI tool as well as the CBCL 
were excluded (n=93), leaving 444 children (Figure 1).  The majority (75%) of these children 
were between the ages of 6-17 years old (Table 1).  Over 90% of participants who completed the 
survey on behalf of their child were mothers and highly educated, with 89-90% having some 
college/AA education or greater.  Children identified as mostly male (83% in 3-5 year olds, 78% 
in 6-17 year olds).  Just over half (52-59% of participants were white, 18-25% were black or 
African-American, 14-16% multiracial, 7-8% Asian, and 7-9% Hispanic/Latino).  The most 
common medical diagnoses were allergies/asthma, gastrointestinal disorders, and sleep disorders.  
The most common psychiatric/developmental disorders endorsed were sensory processing 
disorder, anxiety, panic, or phobia disorder, ADD/ADHD, intellectual disability, and obsessive-
















Table 1. Demographic Characteristics of Study Participants (% or mean (SD)) 
 
 
Ages 3-5 years  
(n=110) 
Ages 6-17 years 
(n=334) 
Child age (years) 4.3 (0.75) 9.5 (3.09) 
Respondent relationship to child 
  Mother 93% 92% 
Parent education level 
  High school graduate/GED or below 12% 11% 
Some college/AA education 32% 19% 
College/AA degree 25% 32% 
Graduate education 32% 39% 
Child biological sex 
  Female 22% 25% 
Male 78% 75% 
Child gender identity 
  Female 17% 21% 
Male 83% 78% 
Non-binary, gender-queer, gender-fluid, or transgender 0% 1% 
Child race/ethnicity 
  White 52% 59% 
Black/African-American 25% 18% 
Multiracial 14% 16% 
Asian 8% 7% 














Table 2. Self-reported Psychiatric and Medical Diagnoses of Study Participants 
 
Ages 3-5 years  
(n=110) 
Ages 6-17 years 
(n=334) 
Psychiatric and Medical Diagnoses   
Any gastrointestinal disorder 19% 20% 
Seizure/Epilepsy disorder 2% 7% 
Intellectual Disability 26% 31% 
ADD/ADHD 12% 55% 
Sensory processing disorder 50% 49% 
Anxiety, panic, or phobia disorder 15% 39% 
OCD 7% 13% 
Tic/Tourette’s disorder 2% 3% 
Depression 1% 8% 
Bipolar disorder 1% 1% 
Sleep disorder 8% 16% 
Autoimmune disorder 2% 3% 
Allergies or Asthma 27% 39% 
Other 13% 18% 
Gastrointestinal Disorder 
  Acid Reflux / GERD / Rumination 8% 6% 
Constipation 6% 6% 
Food Intolerance / Sensitivity / Celiac Disease 2% 1% 
Encopresis 0% 2% 
Medications 
  Antidepressant 2% 12% 
Antipsychotic / Tranquilizer 3% 6% 
Anti-anxiety medication (e.g. benzodiazepine or hypnotics) 1% 14% 
Mood stabilizer 0% 10% 
Stimulant 2% 19% 
Anticonvulsant 1% 4% 
Prescription sleep medication 5% 10% 
Hypotensive medication 1% 5% 
Other 11% 22% 
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4.3.2.  Exploratory Factor Analysis 
Exploratory factor analysis was carried out only among the 6-17 year olds (n=334), because of 
an insufficient sample size in the younger group (n=110).  Two items were dropped for being 
endorsed by <10% participants (BM frequency >3 per day and pushing on their own 
chest/neck/throat).  Seven items were removed for lowering the scale’s overall Cronbach’s alpha 
(reflux or heartburn, having constipation, i.e. type 1 & 2 on Bristol Stool Chart, having diarrhea, 
i.e. types 5, 6, and 7 on Bristol Stool Chart, inflexibility about mealtimes routines (e.g. times for 
meals, place settings, seating arrangements, meal locations), preferring only sweet foods, being 
on a special diet (e.g. gluten free, casein free, FODMAPS, GAPS), and drinking lots of water 
with meals.  Finally, twelve items were dropped for not loading onto a factor (difficulty 
falling/staying asleep, having ideal stool consistency, i.e. types 3 & 4 on Bristol Stool Scale, 
refusing foods that require lots of chewing, chewing on non-edible objects, abdominal swelling 
or distention, avoiding wearing tight clothing or clothing with waistbands, frequent clearing of 
throat, swallowing, coughing, gagging, choking, or throat sounding wet or gurgly, unexplained 
irritability, agitation, aggression, or screaming, bowel movement frequency <3 per week, rushing 
to the bathroom for a bowel movement, moaning or groaning for no apparent reason, alternating 
diarrhea and constipation).  In total, the number of core items dropped from 56 to 35 items. 
 
A seven-factor solution emerged as the best fit for the data (Factor 1: constipation & pain during 
bowel movements, Factor 2: doesn’t want food at times, Factor 3: Particular with foods, Factor 
4: abdominal pain/vomiting/gassiness/diarrhea, Factor 5: incontinence/soiling/wetting the bed, 
Factor 6: aggressive/disruptive at mealtimes, Factor 7: Other behaviors).  Factor loadings for 
each questionnaire item can be found in Table S2.  Table S3 summarizes correlations between 
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factor scores.  Pairwise correlations between factor scores were weak, ranging from 0.04 (factors 
4 and 6) to 0.34 (factors 1 and 4).  The items belonging to each factor are shown in Box 1.  The 
distribution of factor scores can be found in Figure S1.  The RMSEA of the scale was 0.06, 
indicating a good fit, and the TLI was 0.83.  In total, the seven factors accounted 39% of the 
scale, with each factor accounting for 3-7% of the variance.   
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Appear to feel 
pain when having 
a BM 
 
Stiffen their legs 
or squeeze their 
bottom and legs 
together when 
they felt need to 








passing a stool 
Factor 2: 
Doesn’t want food 
at times 
 
Turns their face or 
body away from 
food 
 
Closes their mouth 
tightly when food is 
presented 
 
Spits out food that 
they have put in their 
mouth 
 
Stops eating after 
just a little food 
 
Does no remain 
seated at the table 
until the meal at 
finished 
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Stiffen their legs 
or squeeze their 
bottom and legs 
together when 
they felt need to 
have a BM 
 
Stain or soil 
underwear 
 



























putting their fist 













pushing on it 




















cItems with a factor loading greater or equal to 0.30 were assigned to a factor. Items could load onto more than one factor. 
 
 141 
4.3.3.  Reliability 
Table 3 summarizes the alpha and item-rest coefficients and item prevalences for the final 35 
items in the GI tool.  The Cronbach’s alpha for individual items was 0.84-0.54.  The overall 
alpha for the scale was 0.85.   
 
4.3.4.  Convergent validity 
Children with a parent-reported diagnosis of any GI disorder were significantly more likely to 
have higher clinical scores on factor 1 (constipation & bowel movement pain), factor 3 
(particular with foods), factor 4 (abdominal pain/vomiting/gassiness/diarrhea), factor 5 
(incontinence/soiling/wetting the bed), and factor 7 (other behaviors) (p<0.05).  Children with a 
parent-reported diagnosis of acid reflux, GERD, or rumination were significantly more likely to 
have higher clinical scores on factor 3 (particular with foods) and factor 4 (abdominal 
pain/vomiting/gassiness/diarrhea) (p<0.05).  Children with a parent-reported diagnosis of 
constipation were significantly more likely to have higher clinical scores on factor 1 
(constipation and bowel movement pain) and factor 3 (particular with foods) (Table 4).   
 
Correlations were calculated between factor scores and CBCL subscales (Table S4).  
Correlations between factor scores and the CBCL subscales were weak on average.  The highest 
correlations were between 0.30-0.35, with the following subscales: aggressive behavior, somatic 
complaints, social problems, and thought problems.  Factors 3 (particular with foods) and 5 





We estimated the mean difference in clinical factor scores across levels of functional impairment 
due to GI symptoms (missed school/was late, missed social/family activities, trouble 
falling/staying asleep).  Almost all factor scores were significantly associated with these three 
types of functional impairment (p<0.05) (Table S5). 
 
Lastly, for the factors that were significantly associated with a parent-report GI diagnosis, we 
calculated the sensitivity, specificity, and area under the curve (AUC) of Received Operating 
Characteristic (ROC) Curves, in order to assess how factor scores predict self-reported GI 
diagnoses.  We were primarily interested in maximizing sensitivity (correctly identifying 
children who have GI symptoms), so we set a threshold score of 1, meaning individuals scoring 
at least a 1 on a factor were classified as screening ‘positive’.  Factors 1, 3, 4, and 5 all had 
relatively high sensitivities for detecting any GI disorder at a cut off of 1 point (89%, 91%, 86%, 
and 80%, respectively) (Table 5).  Factor 7 had a low sensitivity for any GI disorder (56%).  We 
chose Factor 1 as the optimal screener for any GI disorder, because it had a high sensitivity 
(89%), and a higher specificity than factor 3 (31% vs. 6%), and a higher AUC than factor 3 (69% 
vs. 51%).  Factors 1 and 3 both had high sensitivity in detecting constipation (both 95%, though 
Factor 1 had a higher specificity than factor 3 (24% vs. 7%) as well as a higher AUC (71% vs. 
55%).  Therefore, Factor 1 was also the optimal predictor of constipation.  Factors 3 and 4 both 
had relatively high sensitivities for predicting acid reflux/GERD/rumination (85% and 90%, 
respectively).  However, Factor 4 had a higher specificity (26% vs. 6%) as well as a higher AUC 
(65% vs. 58%), so it was the optimal screener.   
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Table 3. Cronbach’s Alpha for Total ASD-GIRBI Scale and Individual Items, among Children 6-17 Years  
 
 








Abdominal pain 0.51 0.85 45% 
Nausea, vomiting, or retching/dry heaving 0.37 0.85 23% 
Bloating 0.48 0.84 27% 
Flatulence or gas 0.50 0.85 61% 
Diarrhea 0.41 0.85 39% 
Constipation 0.45 0.85 58% 
Incontinence / Lack of voluntary control or urination or defecation 0.34 0.85 19% 
Fecal Retention / complete elimination of stool 0.36 0.85 19% 
Appear to feel pain when having a BM 0.46 0.85 42% 
Stiffen their legs or squeeze their bottom and legs together when they felt 
need to have a BM 0.56 0.85 39% 
Stain or soil underwear 0.46 0.85 48% 
Wet the bed 0.33 0.85 29% 
Become more active after passing a stool 0.53 0.85 49% 
Become less irritable after passing a stool 0.56 0.85 56% 
Turns their face or body away from food 0.49 0.85 44% 
Closes their mouth tightly when food is presented 0.47 0.85 28% 
Spits out food that they have put in their mouth 0.51 0.85 35% 
Stops eating after just a little food 0.42 0.85 50% 
Remains seated at the table until the meal at finished 0.32 0.85 36% 
Cries or screams during mealtimes 0.34 0.85 18% 
Is aggressive during mealtimes (hitting, kicking, scratching others) 0.40 0.85 14% 

















Is disruptive during mealtimes (pushing/throwing utensils or food) 0.43 0.85 18% 
Is willing to try new foods 0.42 0.85 44% 
Accepts or prefers a variety of foods 0.41 0.85 38% 
Prefers the same foods at each meal 0.34 0.85 84% 
Prefers food prepared in a particular way (e.g. eats mostly fried foods, cold 
cereals, raw vegetables) 0.40 0.85 75% 
Prefers to avoid eating a particular types of food group (e.g. vegetables, meats, 
dairy) 0.40 0.85 73% 
Strongly prefers certain types of food colors, textures, or temperatures 0.46 0.85 74% 
Applying pressure to their abdomen by pushing on it or leaning on furniture 0.49 0.85 30% 
Unusual movements such as thrusting jaw, tilting head, arching back, or twisting 
neck/body 0.40 0.85 19% 
Gritting teeth, wincing, or grimacing for no apparent reason 0.44 0.85 23% 
Biting themselves, putting their fist in their mouth, or hurting themselves in 
other ways 0.34 0.85 16% 
Pointing to stomach/tummy as if in pain 0.39 0.85 16% 









Acid Reflux / GERD / 
Rumination Constipation 
Factor 1 - Constipation & Bowel Movement Pain 3.32 vs.1.89* 3.05 vs.2.4 3.8 vs.2.35* 
Factor 2 - Doesn’t want food at times 1.97 vs.1.98 2.2 vs.2.04 2 vs.2.05 
Factor 3 - Particular with foods 3.77 vs.3.75* 4.15 vs.3.76* 4.1 vs.3.77* 
Factor 4 - Abdominal Pain / Vomiting / Gassiness / Diarrhea 3.02 vs.1.92* 3.3 vs.2.27* 2.4 vs.2.33 
Factor 5 - Incontinence / Soil / Wet bed 2.11 vs.1.1* 1.4 vs.1.41 1.85 vs.1.39 
Factor 6 - Aggressive/ Disruptive at Mealtimes 0.74 vs.0.65 0.85 vs.0.75 0.9 vs.0.74 
Factor 7 - Other behaviors 0.92 vs.0.54* 1.05 vs.0.66 0.85 vs.0.67 




Table 5. Sensitivity, Specificity, and Area Under the Curve of ASD-GIRBI Clinical Factor Scores in Predicting Parent-Report 
Gastrointestinal Disorder Diagnoses 
 
  
Sensitivitya Specificitya Area Under the Curve 
Any gastrointestinal disorderb Factor 1 Score 89% 31% 69% 
Any gastrointestinal disorder Factor 3 Score 91% 6% 51% 
Any gastrointestinal disorder Factor 4 Score 86% 31% 66% 
Any gastrointestinal disorder Factor 5 Score 80% 42% 69% 
Any gastrointestinal disorder Factor 7 Score 56% 62% 61% 
Constipationb Factor 1 Score 95% 24% 71% 
Constipation Factor 3 Score 95% 7% 55% 
Acid Reflux / GERD / Rumination Factor 3 Score 85% 6% 58% 
Acid Reflux / GERD / Ruminationb Factor 4 Score 90% 26% 65% 
aSensitivity and specificity were calculated for a factor score cut-off of 1. 








In this study we developed a parent-report screener for GI symptoms in children with ASD.  This 
tool included GI signs and symptoms, as well as items on mealtime and dietary behaviors, and 
other less-specific behaviors, which could indicate GI distress in a non/hypo-verbal child with 
ASD.  This 35-item screener was derived from two existing tools: The ATN GI Inventory and 
the BAMBI, and also included new items.  Two factors on the screener detected parent-report of 
any GI disorder, constipation, and acid reflux/GERD/rumination with very high sensitivity (89%, 
90%, and 95%).   
  
We found the ASD-GIRBI to be an internally consistent for detecting GI symptoms in children 
with ASD ages 6-17 years old.  The Cronbach’s alpha was good for all items (0.84-0.84) and for 
the whole scale (0.85).  Exploratory factor analysis identified a seven-factor model.  Factor 1 
included items having to do with constipation.  Bloating, pain during bowel movements, fecal 
retention/incomplete elimination, becoming more active or less irritable after a stool, or 
squeezing legs/bottom together when needing to go to the bathroom, are all items that don’t 
directly measure constipation, but all indicate that a child is in distress/pain, is withholding stool, 
and doesn’t want to use the toilet.  The 95% sensitivity of this factor score in identifying 
diagnosis of constipation is therefore not surprising.  Factor 2 had to do with a child not wanting 
food at times.  Indicators of this included the child turning away from food, closing their mouth 
tightly when food is presented, spitting out food, stopping eating after just a little food, crying or 
screaming during a mealtime, or not remaining seated for the duration of a meal.  This factor was 
not significantly associated with any GI disorder, though it was weakly associated with 
aggressive behavior on the CBCL, and associated with missed school or being late, missing 
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social or family activities, and trouble falling or staying asleep.  Factor 3 included items 
reflecting food preferences and aversion.  This factor had quite high sensitivity in identifying 
individuals with any GI disorder, or with constipation, or acid reflux/GERD/rumination.  This 
likely reflects the strong comorbidity between food preferences/aversions and having GI 
symptoms.  Factor 4 was more difficult to interpret, as it included abdominal pain, nausea or 
vomiting, bloating, flatulence, or gas, and diarrhea, and also two indicators of pain (pointing to 
stomach/tummy or direct verbalizations).  This factor was chosen to screen for individuals with 
acid reflux, as it had a sensitivity of 90% and a specificity of 26%.  Factor 5 included items 
having to do with incontinence, soiling, or wetting the bed.  It included items in common with 
the constipation factor (factor 1), which is expected.  Factor 6 had to do with aggressive or 
disruptive behavior during mealtime, including crying, screaming, being aggressive, self-
injurious, and disruptive, for example, pushing or throwing utensils or food.  This factor was not 
significantly associated with any GI disorder, though like factor 2 (not wanting food at times), it 
was still associated with aggressive behavior and thought problems on the CBCL, and with 
trouble falling or staying asleep.  Lastly, factor 7 included 3 non-specific behaviors (e.g.  
‘applying pressure to their abdomen by pushing on it or leaning on furniture’), which could 
indicate GI distress in a non- or hypo-verbal child with ASD.  While we found strong and 
significant associations between factor scores on the ASD-GIRBI and parent-reported diagnoses 
of GI disorders, the association between the items in factor 7 and having any GI diagnosis was 
notable.  However, it was not useful as a screener in ROC analyses, as will be described in 




Correlations between factor scores and the CBCL subscales were weak to moderate on average.  
However, all correlations were positive in magnitude, meaning having worse GI or related 
symptoms were associated with problems on the CBCL.  The highest correlations we found were 
between factor 1 (constipation and bowel movement pain) and somatic complaints (r=0.34), 
factor 2 (not wanting foods at times) with aggressive behavior (r=0.34), factor 4 (abdominal 
pain/vomiting/gassiness/diarrhea) and somatic complaints (r=0.54) and social problems (r=0.34).  
Factor 6 (aggressive/disruptive at mealtimes) was associated with aggressive behavior (r=0.42) 
and thought problems (r=0.34).  Lastly, factor 7 (other behaviors) was correlated with thought 
problems (r=0.34).  Given that none of the CBCL subscales are measuring GI symptoms, we 
would not expect to find very strong associations.  Seeing moderate, positive correlations with 
somatic complaints and aggressive behaviors, for example, provide some evidence of convergent 
validity. 
 
Lastly, every single factor on the ASD-GIRB was significantly associated with greater levels of 
functional impairment at school, in social settings, or with sleeping, or in many cases, all of the 
above.  This not only provides further evidence of convergent validity of our tool, but also 
highlights how GI and related symptoms may impact a child’s functioning across multiple 
settings and may influence other health comorbidities.   
 
In ROC analyses, using a cut-off score of 1, we found that factor 1, having to do with 
constipation and bowel movement pain) detected any parent-reported GI diagnosis and 
constipation with sensitivities of 89% and 95%, respectively.  Factor 4 (abdominal 
pain/vomiting/gassiness/diarrhea) detected parent-report diagnosis of acid 
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reflux/GERD/rumination with a sensitivity of 90%.  We were particularly interested in 
developing a sensitive screener, since children with GI symptoms who are able to self-report 
complaints to their parents are likely to be identified without the need for a GI questionnaire.  
Therefore, we found the low specificities (ranging from 26% to 31%) acceptable.  Factor 3, 
being particular with foods, was also highly sensitive for any GI disorder or constipation (>90% 
sensitivity), but the specificity of this factor was <10%.  This is not surprising, as food 
preferences may reflect other issues such as sensory sensitivities, independent of GI symptoms.  
The high sensitivity of this factor reflects the strong association between having GI symptoms 
and dietary preferences/aversions.  It is striking that in our analysis of 6-17 year old children, 
84% prefer the same foods at each meal, 75% prefer foods prepared a particular way, 73% 
avoids eating a particular type of food group, and 74% strongly prefer certain types of food 
colors, textures, or temperatures.  This is in contrast to 44% who are willing to try new foods and 
38% who accept or prefer a variety of foods.   
 
We expected non-specific behaviors to be more predictive of GI diagnoses.  Following 
psychometric analysis of our tool, we removed seven non-specific items because of either low 
endorsement (n=1) or not loading onto a factor (n=6).  Three items remained in Factor 7: 1) 
applying pressure to their abdominal by pushing on it or leaning on furniture, 2) unusual 
movements such as thrusting jaw, tilting head, arching back, or twisting neck/body, and 3) 
gritting teeth, wincing, or grimacing for no apparent reason.  Three other behavioral items loaded 
onto two other factors.  Having at least one of these Factor 7 items captured 56% of the 
constipation diagnoses, with a specificity of 62%.  Behaviors including pointing to the 
stomach/tummy as if in pain (factor 4), direction vocalizations of pain (factor 4), becoming more 
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active/less irritable after passing a stool (factor 1), and stiffening/squeezing legs or bottom 
together (factor 1) were included in the final screener, and were predictive of GI disorders, 
suggesting that these behavioral items do play a role in helping with the identification of GI 
disorders in children with ASD.  Only 40% of parents reported their child either points to their 
stomach/tummy if in pain or directly verbalizes they are in pain, meaning the majority must rely 
on something else to detect this, or are unsure when their child is in pain.  Indeed, among the 
parents of children 6-17 years old, 12% reported they were not confident at all in assessing their 
child’s GI pain, 23% reported they were slightly confident, 56% were fairly confident, and only 
18% were completely confident.   
 
There were a number of limitations to this study.  Perhaps most importantly, we did not have a 
gold-standard measure of GI symptoms to compare our tool against.  We relied on parent-report 
of GI diagnoses to calculate sensitivity and specificity.  Ideally, every child in our study would 
have been assessed for a GI disorder by a physician; however, this was not feasible.  Even if 
feasible, the more critical issue is that there is currently no gold-standard approach to assessing 
for GI disorders in this population.  Even a trained gastroenterologist may misclassify someone 
as not having a GI disorder, if the patient or a proxy respondent is not able to accurately report 
symptoms.  This is especially the case for ‘functional GI disorders’, which are GI conditions that 
cannot currently be attribute to another medical condition39.  In fact, rates of parent-report of GI 
diagnoses in this study may be an underestimates if children with GI disorders haven’t been 
recognized as having one.  For these reasons, we focused on measures of consistency.  Another 
limitation of this study is that due to an insufficient sample size in children less than six years 
old, we were only able to carry out the psychometric analysis among children 6-17 years old.  
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The performance of individual items and the factor model would likely differ in this younger 
group.  Next, our response rate was relatively low, at 23%.  This is not uncommon in research, 
particularly internet-based research, but likely means our sample is not representative of all 
children with ASD.  Similarly, the frequency of GI and related behaviors from this study should 
not be taken as representative of the underlying ASD population, as parents with children who 
have more severe GI symptoms are more likely to participate in studies like this, though we 
didn’t have data to confirm this.  We unfortunately did not have demographic or clinical 
information on families who did not wish to enroll in the study, so we cannot assess how similar 
or different the non-participants are from our study sample. 
 
Our study also had a number of strengths.  First, we developed a new parent-report tool for 
detecting GI symptoms among children with ASD, using two existing tools as well as new items, 
derived from qualitative interviews with parents of children with ASD and review by an expert 
panel.  Therefore, we feel confident that this tool has a high degree of content validity.  We also 
followed PROMIS guidelines for instrument development and psychometric evaluation.  This 
study is only the second to carry out a psychometric assessment of a GI assessment tool for 
individuals with ASD.  The first psychometric study came out in 2018, was also based off of the 
ATN-GI Inventory, and has items in common with the tool analyzed in the present study22.  
 
Factors 1 and 4, which together consist of 13 items, are the only factors necessary to identify 
children with any GI disorder, constipation, or acid reflux with high sensitivity.  However, the 
other items on this questionnaire may provide useful and contextual information for parents, 
researchers, and clinicians alike.  In addition to including questions on GI symptoms, mealtime 
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and dietary behaviors, and other non-specific GI items, we also included three questions on how 
a child’s GI symptoms affect their functioning.  While not part of the psychometric analysis 
presented here, items on duration of symptoms, how symptoms change following a bowel 
movement, eating, as well as which medications children are taking also provide useful 
information.  The parent-report nature of this tool is useful for epidemiologic studies because it is 
inexpensive and easy to administer to study participants.   
 
The next steps for this project include carrying out item response theory to better understand 
which specific items within each factor are especially informative and useful in predicting GI 
disorders.  Latent class analyses of individuals in this study could also be performed to identify 
subgroups of children with ASD with particular types of GI and related symptoms.  Although not 
without limitations, physician assessment would be very useful to achieve a more accurate 
picture of which children have an underlying GI disorder.  Lastly, other independent ASD 
samples are needed to assess the performance of this questionnaire. 
 
While the need for more accurate assessment of GI issues in ASD has started to receive 
increasing attention, there is still much work to be done.  Parent- and self-report tools need 
further validation efforts in diverse groups of people with ASD.  Tools developed for research 
purposes, such as this one, may provide useful in clinical settings as well.  Individuals with ASD 
deserve to have their GI symptoms recognized and treated with the same quality as typically 
developing individuals do.   
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Table S1. Gastrointestinal Symptoms, Bathroom-Related Behaviors, Mealtime/Dietary Behaviors, and Other Behaviors in Last 
three Months, Stratified by Age (%) 
 
 
Ages 3-5 years 
(n=110) 
Ages 6-17 years 
(n=334) 
Gastrointestinal Symptoms 
  Abdominal pain 25% 40% 
Nausea, vomiting, or retching/dry heaving 24% 22% 
Reflux or heartburn 15% 14% 
Abdominal swelling or distention 12% 13% 
Bloating 22% 24% 
Flatulence or gas 53% 59% 
Diarrhea 46% 37% 
Constipation 64% 54% 
Alternating diarrhea and constipation 33% 22% 
Incontinence / Lack of voluntary control or urination or defecation 24% 18% 
Fecal Retention / complete elimination of stool 22% 16% 
Any of the above 83% 83% 
Bristol Stool Chart – Constipation (Types 1 & 2) 53% 51% 
Bristol Stool Chart – Diarrhea (Types 5,6,7) 34% 25% 
Bristol Stool Chart – Ideal (Types 3 &4) 49% 57% 
Average BM more than 3 per day 5% 3% 
Average BM less than three per week 15% 17% 
Bathroom-Related Behaviors 
  Appear to feel pain when having a BM 40% 36% 
Rush to the bathroom for a BM 35% 52% 
Stiffen their legs or squeeze their bottom and legs together when they  
felt need to have a BM 45% 32% 
Stain or soil underwear 58% 47% 
Wet the bed 43% 29% 
Become more active after passing a stool 53% 37% 
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Become less irritable after passing a stool 48% 45% 
Mealtime and Dietary Behaviors - several times per month or more 
  Turns their face or body away from food 68% 43% 
Closes their mouth tightly when food is presented 57% 27% 
Spits out food that they have put in their mouth 56% 34% 
Stops eating after just a little food 66% 49% 
Remains seated at the table until the meal at finished 45% 62% 
Cries or screams during mealtimes 41% 18% 
Is aggressive during mealtimes (hitting, kicking, scratching others) 25% 14% 
Displays self-injurious behavior during mealtimes (hitting self, biting  
self) 12% 10% 
Is disruptive during mealtimes (pushing/throwing utensils or food) 41% 18% 
Is flexible about mealtime routines (e.g. times for meals, place settings,  
seating arrangements, meal locations) 74% 76% 
Is willing to try new foods 35% 55% 
Accepts or prefers a variety of foods 45% 62% 
Prefers the same foods at each meal 89% 83% 
Prefers food prepared in a particular way (e.g. eats mostly fried foods,  
cold cereals, raw vegetables) 78% 72% 
Prefers to avoid eating a particular types of food group (e.g. vegetables,  
meats, dairy) 76% 71% 
Strongly prefers certain types of food colors, textures, or temperatures 70% 73% 
Refuses to eat foods that require a lot of chewing (e.g. eats only soft or  
pureed foods)  29% 19% 
Prefers only sweet foods (e.g. candy, sugary cereals) 54% 47% 
Is on a special diet (e.g. gluten free, casein free, FODMAPS, GAPS) 14% 15% 
Drinks lots of water with meals 71% 69% 
Other Behaviors 
  Pushing on their own chest/neck/throat 6% 8% 
Applying pressure to their abdomen by pushing on it or leaning on  
furniture 37% 28% 
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Unusual movements such as thrusting jaw, tilting head, arching back, or 
 twisting neck/body 17% 18% 
Frequent clearing of throat, swallowing, coughing, gagging, choking, or  
throat sounds wet or gurgly 25% 34% 
Moaning or groaning for no apparent reason 18% 19% 
Unexplained irritability, agitation, aggression, or screaming 53% 41% 
Gritting teeth, wincing, or grimacing for no apparent reason 24% 22% 
Biting themselves, putting their fist in their mouth, or hurting  
themselves in other ways 10% 16% 
Avoid wearing tight clothing or clothing with waistbands 22% 25% 
Chewing on shirts, eating non-edible objects 43% 39% 
Pointing to stomach/tummy as if in pain 15% 15% 
Direct vocalizations of pain (e.g. “tummy hurts” “stomach pain”) 26% 37% 















Table S2. Factor Loadings of ASD-GIRB Items in Seven-Factor Exploratory Factor Model 
 
 



























Abdominal pain 0.03 0.01 -0.02 0.83 0.04 0.01 -0.05 
Nausea, vomiting, or 
retching/dry heaving -0.18 0.07 0.03 0.51 0.07 0.08 0.04 
Bloating 0.3 -0.13 0.1 0.37 0.07 -0.04 0.17 
Flatulence or gas 0.27 -0.06 0.09 0.45 0.11 0.04 -0.08 
Diarrhea -0.09 0.04 0.09 0.33 0.19 0.22 -0.10 
Constipation 0.58 -0.13 0.04 0.16 0.17 -0.05 -0.01 
Incontinence / Lack of 
voluntary control or urination 
or defecation 
-0.1 0.0 -0.06 0.01 0.78 0.06 0.0 
Fecal Retention / complete 
elimination of stool 0.33 0.0 0.06 0.03 0.45 -0.11 -0.18 
Appear to feel pain when 
having a BM 0.47 0.03 -0.02 0.27 0.01 -0.06 0.04 
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Stiffen their legs or squeeze 
their bottom and legs 
together when they felt need 
to have a BM 
0.35 0.20 0.03 -0.05 0.38 -0.11 0.24 
Stain or soil underwear 0.03 0.11 0.04 0.05 0.53 0.0 0.12 
Wet the bed -0.06 -0.04 0.03 -0.03 0.49 0.18 0.06 
Become more active after 
passing a stool 0.68 0.12 -0.02 -0.02 -0.02 0.05 0.11 
Become less irritable after 
passing a stool 0.79 0.05 0.05 0.02 -0.09 0.13 -0.01 
Turns their face or body away 
from food 0.05 0.82 0.03 0.02 -0.03 -0.02 -0.05 
Closes their mouth tightly 
when food is presented 0.03 0.54 0.13 -0.11 0.04 0.18 0.0 
Spits out food that they have 
put in their mouth -0.06 0.54 0.06 0.10 0.09 0.04 0.11 
Stops eating after just a little 
food 0.02 0.57 -0.03 0.06 0.06 -0.02 0.01 
Remains seated at the table 
until the meal at finished -0.01 0.39 0.03 -0.12 0.08 0.03 0.11 
Cries or screams during 
mealtimes -0.08 0.35 -0.06 0.08 -0.05 0.36 -0.01 
Is aggressive during 
mealtimes (hitting, kicking, 
scratching others) 




behavior during mealtimes 
(hitting self, biting self) 
0.05 -0.09 0.07 -0.08 0.06 0.66 0.13 
Is disruptive during mealtimes 
(pushing/throwing utensils or 
food) 
0.06 0.16 -0.02 0.01 0.06 0.61 -0.07 
Is willing to try new foods -0.19 0.14 0.49 0.08 -0.06 0.04 0.20 
Accepts or prefers a variety of 
foods -0.16 0.11 0.5 0.16 -0.01 -0.08 0.14 
Prefers the same foods at 
each meal -0.03 -0.03 0.61 0.03 0.06 0.07 -0.18 
Prefers food prepared in a 
particular way (e.g. eats 
mostly fried foods, cold 
cereals, raw vegetables) 
0.07 0.01 0.58 0.02 0.09 0.02 -0.18 
Prefers to avoid eating a 
particular types of food group 
(e.g. vegetables, meats, dairy) 
0.06 0.03 0.75 -0.11 -0.05 -0.06 0.03 
Strongly prefers certain types 
of food colors, textures, or 
temperatures 
0.07 0.0 0.61 0.03 -0.07 0.05 0.08 
Applying pressure to their 
abdomen by pushing on it or 
leaning on furniture 
0.18 0.0 0.02 0.26 0.05 0.04 0.36 
Unusual movements such as 
thrusting jaw, tilting head, 
arching back, or twisting 
neck/body 
0.11 -0.13 0.10 0.04 0.11 0.23 0.35 
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Gritting teeth, wincing, or 
grimacing for no apparent 
reason 
0.11 0.05 -0.02 0.02 0.11 0.10 0.51 
Biting themselves, putting 
their fist in their mouth, or 
hurting themselves in other 
ways 
-0.02 -0.06 0.04 -0.05 0.15 0.43 0.22 
Pointing to stomach/tummy 
as if in pain 0.03 0.02 0.04 0.42 -0.03 -0.05 0.24 
Direct vocalizations of pain 
(e.g. “tummy hurts” “stomach 
pain”) 
0.04 0.05 -0.02 0.67 -0.13 -0.05 0.06 
 















Table S3. Correlations between ASD-GIRB Factors, among Children 6-17 Years 
 
 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 Factor 7 
Factor 1 1 0.13 0.18 0.34 0.23 0.11 0.17 
Factor 2 0.13 1 0.33 0.12 0.11 0.29 0.15 
Factor 3 0.18 0.33 1 0.17 0.07 0.11 0.15 
Factor 4  0.34 0.12 0.17 1 0.17 0.04 0.16 
Factor 5 0.23 0.11 0.07 0.17 1 0.22 0.15 
Factor 6 0.11 0.29 0.11 0.04 0.22 1 0.15 
Factor 7  0.17 0.15 0.15 0.16 0.15 0.15 1 
 
Factor 1 - Constipation & Bowel Movement Pain; Factor 2 - Doesn’t want food at times; Factor 3 - Particular with foods; Factor 4 - 
Abdominal Pain / Vomiting / Gassy / Diarrhea; Factor 5 - Incontinence / Soil / Wet bed; Factor 6 - Aggressive/ Disruptive at 




















Table S4. Correlation between ASD-GIRB Factor Scores and CBCL Subscales, among Children 6-17 Years 
 

















Factor 1 - Constipation 
& Bowel Movement 
Pain 
0.11 0.16 0.04 0.34 0.27 0.23 0.20 
Factor 2 - Doesn’t want 
food at times 0.31 0.16 0.20 0.09 0.22 0.23 0.27 
Factor 3 - Particular with 
foods 
 
0.16 0.19 0.03 0.09 0.18 0.24 0.16 
Factor 4 - Abdominal 
Pain / Vomiting / Gassy 
/ Diarrhea 
0.20 0.11 0.14 0.54 0.35 0.29 0.18 
120Factor 5 - 
Incontinence / Soil / 
Wet bed 
0.19 0.06 0.09 0.07 0.21 0.23 0.24 
Factor 6 - Aggressive/ 
Disruptive at Mealtimes 0.42 0.18 0.21 0.10 0.18 0.34 0.25 
Factor 7 - Other 
behaviors 
 
0.27 0.17 0.03 0.25 0.24 0.34 0.28 
 







Table S5. Mean Difference in ASD-GIRB Factor Scores by Functional Impairment 
 
 Functional Impairment 










Factor 1 - Constipation & Bowel Movement Pain 3.92 vs.2.19 3.66 vs.2.2 2.99 vs.1.99 
Factor 2 - Doesn’t want food at times 2.8 vs.1.93 2.63 vs.1.92 2.42 vs.1.81 
Factor 3 - Particular with foods 4.14 vs.3.72 4.25 vs.3.68 3.94 vs.3.64 
Factor 4 - Abdominal Pain / Vomiting / Gassy / Diarrhea 3.72 vs.2.08 3.18 vs.2.16 3.04 vs.1.78 
Factor 5 - Incontinence / Soil / Wet bed 2.08 vs.1.3 1.96 vs.1.29 1.72 vs.1.16 
Factor 6 - Aggressive/ Disruptive at Mealtimes 0.94 vs.0.72 1.02 vs.0.69 1.02 vs.0.52 
Factor 7 - Other behaviors 1.18 vs.0.59 0.93 vs.0.62 0.92 vs.0.46 
Table S5 shows the mean factor scale in children by presence versus absence of functional impairment. Bolded cells have a mean 







Autism Spectrum Disorder Gastrointestinal and Related 
Behaviors Inventory 
 
Instructions for Parents/Primary Caregivers: 
The purpose of this questionnaire is to assess the presence of gastrointestinal (GI) 
symptoms and related issues in children with autism spectrum disorder. This 
questionnaire may take up to 30 minutes to complete. The questionnaire should only be 
completed by the child’s parent or another primary caregiver. There are no right or wrong 
answers to these questions, but please answer each question to the best of your ability. You 
may choose not to answer questions that make you feel uncomfortable.  
Please note that all information will be kept strictly confidential. 
 




Please indicate your relationship to the child: 
o Mother  
o Father  
o Other primary caregiver  
 
 




Please indicate your highest level of education completed. 
o Some high school  
o High school graduate or GED  
o Some college or associate degree education  
o College or associate degree  





Please indicate your child's biological sex at birth. 
o Female  
o Male  
 
 
Please indicate your child's gender identity. 
o Female  
o Male  
o Transgender  
o Non-binary, Gender-queer, or Gender-fluid  
o Other  
 
 
Please indicate your child's race/ethnicity (select all that apply). 
▢ American Indian or Alaska Native  
▢ Asian  
▢ Black or African American  
▢ Hispanic or Latino  
▢ Native Hawaiian or Other Pacific Islander  
▢ White  
 
 







Has your child been diagnosed with any of the following conditions? 
 
 No Yes Not Sure 
Any gastrointestinal disorder     
Epilepsy/Seizure disorder     
Intellectual disability     
ADD/ADHD     
Sensory processing disorder     
Anxiety, panic, or phobia disorder     
OCD     
Tic/Tourette's disorder     
Depression     
Bipolar Disorder     
Sleep disorder     
Autoimmune disorder     
Allergies or Asthma     
Other     
 
If your child has been diagnosed with a gastrointestinal disorder, which gastrointestinal 









If other, please specify which other psychiatric/behavioral/medical condition(s) has your 











In the last 3 months, has your child experienced any of the following gastrointestinal 
symptoms?  
 
 No Yes Not Sure 
Abdominal Pain     
Nausea, Vomiting, or Retching/Dry Heaving     
Reflux or Heartburn     
Abdominal swelling or distension     
Bloating     
Flatulence or Gas     
Diarrhea     
Constipation     
Alternating constipation and diarrhea     
Incontinence / Lack of voluntary control over 
urination or defecation     

















1 year or 
longer Not Sure 
NA, has not 
experienced 
symptom in 
last 3 months 




      
Reflux or Heartburn        
Abdominal swelling 
or distension        
Bloating        
Flatulence or Gas        
Diarrhea        




      
Incontinence / Lack 
of voluntary control 
over urination or 
defecation  
      
Fecal retention / 
incomplete 
elimination of stool  





In the last 3 months of your child having these symptoms... 
 
 No Yes Not Sure 




last 3 months 
Do the symptoms get better 
after having a bowel 
movement (pooping)?  
   
 
Do the symptoms occur before 
eating or when hungry?     
Do the symptoms improve 
after your child eats?     
Do the symptoms worsen after 
your child eats?     
Has your child had trouble 
gaining weight?     
 
 
It can be difficult for parents/caregivers to accurately assess their child's pain level. How 
confident do you feel in your ability to assess your child's gastrointestinal pain? 
o Not confident at all  
o Slightly confident  
o Fairly confident  





In the last 3 months, how often did your child usually have a bowel movement (BM), i.e. 
pooping?  
o Once a day  
o Less than once a day  
o More than once a day  
o Not sure  
 
 
If you selected less than once a day, in the last 3 months, how often did your child usually 
have a bowel movement (BM), i.e. pooping?  
o 3-6 times per week  
o 1-2 times per week  
o Less than once per week  
o Not sure  
 
 
If you selected more than once a day, in the last 3 months, how often did your child usually 
have a bowel movement (BM), i.e. pooping?  
o 2-3 times per day  
o 3+ times per day  







In the last 3 months, what was your child's stool usually like? Of the 7 options below, please 
order them from most commonly like your child's stool to least commonly like your child's 
stool.  
Write a 1 next to the most common stool, a 2 next to the second most common down to 
stool, etc. all the way to 7, the least common type of stool. 
 
Please see the image above for reference. 
 
______ Type 1: Separate hard lumps 
 
______ Type 2: Lumpy and sausage like 
 
______ Type 3: A sausage shape with cracks in the surface 
 
______ Type 4: Like a smooth, soft sausage or snake 
 
______ Type 5: Soft blobs with clear-cut edges 
 
______ Type 6: Mushy consistency with ragged edges 
 




In the last 3 months, did your child... 
 
 No Yes Not Sure 
...Appear to feel pain when 
having a BM?     
...Rush to the bathroom for a 
BM?     
...Stiffen their legs or squeeze 
their bottom and legs together 
when they felt the need to 
have a BM?  
   
...Stain or soil underwear?     
...Wet the bed?     
...Become more active after 
passing a stool?     
...Become less irritable after 





Think about mealtimes with your child over the past 3 months. Rate the following items 












...Turns their face or body 
away from food       
...Closes their mouth 
tightly when food is 
presented  
     
...Spits out food that they 
have put in their mouth       
...Stops eating after just a 
little food       
...Remains seated at the 
table until the meal is 
finished  
     
...Cries or screams during 
mealtimes       




     
...Displays self-injurious 
behavior during 
mealtimes (hitting self, 
biting self)  
     
...Is disruptive during 
mealtimes 
(pushing/throwing 
utensils or food)  
     
...Is flexible about 
mealtime routines (e.g. 




     
...Willing to try new foods       
...Accepts/prefers variety 




Think about mealtimes with your child over the past 3 months. Rate the following items 












...Prefers the same foods 
at each meal       
...Prefers food prepared 
in a particular way (e.g. 
eats mostly fried foods, 
cold cereals, raw 
vegetables)  
     
...Prefers to avoid eating 
a particular type of food 
group (e.g. vegetables, 
meats, dairy)  
     
...Strongly prefers 
certain types of food 
colors, textures, or 
temperatures  
     
...Refuses to eat foods 
that require a lot of 
chewing (e.g. eats only 
soft or pureed foods)  
     
...Prefers only sweet 
foods (e.g. candy, sugary 
cereals)  
     
...Is on a special diet (e.g. 
gluten free, casein free, 
FODMAPS, GAPS)  
     
...Drink lots of water 




In the last 3 months, please indicate whether or not you've observed the following 
behaviors in your child? 
 
 No Yes Not Sure 
Pushing on their own 
chest/neck/throat     
Applying pressure to their 
abdomen by pushing on it or 
leaning on furniture  
   
Unusual movements such as 
thrusting jaw, tilting head, 
arching back, or twisting 
neck/body  
   
Frequent clearing of throat, 
swallowing, coughing, 
gagging, choking, or throat 
sounds wet or gurgly  
   
Moaning or groaning for no 
apparent reason     
Unexplained irritability, 
agitation, aggression, or 
screaming  
   
Gritting teeth, wincing, or 
grimacing for no obvious 
reason  
   
Biting themselves, putting 
their fist in their mouth, or 
hurting themselves in other 
ways  
   
Avoid wearing tight clothing 
or clothing with waistbands     
Chewing on shirts, eating 
non-edible objects     
Pointing to stomach/tummy 
as if in pain     
Direct verbalizations of pain 
(e.g. "tummy hurts" "stomach 
pain")  
   
Difficulty falling asleep or 





Please select whether or not your child currently takes any of the following medications. 
 No Yes Not Sure 
Antidepressant     
Antipsychotic or 





   
Mood stabilizer     
Stimulant     
Anticonvulsant     
Prescription sleeping 
medication     
Hypotensive 
medication     
Other     
 
































Get to school late, miss 
school, or leave school 
early (including missing 
parts of class)?  
     
Miss social or family 
activities?       
Have trouble falling 
























This GI questionnaire was designed using items from the Autism Treatment Network GI 
Inventory and the Brief Autism Mealtime Behaviors Inventory (BAMBI). This Network 
activity was supported by Autism Speaks and cooperative agreement UA3 MC11054 
through the U.S. Department of Health and Human Services, Health Resources and Services 
Administration, Maternal and Child Health Research Program to the Massachusetts General 
Hospital. This work was conducted through the Autism Speaks Autism Treatment Network. 
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Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by two core 
domains of symptoms: social communication and impairment, and restricted, repetitive 
behaviors, interests, or activities1.  The prenatal period and early-life period are considered to be 
the critical windows for the development of ASD, given the brain’s susceptibility to 
environmental stressors2–6.   
 
Prenatal exposure to maternal immune activation (MIA) has been implicated as a risk factor for 
the development of neuropsychiatric disorders, and in particular, schizophrenia and ASD7–9.  
Animal studies have demonstrated that maternal immune activation leads to behavioral 
abnormalities such as decreased social approach and ultrasonic vocalizations, and increased 
repetitive grooming and marble burying behavior in the offspring10–14.  These behavioral 
changes are paralleled by alterations in the immune profiles of offspring, in particular levels 
of IL-6 and IL-17α13,15–17.   
 
Human studies have also found a strong link between prenatal exposure to MIA and risk of ASD 
in the offspring.  Overall, bacterial 18–20, viral 19,20, and genitourinary infections18,21, as well as 
fever21–23 have been implicated as risk factors for ASD.  However, there is substantial 
heterogeneity in the findings across these studies.  A meta-analysis and systematic review by 
Jiang et al.  found that overall, maternal infections, particularly those requiring hospitalization, 
increase the risk for ASD24.  Any maternal infection in the second trimester in particular, 
bacterial infections overall and in particular during the second and third trimesters, and viral 
infections over the entire pregnancy (but not within a particular trimester) were all significantly 
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associated with higher risk of ASD24.  Despite the overwhelming evidence that an activated 
immune system in the pregnant mother increases the risk for neurodevelopmental abnormalities 
in the child, the conditions under which this elevated risk occurs are unclear. 
 
Human gut microbiota, or the microbes living in our gastrointestinal tract, and their genetic 
material (the gut microbiome) have emerged as key players in health and disease.  The gut 
microbiome is malleable across the life course, which makes it an attractive target for 
intervention25.  Until recently, the infant gut microbiome was thought to be sterile until birth, 
when the infant is inoculated with the mothers vaginal (vaginal delivery) or skin microbiome (C-
section)26.  However, studies now show that bacteria can be detected in fetal membranes, 
amniotic fluid, and placenta, although this finding is not without controversy27–33.  Early 
immunological and metabolic programming by the gut microbiome may have long-term 
consequences for human health34–40.  Further, breast milk microbiota, which is critical to an 
infant’s development, is influenced by both delivery mode and intrapartum antibiotic exposure41–
44.  Given that the development of the infant gut microbiome parallels critical windows of 
neurodevelopment, and that the microbiome is particularly susceptible to environmental 
influences during pregnancy and early life, the infant gut microbiome represents a potential 
opportunity for better understanding neurodevelopment and potentially preventing or treating 
neuropsychiatric disorders, including ASD45,46.   
 
Very recent animal studies indicate that the maternal gut microbiome plays a critical role in 
regulating the maternal immune response and subsequent neurodevelopment of the offspring47, 
specifically that among pregnant dams exposed to immune activation, antibiotic use protects 
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against the MIA-associated neurodevelopmental abnormalities seen in the offspring.  The aim of 
this study was to assess whether antibiotic use during pregnancy modifies the association 
between prenatal exposure to maternal immune activation and subsequent risk of autism 
spectrum disorder, in a prospective, enriched-risk cohort, the Boston Birth Cohort (BBC) study.  
We hypothesized that antibiotic use would be protective against ASD in the presence of maternal 
immune activation. 
5.2 Methods 
5.2.1.  Sample 
Our sample consisted of mother-child pairs from the Boston Birth Cohort (BBC), a prospective 
birth cohort recruited from the Boston Medical Center48,49.  Initiated in 1998, the BBC was 
designed to investigate environmental and genetic determinants for preterm delivery.  Because it 
is enriched for preterm deliveries, it is a useful cohort for studying autism epidemiology, given 
that preterm delivery is a risk factor for the development of ASD50.  The BBC has been described 
in detail elsewhere 23,48, but briefly: Women with a live, singleton birth at Boston Medical Center 
are eligible for recruitment.  Pregnancies involving IVF, chromosomal abnormalities, major birth 
defects, and preterm deliveries due to maternal trauma are excluded.  Eligible participants are 
contacted 24-72 hours following birth for consent and study enrollment.  Children who seek 
postnatal care at Boston Medical Center are able to be followed up for developmental outcomes, 
such as ASD status.  Most pregnant women in the Boston Medical Center are urban, low-income 





5.2.2.  Outcome Classification 
Electronic medical record ICD-9 CM diagnostic codes from inpatient, outpatient, and emergency 
department visits at the Boston Medical Center (October 1, 2003 through September 31, 2015) 
were used to classify children as ASD cases or non-ASD controls.  Children were classified as 
having ASD if their medical recordings contained any of the ICD-9 CM codes at least once: 
299.00, 299.01, 299.80, 299.81, 299.90, or 299.9123.  Children were classified as non-ASD 
controls if they had none of the above ICD-9 CM codes. 
 
5.2.3.  Definition of maternal immune activation 
The details of defining maternal immune activation have previously been described elsewhere23.  
Briefly, maternal immune activation was defined as any of the following exposures: prenatal flu, 
prenatal fever (excluding intrapartum), prenatal genitourinary (GU) tract infections, and 
intrapartum (labor and delivery) fever.  A standardized postpartum questionnaire was 
administered to the mother 24-72 hours following delivery for self-report of flu, fever, and GU 
infection.  Intrapartum fever was defined as a >38° C temperature in the mother and abstracted 
from medical charts during labor and delivery.  For flu and fever, overall as well as trimester-
specific variables were used, and an overall variable only was used for genitourinary infection.  
All individuals were dichotomized as “exposed” or “unexposed” for these four MIA variables.  
Lastly, a combined MIA variable was created; women were classified as being exposed to MIA 




5.2.4.  Definition of antibiotic use during pregnancy 
Use of an antibiotic during pregnancy/labor and delivery was derived from three sources of 
information.  First, in the standardized postpartum questionnaire, mothers were asked ‘What 
medicines did you take during your pregnancy excluding vitamins?’.  Women could list up to 5 
medications and indicate which trimester the medication was taken.  Second, inpatient and 
outpatient antibiotic treatments during the entire pregnancy were extracted from electronic health 
records (EHR).  Lastly, use of intrapartum antibiotics was extracted from medical charts during 
labor and delivery.  We combined these three sources of information to obtain one aggregate, 
binary variable representing whether or not a woman was exposed to an antibiotic during 
pregnancy or the labor and delivery period.  Women who did not have EHR antibiotic 
information, who did not report antibiotic use on the standardized questionnaire, and who did not 
receive an intrapartum antibiotic were classified as not exposed to antibiotics during pregnancy.  
We were not able to separate antibiotic use by the type of antibiotic or by trimester because of 
sparse data.  For a list of which antibiotics were extracted from the postpartum maternal 
questionnaire and the EHR records, see Supplemental Table 10. 
 
5.2.5.  Covariate definitions 
We controlled for the following covariates in our analysis: demographic characteristics of the 
mother (maternal education, marital status, age at delivery), clinical or health characteristics of 
the mother or having to do with the pregnancy (BMI, diabetes or gestational diabetes, 
preeclampsia, preterm delivery, mode of delivery).  Maternal education and marital status were 
obtained from the postpartum maternal questionnaire.  Child sex, preterm status, and C-section 
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delivery was obtained from medical charts.  Maternal BMI, diabetes/gestational diabetes, and 
preeclampsia were obtained from the postpartum maternal questionnaire. 
 
We defined mothers’ educational attainment as a binary variable (high school graduation/GED or 
lower versus some college or higher).  Marital status was dichotomized to “married” or “not 
married”, with not married including women who were single, divorced, separated, or widowed.  
BMI was categorized as “not overweight” (BMI <25), “overweight” (BMI 25-29.9), or “obese” 
(BMI >29.9) Race was self-reported by choosing one of the nine categories: Black/African 
American (Black, African American, Haitian, Cape Verdean, Caribbean), Asian (Asian and 
Pacific Islander), White, Hispanic, mixed race, and all others.  However, race was not included 
as a covariate in our regression models because of sparseness across racial categories. 
 
5.2.6.  Analytic dataset 
Out of 3,123 mother-child pairs with non-missing ASD information, 28 were removed for 
missing information on child sex (n=15), delivery type (n=28), or preterm status (n=15), leaving 
3,095 pairs (n=142 ASD, n=2,953 non-ASD).  Complete-cases analyses were used for regression 
models.   
 
5.2.7.  Statistical analyses 
All data cleaning and analyses were performed in R Studio version 1.1.383 (R version 3.4.3).  
Descriptive characteristics of the analytic sample were carried out, stratified by ASD and 
antibiotic use.  We first carried out unadjusted and adjusted logistic regression models examining 
the main effect of each of 11 MIA exposures (binary MIA reflecting any infection during 
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pregnancy and birth, flu overall and in each trimester, fever overall and in each trimester, GU 
infection overall, and intrapartum fever) with ASD as the outcome.  Then, we conducted a series 
of 11 logistic regression models with each MIA exposure, as a predictor, antibiotic use as an 
interaction term, and ASD diagnosis as the outcome.  We ran both unadjusted models and 
models adjusted for child sex, maternal education, marital status, maternal age, maternal BMI, 
diabetes/gestational diabetes, preeclampsia, and C-section.  Models with an interaction term p-
value < 0.10 were suggestive of possible interaction, and were followed up with stratified 
analyses.  These models estimated the association between MIA and odds of ASD, stratified by 
antibiotic use.   
 
We carried out a series of 5 stratified analysis models: Model 1 was unadjusted.  Model 2 
included child sex, maternal education, marital status, maternal age, maternal BMI, 
diabetes/gestational diabetes, and preeclampsia.  Model 3 included model 2 covariates as well as 
preterm status.  Model 4 included model 2 covariates as well as C-section delivery.  Model 5 
included model 2 covariates and both preterm status and C-section delivery.   
 
Lastly, we carried out some sensitivity analyses.  First, we repeated our regression modeling 
excluding children less than three years old, and again, less than two years old, to account for the 
possibility that ASD diagnosis would be much less likely before the age of three.  We also 
excluded women who did not have EHR antibiotic information, and who did not report antibiotic 





5.3.1.  Sample characteristics 
Out of 3,095 children, 142 (4.6%) had a diagnosis of ASD, 79% of mothers used an antibiotic 
during pregnancy or in labor and delivery and over half (54%) experienced maternal immune 
activation.  Over 90% of our study population was of non-white race.  The most common type of 
maternal immune activation was genitourinary infection, followed by flu and then fever.  
Children with ASD were significantly more likely to be male, younger in age, have an older 
mother, have a mother with obesity or diabetes/gestational diabetes, and be born preterm (Table 
1).  Children with maternal exposure to antibiotics were more likely to have a mother with 
diabetes/gestational diabetes, and be born preterm or by C-section.  The frequencies of maternal 
immune activation exposures, stratified by ASD status and by antibiotic use during pregnancy, 
are shown in Table 2.  In these crude estimates, the only significant association was between 
having intrapartum fever and intrapartum antibiotics. 
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ASD 5% 100% 0% --- 5% 3% 0.05 
Antibiotic Use during Pregnancy 79% 86% 79% 0.05 100% 0% --- 
Male child 51% 75% 49% <0.0001 51% 49% 0.36 
Child age 8.1 (3.7) 7.5 (3.8) 8.1 (3.7) <0.0001 6.9 (2.9) 11.2 (3.6)  
Maternal age 28.5 (6.5) 30.0 (6.2) 28.5 (6.5) <0.0001 28.1 (6.4) 28.5 (6.6)  
Maternal education: high school grad or 
below 64% 58% 65% 0.11 64% 66% 0.32 
Mother not married 67% 64% 67% 0.59 67% 66% 0.69 
Maternal race: Black, Hispanic, Asian, 
Mixed, Other (not white) 93% 96% 93% 0.20 92% 94% 0.41 
Maternal BMI        
Not overweight 49% 43% 49% 
0.04 
49% 52% 
0.11 Overweight 27% 24% 27% 27% 28% 
Obese 24% 33% 23% 25% 20% 
Diabetes/Gestational Diabetes 11% 18% 11% 0.02 13% 7% <0.001 
Preeclampsia 11% 9% 12% 0.34 12% 10% 0.24 
Maternal Immune Activation 
(combined) 54% 51% 54% 0.52 54% 52% 0.57 
Preterm 29% 37% 29% 0.03 31% 21% <0.0001 
C-section 36% 40% 36% 0.34 39% 26% <0.0001 
aP-value for Chi-square or T-test difference between strata (ASD vs. no ASD and Antibiotic vs. No Antibiotic during Pregnancy) 
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Table 2. Frequency of maternal immune activation, stratified by ASD and Antibiotic Use in Pregnancy (%) 
 










Maternal immune activation (any) 51% 54% 0.52 54% 52% 0.57 
Intrapartum fever 7% 6% 0.88 7% 3% <0.001 
Genitourinary infection 28% 35% 0.16 35% 32% 0.10 
Flu overall pregnancy 20% 18% 0.72 17% 21% 0.04 
Flu Trimester 1 5% 5% 0.97 5% 6% 0.20 
Flu Trimester 2 10% 8% 0.44 8% 8% 0.55 
Flu Trimester 3 8% 8% 1.00 7% 10% 0.01 
Fever overall pregnancy 12% 11% 0.64 11% 10% 0.77 
Fever trimester 1 3% 4% 0.94 3% 4% 0.13 
Fever trimester 2 5% 4% 0.60 4% 3% 0.40 
Fever trimester 3 5% 4% 0.81 4% 3% 0.72 






5.3.2. Main effect of maternal immune activation on odds of ASD 
In both unadjusted and adjusted analyses there were no significant associations between any 
MIA exposure and ASD as the outcome (Table 3). We chose to include C-section as a covariate 
in these main effect models, since they were included as a covariate in our interaction models. 
However, we also repeated the models without adjusting for C-section, given its potential role as 
a mediator of the association between maternal immune activation and ASD. Removal of this 
variable did not change the magnitude, significance, or inference of our findings.
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Table 3. Regression Models Estimating Association between Maternal Immune Activation Exposures and Odds of ASD 
 
Maternal Immune Activation 
Exposure 
Unadjusted Odds Ratio 
(95% Confidence Interval) 
Adjusted Odds Ratiob 
(95% Confidence Interval) 
Flu Overall Pregnancy 1.11 (0.70 , 1.70) 1.30 (0.80, 2.03) 
Flu, Trimester 1 0.90 (0.35 , 1.92) 1.05 (0.40 , 2.27) 
Flu, Trimester 2 1.32 (0.70 , 2.30) 1.34 (0.68 , 2.4) 
Flu, Trimester 3 0.97 (0.47 , 1.78) 1.21 (0.58 , 2.26) 
Fever Overall Pregnancy 1.18 (0.67 , 1.97) 1.39 (0.77 , 2.35) 
Fever, Trimester 1 0.85 (0.26 , 2.07) 1.02 (0.31 , 2.54) 
Fever, Trimester 2 1.35 (0.56 , 2.76) 1.40 (0.57 , 2.93) 
Fever, Trimester 3 1.23 (0.47 , 2.63) 1.48 (0.56 , 3.24) 
Genitourinary Infection Overall 
Pregnancy 0.74 (0.50 , 1.09) 0.78 (0.51 , 1.16) 
Intrapartum fever 1.13 (0.52 , 2.14) 0.93 (0.35 , 2.0) 
Maternal Immune Activation (any) 0.87 (0.60 , 1.26) 0.96 (0.65 , 1.44) 
bModels are adjusted for child sex, maternal education, marital status, maternal age, maternal BMI, diabetes/gestational diabetes, 




5.3.3.  Interaction between maternal immune activation and antibiotic use 
  In unadjusted analyses, there were no significant interactions at the p<0.10 level (Supplemental 
Tables 1-9).  After adjusting for child sex, maternal education, marital status, maternal age, 
maternal BMI, diabetes/gestational diabetes, and preeclampsia, there was suggestive evidence of 
an interaction between flu in the second trimester and antibiotic use on odds of ASD (p<0.10).  
No other regression models showed evidence of any significant interaction (Supplemental Tables 
1-9).   
 
We further examined the association between flu and ASD risk, stratified by antibiotic use in 
pregnancy or labor and delivery.  Among women who received an antibiotic, there was no 
significant association between flu in trimester two and odds of ASD, in either unadjusted or 
adjusted models (Figure 1).  In this subgroup, women with a high school diploma/GED or less, 
relative to women with some college experience, were significantly less likely to have a child 
with ASD (OR=0.61, 95% CI 0.40-0.95), while mothers with a male child (OR=2.89, 95% CI 
1.81-4.79) or a preterm birth (OR =1.72, 95% CI 1.09-2.68) were more likely to have a child 
with ASD (p<0.05) (Table 4 and Figure 1).   
 
However, among women who did not receive an antibiotic during pregnancy, flu in the second 
trimester significantly increased the odds of ASD in the child after adjusting for potential 
confounders.  In this subgroup of women, flu in the second trimester was associated with a 4.43 
fold increase in the odds of ASD (95% CI 1.13-14.69), adjusting for demographic and clinical 
characteristics, including preterm birth and C-section delivery, although the confidence interval 
was wide, reflecting the small sample size in this strata.  Across these models, child male sex 
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(OR=3.67, 95% CI 1.24-13.48) and maternal education at or below high school diploma/GED 
(OR=4.78, 95% CI 1.28-31.35) were both associated with significantly greater odds of ASD 
(Table 4 and Figure 1).   
 
The magnitude, significance, and interpretation of our results did not differ when restricting to 
children >=2 years old or to children >= 3 years old (data not shown).  Further, our inference did 
not change after excluding women with missing EHR antibiotic information, though some of the 
models were not estimable given the smaller sample size of our sample (data not shown).
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Table 4. Regression Models Estimating Association between Flu in Second Trimester and Odds of ASD, Stratified by 
Antibiotic Use during Pregnancy 
 
 Odds Ratio (95% Confidence Interval) 
Model 
Flu Trim 2, among Women who did use 
Antibiotic during Pregnancy 
Flu Trim 2, among Women who did not 
use Antibiotic during Pregnancy 
Model 1 1.13 (0.52 , 2.16) 3.06 (0.85 , 8.86) 
Model 2 1.06 (0.46 , 2.12) 4.48 (1.14 , 14.82)* 
Model 3 1.06 (0.46 , 2.13) 4.50 (1.15 , 14.91)* 
Model 4 1.06 (0.46 , 2.12) 4.40 (1.12 , 14.60)* 
Model 5 1.06 (0.46 , 2.13) 4.43 (1.13 , 14.69)* 
Model 1 was unadjusted.  Model 2 included child sex, maternal education, marital status, maternal age, maternal BMI, 
diabetes/gestational diabetes, and preeclampsia.  Model 3 included model 2 covariates as well as preterm status.  Model 4 included 
model 2 covariates as well as C-section delivery.  Model 5 included model 2 covariates and both preterm status and C-section 




Figure 1. Odds Ratio Estimates and Confidence Intervals for Association between Flu in Second Trimester and ASD, 




Model 1 was unadjusted.  Model 2 included child sex, maternal education, marital status, maternal age, maternal BMI, 
diabetes/gestational diabetes, and preeclampsia.  Model 3 included model 2 covariates as well as preterm status.  Model 4 included 
model 2 covariates as well as C-section delivery.  Model 5 included model 2 covariates and both preterm status and C-section 





We examined whether the prospective relationship between maternal immune activation on risk 
for ASD is modified by antibiotic use in pregnancy, in a predominantly urban minority 
population.  Our results suggest that flu during the second trimester increases the risk for ASD in 
the offspring, among women who are not exposed to antibiotics during pregnancy.  In other 
words, among women who have flu in their second trimester, exposure to an antibiotic during 
pregnancy appears to protect against the increased risk for ASD in the child.  Our finding was 
specific to second trimester, and was not replicated in first or third trimester, or in overall 
pregnancy.  We also did not find any evidence of significant interactions between other non-flu 
MIA exposures and antibiotic use.   
 
To our knowledge, this is the first study in humans to test for interaction between maternal 
immune activation and antibiotic use in pregnancy on ASD risk.  However, this study follows a 
number of papers examining antibiotic use or treatment of infection on ASD.  Fever-associated 
risk for ASD or developmental disabilities has been found to be decreased among mothers who 
took antipyretic medications during pregnancy, implying that treatment for the maternal immune 
activation was protective21.  The literature regarding treatment with antibiotic use in particular on 
ASD risk has been mixed.  A 2012 study of the Danish National Birth Cohort found a small but 
elevated risk of ASD and infantile autism among women who self-reported taking an antibiotic 
in pregnancy, though the study did not disentangle whether the association was causal or due to 
confounding by indication51.  A 2018 study using Danish registry data found that infections since 
birth treated with anti-infective agents were associated with increased of being diagnosed with a 
mental disorder or redeeming a prescription for psychotropic medication.  Antibiotic use in 
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particular was associated with increased risk for a mental disorder9.  A study out of the Autism 
Treatment Network similarly found that antibiotic use and ear infections were associated with 
increased risk for ASD, and the antibiotic in particular seemed to account for the association 
between ear infection and ASD52.  However, another recent study also using Danish registry data 
aimed to assess whether otitis media, previously associated with risk for ASD53, was itself 
associated with ASD or whether antibiotic treatment for otitis media was the true risk factor54.  
The authors found that exposure to exposure to otitis media and antibiotic use were both 
independently associated with increased risk for ASD.  Otitis media remained a significantly 
associated with ASD even after controlling for exposure to antibiotics.  There was no evidence of 
any interaction between otitis media and antibiotic use on ASD, given that the risk for ASD 
among children who were exposed to both otitis media and antibiotics did not change 
meaningfully from the risk among children only exposed to antibiotics54.  Importantly, these 
studies differ from the present study in that they examined infections and antibiotics during 
early-life, but not during pregnancy.   
 
The findings from our study support recent animal literature demonstrating that antibiotics 
mitigate the maternal immune activation insult on the risk for ASD in the developing offspring, 
and suggest that the maternal gut microbiome may play a critical role in modulating the immune 
system’s response on the developing brain47.  Specifically, MIA-associated phenotypes 
(increased repetitive behaviors, anxiety, social interaction deficits, as well as cortical patches) 
require maternal gut bacteria that promote differentiation of Th17 cells, for secretion of Il-17a.  
Treatment of pregnant dams with vancomycin, a broad-spectrum antibiotic prevented the 
neurodevelopmental abnormalities associated with MIA by decreasing the amount of Th17 cells 
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in the small intestine, thus decreasing levels of IL-17a circulating in the maternal plasma.  
Critically, transplantation of the mouse intestinal microbiome with commensal bacteria from 
humans previously found to induce Th17 cells also led to the neurodevelopmental 
abnormalities47.  In sum, this demonstrates that the composition of the maternal gut microbiome, 
as well as factors that influence it such as antibiotics, seem to determine whether exposure to 
maternal immune activation leads to increased risk of neurodevelopmental abnormalities in the 
offspring.  Notably, animal research has shown that the influence of MIA on the offspring is 
modified by the genetic strain of the mice10,55, and that strains differ in their immune and 
microbiota profiles, in a sex-dependent manner56.   
 
In this study, we found that flu in the second trimester increased risk for ASD in the child, 
among women who did not receive any antibiotic during pregnancy or labor and delivery.  Viral 
infections during pregnancy have previously been implicated with increased for ASD, though 
findings have not been specific to a particular trimester, and bacterial infections during second 
and third trimester in particular, have been associated with increased ASD risk18–20,24.  One 
possibility is that women who self-reported having the flu during pregnancy may not have truly 
had influenza, but might have had a different infection, perhaps of bacterial nature.  We also 
cannot rule out that the possibility that other trimester-specific flu/fever exposures would have 
been implicated had enough observations been present.  Our interaction models included 
between 4-61 individuals with both ASD and some MIA exposure, and these individuals were 
further stratified by antibiotic use.  Among this group, exposure to an antibiotic was more 
common.  Among those that did not receive an antibiotic, women who had flu in second 
trimester made up the largest group (n=4), compared to the other trimester-specific flu/fever 
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variables.  As evidenced in Tables 3a and 3b and Figure 1, we had very wide confidence 
intervals for our estimates, and some of our models were not estimable.  Therefore, we may have 
been underpowered to detect effects from other trimester-specific exposures.  Because this study 
was enriched for preterm births, infections in third trimester are less likely.  Further, women may 
not recall first-trimester infections or may not have known they were pregnant during that time.  
For these reasons, our second-trimester finding may not necessarily reflect a true critical window 
compared to other trimesters. Prior literature stresses the importance of considering ASD risks in 
the context of specific infectious agents as well as the timing in pregnancy.  It’s possible that we 
did not find any combined effect of flu, fever, genitourinary infection, or any MIA for these 
reasons.   
 
This study should be interpreted in the context of several limitations.  First, our sample size was 
quite small when looking at the interaction of MIA with antibiotic use on ASD status.  Our effect 
estimates were not precise, and we were underpowered.  We used a complete-case analysis, 
which has the potential to introduce biases. However, the ASD outcome was not associated with 
complete case status after adjusting for our covariates57. Future studies in larger cohorts are 
needed to replicate our findings.  Second, we relied on self-report information on infections.  
Therefore, our data may be susceptible to recall errors and misclassification.  However, we do 
not think recall bias by ASD status is likely, since women recalled their infectious exposures just 
after the birth of their child, prior to ASD diagnosis.  For women who did not have antibiotic 
information in EHR (because only women with an antibiotic prescription are included in EHR), 
we assumed that these women were not exposed to antibiotics, provided that they also did not 
self-report antibiotic use on the standardized questionnaire and did not receive intrapartum 
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antibiotic.  However, our sensitivity analyses revealed similar inferences when excluding these 
women. Next, if a pregnant woman was prescribed an antibiotic outside of Boston Medical 
Center and did not self-report this in the postpartum maternal questionnaire, she would be 
incorrectly classified as not being exposed to antibiotics during her pregnancy. Assuming this 
missingness is not differential with respect to ASD, our inference would not be affected. 
However, if the likelihood of being incorrectly classified as being unexposed were related to 
ASD, then our strata-specific associations would be more similar to each other, meaning we 
would have less evidence of an interaction effect. 
 
An important consideration is that this study did not look at the effect of treatment of an 
infection with an antibiotic on ASD risk.  Rather, antibiotics could have been prescribed for any 
reason.  Because we were interested in the effect of antibiotics at any point in pregnant on the 
maternal gut microbiota, this study does not suggest that treatment of infections with an 
antibiotic completely negates the risk of ASD on the offspring.  Rather, it suggests that the effect 
of the antibiotic on the mother and on the intrauterine environment potentially modifies the 
influence of MIA on the child.  While we adjusted for a number of potential confounders 
(demographic and clinical variables, and in particular preterm status and C-section delivery), it is 
still possible that antibiotic use was a proxy for the condition it was initially prescribed for.  
 
The findings from this study do not suggest that antibiotics should be unnecessarily prescribed or 
are by themselves protective against ASD.  Indeed, antibiotics also carry risks to the mother and 
developing fetus, and prior literature has shown that antibiotics themselves might increase the 




Our study had a number of strengths, however.  First, we assessed for the first time the 
interaction between maternal immune activation and antibiotic use on ASD.  Within a 
prospective, enriched-risk birth cohort, we demonstrated that the association between maternal 
immune activation is modified by the use of antibiotics during pregnancy.  Antibiotic use and 
ASD were both assessed by electronic health record data, and we relied on self-report of 
infections, slightly after pregnancy, which is more sensitive than use of electronic health record 
data, which only capture more serious infections.  The interaction effect we found was 
maintained after adjusting for demographic factors (child sex, maternal education, marital status 
and age) as well as clinical variables (maternal BMI, diabetes/gestational diabetes, preeclampsia, 
preterm status, C-section delivery).  The findings from this study are in line with recent animal 
literature showing that antibiotic use affects the maternal gut microbiome, modifying the 
influence of maternal immune activation on neurodevelopment and autism-like symptoms in the 
offspring.  The maternal gut microbiome may very well be the missing link in understanding 
why maternal exposures, including immune activation, have heterogeneous effects on the 
neurodevelopment of children. 
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Table S1. Interaction between Flu in Overall Pregnancy and Antibiotic Use during Pregnancy on Odds of ASD 
 
 
OR (95% CI) P-value OR (95% CI) P-value 
Flu Overall Pregnancy 1.77 (0.61 , 4.57) 0.26 2.12 (0.71 , 5.77) 0.15 
Antibiotic during Pregnancy 1.78 (1.02 , 3.36) 0.06 1.67 (0.91 , 3.37) 0.12 
Child sex: male --- 3.04 (1.97 , 4.82) 0.00 
Maternal education: HS graduation or below --- 0.79 (0.53 , 1.19) 0.25 
Marital status: nor married --- 1.05 (0.69 , 1.62) 0.83 
Maternal age (years) --- 1.03 (1.0 , 1.07) 0.04 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.15 (0.70 , 1.86) 0.58 
Obese --- 1.55 (0.96 , 2.50) 0.07 
Diabetes/Gestational Diabetes --- 1.54 (0.89 , 2.54) 0.11 
Pre-eclampsia --- 0.70 (0.34 , 1.32) 0.31 
Flu Overall Preg*Antibiotic during Pregnancy 0.59 (0.20 , 1.89) 0.35 0.55 (0.18 , 1.83) 0.31 
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Table S2. Interaction between Flu in Trimester 1 and Antibiotic Use during Pregnancy on Odds of ASD 
 
 OR (95% CI) P-value OR (95% CI) P-value 
Flu Trim 1 0.86 (0.05 , 4.38) 0.89 0.86 (0.05 , 4.49) 0.89 
Antibiotic during Pregnancy 1.54 (0.95 , 2.65) 0.10 1.38 (0.82 , 2.47) 0.25 
Child sex: male --- 3.04 (1.98 , 4.83) 0.00 
Maternal education: HS graduation or below --- 0.80 (0.53 , 1.19) 0.27 
Marital status: nor married --- 1.03 (0.68 , 1.59) 0.88 
Maternal age (years) --- 1.03 (1.0 , 1.07) 0.04 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.15 (0.70 , 1.86) 0.58 
Obese --- 1.55 (0.96 , 2.50) 0.07 
Diabetes/Gestational Diabetes --- 1.52 (0.88 , 2.51) 0.12 
Pre-eclampsia --- 0.70 (0.33 , 1.31) 0.29 




Table S3. Interaction between Flu in Trimester 2 and Antibiotic Use during Pregnancy on Odds of ASD 
 
 OR (95% CI) P-value OR (95% CI) P-value 
Flu Trim 2 3.06 (0.85 , 8.86) 0.06 3.56 (0.95 , 10.81) 0.04 
Antibiotic during Pregnancy 1.78 (1.06 , 3.21) 0.04 1.66 (0.95 , 3.16) 0.09 
Child sex: male --- 3.03 (1.97 , 4.80) 0.00 
Maternal education: HS graduation or below --- 0.80 (0.54 , 1.20) 0.27 
Marital status: nor married --- 1.05 (0.69 , 1.63) 0.81 
Maternal age (years) --- 1.03 (1.0 , 1.07) 0.04 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.15 (0.70 , 1.86) 0.59 
Obese --- 1.55 (0.96 , 2.50) 0.07 
Diabetes/Gestational Diabetes --- 1.52 (0.88 , 2.51) 0.11 
Pre-eclampsia --- 0.69 (0.33 , 1.30) 0.29 




Table S4. Interaction between Flu in Trimester 3 and Antibiotic Use during Pregnancy on Odds of ASD 
 
 OR (95% CI) P-value OR (95% CI) P-value 
Flu Trim 3 0.46 (0.03 , 2.31) 0.46 0.55 (0.03 , 2.84) 0.57 
Antibiotic during Pregnancy 1.43 (0.88 , 2.46) 0.17 1.28 (0.76 , 2.30) 0.37 
Child sex: male --- 3.05 (1.98 , 4.84) 0.00 
Maternal education: HS graduation or below --- 0.80 (0.53 , 1.19) 0.26 
Marital status: nor married --- 1.03 (0.67 , 1.58) 0.91 
Maternal age (years) --- 1.03 (1.00 , 1.07) 0.04 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.15 (0.70 , 1.86) 0.57 
Obese --- 1.56 (0.96 , 2.52) 0.07 
Diabetes/Gestational Diabetes --- 1.51 (0.88 , 2.51) 0.12 
Pre-eclampsia --- 0.70 (0.34 , 1.32) 0.31 





Table S5. Interaction between Fever in Overall Pregnancy and Antibiotic Use during Pregnancy on Odds of ASD 
 
 OR (95% CI) P-value OR (95% CI) P-value 
Fever Overall Pregnancy 1.05 (0.16 , 3.80) 0.95 1.13 (0.17 , 4.24) 0.87 
Antibiotic during Pregnancy 1.51 (0.92 , 2.64) 0.12 1.35 (0.79 , 2.47) 0.30 
Child sex: male --- 3.03 (1.97 , 4.81) 0.00 
Maternal education: HS graduation or below --- 0.80 (0.54 , 1.21) 0.29 
Marital status: nor married --- 1.03 (0.68 , 1.59) 0.89 
Maternal age (years) --- 1.03 (1.00 , 1.07) 0.04 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.15 (0.70 , 1.86) 0.58 
Obese --- 1.53 (0.94 , 2.46) 0.08 
Diabetes/Gestational Diabetes --- 1.51 (0.88 , 2.50) 0.12 
Pre-eclampsia --- 0.70 (0.33 , 1.31) 0.30 





Table S6. Interaction between Fever in Trimester 1 and Antibiotic Use during Pregnancy on Odds of ASD 
 
 OR (95% CI) P-value OR (95% CI) P-value 
Fever Trim 1 1.20 (0.07 , 6.21) 0.86 1.22 (0.07 , 6.53) 0.85 
Antibiotic during Pregnancy 1.57 (0.97 , 2.70) 0.08 1.42 (0.84 , 2.54) 0.21 
Child sex: male --- 3.04 (1.97 , 4.82) 0.00 
Maternal education: HS graduation or below --- 0.79 (0.53 , 1.19) 0.26 
Marital status: nor married --- 1.03 (0.68 , 1.60) 0.88 
Maternal age (years) --- 1.03 (1.00 , 1.07) 0.04 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.14 (0.69 , 1.85) 0.60 
Obese --- 1.54 (0.95 , 2.48) 0.08 
Diabetes/Gestational Diabetes --- 1.51 (0.88 , 2.49) 0.12 
Pre-eclampsia --- 0.70 (0.34 , 1.32) 0.31 




Table S7. Interaction between Fever in Trimester 3 and Antibiotic Use during Pregnancy on Odds of ASD 
 
 OR (95% CI) P-value OR (95% CI) P-value 
Fever Trim 3 1.60 (0.09 , 8.42) 0.65 1.68 (0.09 , 9.36) 0.63 
Antibiotic during Pregnancy 1.57 (0.97 , 2.70) 0.08 1.42 (0.84 , 2.54) 0.21 
Child sex: male --- 3.05 (1.98 , 4.83) 0.00 
Maternal education: HS graduation or below --- 0.80 (0.54 , 1.20) 0.28 
Marital status: nor married --- 1.03 (0.67 , 1.58) 0.91 
Maternal age (years) --- 1.03 (1.00 , 1.07) 0.04 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.14 (0.69 , 1.84) 0.60 
Obese --- 1.53 (0.94 , 2.46) 0.08 
Diabetes/Gestational Diabetes --- 1.51 (0.88 , 2.49) 0.12 
Pre-eclampsia --- 0.71 (0.34 , 1.33) 0.32 




Table S8. Interaction between Genitourinary Infection and Antibiotic Use during Pregnancy on Odds of ASD 
 
 OR (95% CI) P-value OR (95% CI) P-value 
Genitourinary Infection 0.61 (0.17 , 1.73) 0.39 0.64 (0.18 , 1.85) 0.44 
Antibiotic during Pregnancy 1.51 (0.87 , 2.81) 0.17 1.27 (0.71 , 2.45) 0.45 
Child sex: male --- 3.04 (1.98 , 4.82) 0.00 
Maternal education: HS graduation or below --- 0.79 (0.53 , 1.19) 0.26 
Marital status: nor married --- 1.04 (0.68 , 1.61) 0.86 
Maternal age (years) --- 1.03 (1.00 , 1.07) 0.05 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.14 (0.70 , 1.85) 0.59 
Obese --- 1.57 (0.97 , 2.53) 0.06 
Diabetes/Gestational Diabetes --- 1.50 (0.87 , 2.49) 0.13 
Pre-eclampsia --- 0.70 (0.33 , 1.31) 0.29 




Table S9. Interaction between any Maternal Immune Activation and Antibiotic Use during Pregnancy on Odds of ASD 
 
 OR (95% CI) P-value OR (95% CI) P-value 
Any Maternal Immune Activation 0.91 (0.35 , 2.36) 0.84 0.81 (0.30 , 2.16) 0.67 
Antibiotic during Pregnancy 1.55 (0.79 , 3.41) 0.24 1.17 (0.58 , 2.63) 0.67 
Child sex: male --- 2.92 (1.88 , 4.69) 0.00 
Maternal education: HS graduation or below --- 0.73 (0.49 , 1.11) 0.14 
Marital status: nor married --- 1.08 (0.70 , 1.70) 0.73 
Maternal age (years) --- 1.03 (1.00 , 1.06) 0.08 
Maternal BMI (ref: not overweight) --- 
  Overweight --- 1.20 (0.72 , 1.96) 0.47 
Obese --- 1.59 (0.96 , 2.59) 0.07 
Diabetes/Gestational Diabetes --- 1.37 (0.77 , 2.33) 0.26 
Pre-eclampsia --- 0.59 (0.26 , 1.16) 0.16 






CHAPTER 6: DISCUSSION 
This dissertation took a tripartite approach to 
studying the gastrointestinal (GI) system/gut 
in ASD (Figure 1). 
 
In Chapter 2 (Aim 1), the first study of this 
dissertation, we summarized the core themes 
that emerged from a dozen qualitative 
interviews with parents of children with ASD 
and co-occurring GI symptoms.  These 
interviews were useful in helping derive the item pool for the ASD-GIRBI (Aim 3). We 
identified a number of indicators of GI symptoms in children who may not otherwise self-report 
experiencing GI symptoms.  A limitation, however, is that these indicators may differ by child 
and may also not be specific to GI symptoms.  Therefore, the consideration of a large number of 
indicators (e.g. poor sleep, irritability, aggression, weird postures) may be necessary to screen for 
GI symptoms in individuals with ASD, with follow-up for more comprehensive evaluation for 
GI disorders/pathology. 
 
For some children in our study, indicators of severe GI distress included aggressive or violent 
behavior.  As greater attention is paid to the management of crises in ASD, it will be critical to 
consider the role of medical symptoms in creating crisis situations10,11.  Further, the strong link 
between GI symptoms and behaviors such as aggression and irritability is a reminder that these 
problem behaviors are often responses to stressors (e.g. GI distress and pain) rather than inherent 
Figure 1.  Tripartite Approach to 




features of ASD12,13.  Behavioral as well as clinical interventions need to consider that GI 
symptoms contribute to a portion of problematic behaviors, and that resolution of these behaviors 
may require treating the underlying medical issue.   
 
The qualitative interviews also highlighted the significant toll that GI symptoms take on children 
with ASD as well as their families.  Children with GI symptoms face difficulties attending and 
staying in class, participating in social or extracurricular activities, and experienced significant 
pain and distress due to their GI symptoms.  Families described challenges to the overall 
wellbeing of the household, and in particular the overall temperament and stress level of 
families, and the ability for the family to leave the house or eat out at restaurants.  Parents also 
described financial challenges associated with GI symptoms.  It is important to remember how 
common these GI symptoms are for individuals with ASD when we consider the burden the 
wellbeing of the child and family.  In Aim 1, we found that the median frequency of GI 
symptoms across the studies was 46.8%, meaning nearly half of individuals with ASD 
experience at least one GI symptom, though the range is wide and that number could be lower or 
much higher. 
 
As we consider this burden, it is crucial to recognize the obstacles individuals in ASD face in 
having these symptoms recognized, evaluated, and treated.  As discussed above, GI symptoms 
may be difficult to detect in individuals with ASD, especially in people who are non- or hypo-
verbal or have cognitive impairments.  Assuming that these GI symptoms do get recognized 




The last major theme that emerged from the qualitative interviews was the negative experience 
that families tended to have when seeking healthcare for their child with ASD and GI symptoms.  
Challenges including long wait times between making an appointment and seeing a physician 
and financial costs and difficulties navigating the insurance system.  Further, parents felt that 
medical offices were difficult places to bring their child with ASD, due to the loud, bright 
environment and the long wait times.  Blood draws, which are often used for the assessment of 
various conditions, can be very difficult for individuals with ASD, and one parent in our study 
noted they would have to ‘gas’ their child to get blood work done. 
 
A very troubling finding was that parents felt that the physician attributed the child’s GI 
symptoms to autism and therefore their children did not receive the same evaluation, as would a 
child without ASD.  In line with this, one parent stated that they wished they hadn’t told the 
provider about their child having ASD.  Diagnostic overshadowing, a process in which physical 
symptoms are inappropriately attributed to mental illness, is a reality for individuals with ASD, 
other developmental disability, and mental illnesses more broadly, and contribute to worse 
care7,14.   
 
The negative experiences and frustrations that parents have in seeking treatment for their child’s 
GI symptoms likely contributes to the increasing popularity of complementary and alternative 
medicines/treatments (CAMs)15.  In fact, one parent in our qualitative study described that 
among parent circles, CAMs such as bowel cleansing, are promoted given the long wait times in 
being able to see physician for their child’s GI distress.  This is expected and understandable, but 
also concerning given the lack of data on not only effectiveness of CAMs but also safety.  
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Research is urgently needed to study CAMs in general and in particular how they influence GI 
symptoms. 
 
The next main goal of this dissertation work was to improve the measurement of GI symptoms in 
epidemiologic studies of ASD.  In Chapter 3 (Aim 2), we reviewed studies of ASD dating from 
1980 that reported GI symptoms, in order to understand the approaches to assessing GI 
symptoms in this population.  As expected, we identified a wide range of tools that are used to 
ascertain GI symptoms.  Most studies relied on questionnaires given to parents, while some 
studies used medical records to identify GI diagnoses, and a smaller portion of studies used 
symptom or stool diaries to prospectively measure GI symptoms. While there were several GI 
questionnaires designed specifically for the ASD population, at the time of the review none had 
been psychometrically assessed and we had no information on the reliability or validity of any of 
these tools.  We found a very wide range (4.2 to 96.8%) of participants to have GI symptoms 
across the studies, with variability for symptom-specific estimates as well.  Further, the 
frequency of specific GI symptoms across studies was associated with the assessment tool.  For 
example, reflux symptoms were highest in studies that used medical records or claims data, 
likely because it’s one of the GI disorders that are difficult to observe, and usually rely on 
physician examination or for someone to self-report symptoms such as “burning”.   
 
After having reviewed these studies of ASD, we were better able to identify gaps in current 
assessment tools.  An important theme emerged: we need more standardized, reliable, and valid 
tools to estimate GI symptom prevalence since because current estimates are so varied across 
epidemiologic studies and because these symptom estimates are associated with the 
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measurement approach.  This is critical given that GI symptoms appear to be one of the most 
common comorbid conditions in ASD and can significantly affect someone’s quality of life1,2.  
In addition, the gut is quickly emerging as a possible risk factor for the development of ASD and 
comorbid conditions.  The autism field desperately needs valid tools for assessing GI issues in 
both epidemiologic and clinical settings.   
 
The review work led to the development and validation of a parent-report screener for GI 
symptoms, which we termed the ASD Gastrointestinal and Related Behaviors Inventory (ASD-
GIRBI), described in Chapter 4.  The ASD-GIRBI included items from two existing tools (the 
Autism Treatment Network GI Inventory3 and the Brief Autism Mealtime Behaviors Inventory4) 
as well as new items.  Critically, this item pool was more comprehensive and therefore had 
stronger content validity compared to prior tools, as it included GI symptoms, mealtime and 
dietary behaviors, as well as less specific behaviors that could reflect GI distress in a non-verbal 
or hypo-verbal child with ASD.  We found the ASD-GIRBI to be an internally sound, i.e. 
reliable, tool for assessing the presence of GI symptoms and related behaviors.  A 35-item 
screener with seven factors emerged from exploratory factor analysis: Factor 1: constipation & 
pain during bowel movements; Factor 2: doesn’t want food at times; Factor 3: Particular with 
foods; Factor 4: abdominal pain/vomiting/gassiness/diarrhea; Factor 5: 
incontinence/soiling/wetting the bed; Factor 6: aggressive/disruptive at mealtimes; Factor 7: 
Other behaviors).  Two factors on the screener (Factors 1 and 4, comprising of 13 items) detected 
parent-report of any GI disorder, constipation, and reflux with very high sensitivity, although the 
other 22 items on the questionnaire provide contextual information in research and clinical 




There were some limitations to our GIRBI development and evaluation.  First, because of 
insufficient sample size, children ages 3-5 were not included in the psychometric analysis.  
Therefore, our results apply only to the group of 6-17 years old.  Further, no adults with ASD 
were included in this study.  Follow-up work will focus on developing an adult-version of this 
tool, which may be different from children.  Second, we did not carry out item response theory 
analyses, so we do not know which of the 13 items among Factors 1 and 4 are particular 
important for detecting GI symptoms.  Future work will include these analyses.  And lastly, we 
did not have a gold-standard measure of GI symptoms in this population.  While another recently 
validated ASD GI tool did have physician diagnosis, rather than parent-report diagnosis of GI 
symptoms5, this also has limitations, as a patient’s subjective experience of having GI symptoms 
may not be captured by a physician, especially if the patients is non- or hypo-verbal6.   
 
Challenges associated with medical testing in individuals with ASD also complicate the 
evaluation of these patients.  The negative experiences parents had with providers described in 
Chapter 2 support this possibility.  Parents reported that physicians did not take their child’s GI 
symptoms as seriously because they assumed the symptoms to simply be part of their autism 
presentation.  Diagnostic overshadowing is unfortunately common in ASD, as well as 
developmental disabilities and mental illnesses more broadly7.  However, ASD-specific issues 
such as communication impairments, sensory issues, and severe food aversions seriously 
complicate this issue.  Short parent-report screeners for individuals with ASD, such as the ASD-
GIRBI, may improve the recognition of GI symptoms in both epidemiologic and clinical studies.  
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However, this tool is not particularly specific, and like with any screener, false positives need to 
be ruled out with further evaluation.  Future work on this tool may improve the specificity.   
 
Referring back to the orientating figure for this dissertation (Figure 1), the third goal for this 
study was to assess the role of the gut as a risk factor for the development of ASD.  Prior 
research has implicated dysbiosis of the gut microbiome and dysregulation of the immune 
system in ASD.  Animal and human studies have demonstrated that maternal immune activation 
and early-life infections increase the risk for ASD.  Our growing understanding of the role of the 
gut microbiome in regulating the immune system has led to research demonstrating that in a 
mouse model, the maternal gut microbiota influences whether exposure to maternal immune 
activation in utero increases the risk of neurodevelopmental abnormalities and ASD-like 
symptoms in the offspring8,9.  In Chapter 5 (Aim 4), using the Boston Birth Cohort, a prospective 
enriched-risk birth cohort of mother-newborn pairs enrolled and followed at the Boston Medical 
Center, we examined the interaction between maternal immune activation and antibiotic use in 
pregnancy on the risk of ASD in the offspring.  In concordance with the animal literature, we 
show for the first time that antibiotic use in pregnancy appears to block the association between 
maternal immune activation, specifically flu in the second trimester, and risk of ASD in the 
child.  In other words, flu in the second trimester was only a risk factor for ASD in the child in 
pregnant women who did not receive an antibiotic.  This result remained after adjusting for a 
number of confounders, including C-section and preterm delivery; however, our study was 




The findings from Chapter 5 are consistent with the strong evidence that the gut is a critical 
component in the development of neuropsychiatric disorders, given the animal literature linking 
maternal immune activation with maternal gut microbiome and fetal neurodevelopment.  If the 
findings from this and other studies are replicated, the implications are profound.  The conditions 
under which MIA increases the risk of neuropsychiatric conditions are unclear.  This research 
highlights a potential modifying factor.  Because the gut microbiome is malleable across the life 
course, including during pregnancy and in early-life, it is an attractive target for intervention.  As 
we better understand what particular microbes protect against the negative sequelae of MIA, we 
may be able to develop therapies and ultimately decrease the incidence of ASD and other 
neuropsychiatric disorders such as schizophrenia.  This work is preliminary but promising, and 
emphasizes the critical need for further studies of the gut microbiome and immune system.   
 
 
A limitation of this dissertation overall is that most of the work was done in children.  While our 
literature review of GI measurement approaches focused on all individuals, only 5 of those 
studies (5.7%) included individuals greater than 18 years of age.  The opportunity to pilot our GI 
questionnaire, the ASD GIRBI, in a registry of families with a child with ASD was convenient, 
and the tool should indeed be piloted separately in children and adults.  Future work on this 
questionnaire will involve adults with ASD.  Because our qualitative study was in part designed 
to help us derived the item pool for the ASD GIRBI, we asked families to report on GI 
symptoms in their child with ASD at some point in childhood.  We did have three families that 
had a child with ASD 18 years or older, but in future work we will also focus on recruitment of 
adults with ASD.  Lastly, while Chapter 5 was focused on the etiology of ASD, we recognize the 
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importance of supporting individuals with ASD after the diagnosis, and not just preventing ASD 
and related disabilities.   
 
The ultimate goal of this dissertation was to improve the detection of GI symptoms in individuals 
with ASD, assess the role of the gut as a causal risk factor for the incidence of ASD, and to 
decrease burden that GI symptoms place on individuals with ASD and their families, by 
shedding light on this issue.  However, this work has implications for other developmental 
disabilities and mental illnesses more broadly.  Gastrointestinal symptoms and other medical 
comorbidities are common in psychiatric disorders, and like in the case of ASD, can emerge for a 
number of reasons16,17.  Accurate measurement of GI symptoms is particularly relevant to other 
developmental/intellectual disabilities or psychiatric conditions in which a person may not be 
able to self-report, such as during a serious episode of mental illness or in a person with 
dementia18.  GI symptoms can take a toll on the wellness of any individual, and in particular 
individuals with a co-occurring psychiatric disorder.  Individuals with mental illness also have 
negative experiences with the health care system and face disparities in access to quality health 
care, in part due to the complexity of their health conditions and also because of diagnostic 
overshadowing7.  On a more hopeful note however, the gut likely plays an important role in the 
incidence, presentation, and course of mental illness broadly, and holds promise as a window for 
intervention19,20.  The future of gut-brain research is exciting, has the potential to be a missing 
link in our understanding of psychopathology, and may help us in developing preventions and 
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